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Abstract
HUNTINGTON’S disease (HD) is an inherited, progressive, neurodegenerative disorder for which there is no effective treatment It is one of nine disorders 
known to  be caused by the expansion o f a genomic CAG repeat sequence, producing 
a protein with an expanded array o f  polyglutamine residues. The mechanisms 
underlying the degeneration and death o f neurons in HD remain unclear, and are the 
subjects o f this investigation.
Several animal models have been generated to  investigate the pathogenic 
mechanisms underlying HD, o f which this thesis uses two: the Bates R6/2 mouse, 
which has the affected region o f the human gene inserted into its genome; and the 
Shelboume Hdh ‘knock-in’ mice, in which the CAG repeat sequence o f the murine 
huntingtin gene homologue has been expanded into the pathogenic range.
Ultrastructural analyses have been undertaken on the CNS from each o f the 
mouse models, detailing the subcellular changes that occur. This has been furthered 
by analyses o f the molecular machinery o f apoptosis in an attempt to  identify factors 
involved in neurodegeneration.
Affected neurons in each o f the HD models, and in aged wild-type mice, 
exhibit very similar morphologies: a condensation o f cytoplasm and nucleoplasm, 
disturbances in the nuclear membrane, dilation and disruption o f cell organelles and 
increased autophagic activity. These morphologic changes do not correlate with those 
reported to  occur during apoptosis. Furthermore, molecular analyses reveal the 
involvement o f none o f the components o f apoptosis.
In relating each o f the mice, it is clear that neurodegenerative changes do not 
correlate with phenotypic changes; rather the early and most pronounced symptoms 
of HD are a result o f neuronal dysfunction. It is also concluded that the increased 
autophagic activity and cell condensation occur in adult neurons under stress and thus 
may be indicative o f a common process by which adult neurons die.
In loving memory
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Introduction
1.1 Huntington's Disease
1.1.1 Huntington's Disease
JNTINGTON’S disease is an inherited, progressive neurodegenerative
disorder. The disorder was originally termed Huntington's Chorea, after the
lacks chorea, and the fact that adult symptoms include far more than just chorea led to  
the renaming. Other motor abnormalities exhibited by Huntington’s disease (HD) 
patients include athetosis (slower writhing movements o f  the limbs), bradykinesia 
(slowing o f voluntary movements, similar to  Parkinson’s disease), myoclonus (sudden 
jerking m ovem ents), dystonia (strange posture due to  muscle spasms), and 
oculomotor apraxia (difficulty in making rapid eye movements).
Patients also experience cognitive decline and psychiatric symptoms, which 
may begin up to  ten years prior to  onset o f motor symptoms. Such symptoms usually 
begin with personality changes, a lack o f interest in life and increased irritability; 
followed by behavioural changes, including social disinhibition and a tendency to  act 
impulsively and violently. Psychiatric symptoms may also include affective disorder and 
schizophrenia, with some patients occasionally experiencing seizures and convulsions 
(for a comprehensive review o f the clinical profile o f HD, see Huntington’s Disease P.S. 
Harper, Saunders Press).
Severe weight-loss is also associated with the disorder and in the past has 
been attributed to  the dysphagia also seen. However, it has since been shown that 
weight loss cannot be attributed to  diet rather that HD patients have a higher resting 
energy expenditure, possibly due to  the increased motor activity (Pratley et al. 2000; 
Morales eto/. 1989).
The juvenile form o f HD lacks chorea and presents more like Parkinson’s 
disease (PD) with the bias o f symptoms towards bradykinesia and psychiatric 
abnormalities, whilst the late-onset form tends more towards a pure movement
dancing movements exhibited by sufferers, but the discovery o f a juvenile form which
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disorder. The distinction between the tw o is somewhat arbitrary with onset below 20 
years o f age generally considered juvenile presentation.
1.1.2 Prevalence and Progression
Globally, HD has a prevalence o f approximately 10 per 100,000 but varies widely. 
The lowest incidence is found among the Japanese and Chinese with prevalence 
around 0.5 per 100,000 (Nakashima et al. 1996; Chang et al. 1994) whilst the highest 
prevalence, 700 per 100,000, is found near Lake Maracaibo in Venezuela (jenkins and 
Conneally 1989). The figures for the UK and the USA are approximately 8 and 5 per 
100,000 respectively Juvenile HD accounts for approximately 6% o f Huntington’s 
cases. The reason for the global variation is explained further in 1.3.3.
The mean age o f onset o f symptoms is approximately 40 years, which is 
followed by a progressive deterioration with death occurring 10 to  17 years after 
onset Death normally occurs as a result o f secondary complications from the disease, 
the commonest being pneumonia and cardiovascular disease.
1.1.3 Gross Pathology
Post-mortem examination o f an end-stage HD brain reveals massive enlargement o f  
the lateral ventricle due to  atrophy o f the caudate and putamen -  as a result o f  
abundant cell loss -  and to  a lesser extent thinning o f the cortex (see figure I). 
During the course o f the disease there is also cell loss and shrinkage in the globus 
pallidus, hippocampus and thalamus. There is also a progressive decrease in size and 
weight o f various parts o f the brain. Interestingly, patients show up to  a thirty percent 
reduction in weight o f  the cortex, hippocampus and thalamus before pathology is 
visible to  gross examination (de la Monte et al. 1988).
Control
Figure I A comparison of normal and HD post-m ortem  brains. Coronal sections 
through the basal ganglia. N ote the enlargement of the lateral ventricle (LV) due to  
shrinkage of the caudate nucleus (C) putamen (P) and globus pallidus (GP). N ote also 
the thinning of the cortex (cx).
Taken from Pathological Basis o f  Disease Saunders Press, 5th Ed.
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Vonsatell (Vonsattel et al. 1985) devised a classification system for disease severity 
based on macroscopic and microscopic post-mortem observations. His system is 
based on five grades of pathology. Grade 0 includes those with psychiatric symptoms 
but no observable gross pathological changes. In some Grade 0 brains astrocytosis 
can be detected. As with Grade 0, Grade I brains show no macroscopic changes, but 
histologically a large proportion o f the striatal medium spiny projection neurons can be 
found to  have been lost Throughout Grades 2 to  4  there is further loss o f the striatal 
neurons with shrinkage o f the areas already mentioned. By Grade 4 95% of the 
striatal projection neurons are lost, figure I contains an example o f such a brain. The 
majority o f HD patients are Grades 3 or 4 at time o f death.
The initial pathology is confined to  the medium spiny neurons o f the caudate 
nucleus (CN), spreading from the medial paraventricular parts to  the tail o f the CN, 
and thence to  the dorsal putamen and its medium spiny neurons (Vonsattel and 
DiFiglia 1998). It seems somewhat counterintuitive that the initial damage should be 
in the basal ganglia and yet the initial symptoms are typically psychiatric. However, 
one group has developed a technique for detecting HD in presymptomatic patients by 
testing motor skills (Smith et al. 2000). Through accurate measurements o f  
movements during reaching tasks they are able to  detect abnormalities in HD gene 
carriers up to  seven years before predicted onset o f ‘classical’ symptoms.
The most striking pathological changes are found in cases o f juvenile HD, with 
neuronal loss spreading beyond the regions affected in adult HD, such as the Purkinje 
cells o f the cerebellum. Along with increased severity o f symptoms and a faster rate 
of decline, this suggests juvenile HD is a more aggressive form o f the adult disease 
(Myers eto/. 1988)
1.2 The History o f Chorea
12.1 The History o f Chorea
TINGTON’S disease was originally on e o f many disorders bounded
gether under the title o f ‘‘Dancing Manias”, or what would become known
as choreas. The earliest descriptions o f what may have been choreas include ancient 
Egyptian papyri and the Bible. In fact it seems that the ancient Egyptians were even 
partially aware o f the causative element o f the diseases, ascribing the symptoms to  
brain dysfunction (Edwin Smith papyrus, 3000BC). Considering the ancient Egyptians 
regarded the brain as an origan o f little importance it is even more surprising that they 
would have made this conclusion. O f course, this suggestion was lost and it was not 
until the early sixteenth century that the nature o f the diseases came to  be 
investigated again.
There are reports o f dancing manias throughout the middle ages. At the time 
the symptoms were attributed to  the work o f the Devil. It was believed affected 
individuals w ere possessed, or being punished by God for som e unknown 
transgression. Paracelsus ( 1493 -  15 4 1) contradicted this general belief stating they 
are not due to  ‘‘ghostly beings or spirits” but the “result o f  some fault in the affected 
person’s personality”. O f course, contradicting the Church was not a healthy idea at 
the time and he was denounced as the “Luther o f Medicine”.
It was Paracelsus who introduced the term chorea - from the Latin chorea, a 
dance (in a ring). He also subdivided choreas into three types: “chorea imaginative 
aestimative" arising from the ‘imagination’; “chorea lasciva” arising from ‘sensual desires’ 
and “chorea naturalis coatta", arising form an organic basis. The latter classification may 
have been based on his work with Huntington’s disease patients.
John Elliotson ( 17 9 1 -  1868) provided us with the first definite mention o f  
heredity in causation o f  adult chorea in 1832 (Elliotson 1832). The Professor o f  
Medicine at University College London states that when chorea:
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"...occurs in adults it is frequently connected with paralysis or 
idiotism and will perhaps never be cured. It appears to arise 
for the most part from something in the original constitution of 
the body, for I have often seen it hereditary."
1.2.2 George Huntington (1850-1916)
George Sumner Huntington was bom on April 9th 1850 in East Hampton, Long Island. 
He was the son and grandson o f physicians and graduated from the College o f  
Physicians and Surgeons himself in 18 7 1. A year after his graduation he gave a lecture 
entitled “On Chorea” to  the Me/gs and Mason Academy o f Medicine, the subject 
matter for this talk he subsequently published in the Philadelphia-based Medical and 
Surgical Reporter (Huntington 1872) (figure 3, see 6 .1 for transcript). Both the lecture 
and the paper dealt with what he called the “hereditary chorea”, his work on which he 
described in a very anecdotal way, as a reminiscence o f his childhood in Long Island. 
He recalled patients and their families from his father’s surgery:
"...It is spoken of by those in whose veins the seeds of the 
disease are known to exist, with a kind of horror, and not at 
all alluded to except through dire necessity, when it is 
mentioned only as 'that7 disorder."
Huntington notes three essential features, or ‘peculiarities’ in this disease:
Its hereditary nature
A tendency to insanity and suicide
Its manifesting itself as a grave disease only in adult life
Even today, George Huntington is still commended for the detailed yet succinct nature 
o f his account and it is fitting that such an excellent description earned the labelling of 
the disease with his name.
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Figure 2 Lef t : Paracelsus (Aureolus Philippus Theophrastus Bombastus von
Hohenheim). Right. George Sumner Huntington. Taken around the time he w rote On 
Chorea.
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Chorea >• essen tia lly  a d isease of the ner­
vous system . T b e oaiue " ch orea”  ia given to 
the dl»ea*e on account o f tha dancing  propeu- 
ailiea of those a ho are affected by it . and it ia 
a eery  appropriate designation . T be d isease, 
a t it is coiuiuouly seen , ia by no mentis a 1 
dangerous or serious affection, how ever dis- 
ttes*ing it may be to the oue suffering from it, 
or fo lila friends. Its moat m m ked and char­
acteristic feature ia a  clon ic apasra adectiug  
the voluntary m uscles. T h ere ia uo loaa of 
senae or o f volition attending these con - 
tractlooa, as there ia In ep ilep ay ; the w ill la 
there, but its power to perform ia deficient, 
the desired m ovem ents are after a manner 
perform ed, hut there aeems to ex ist some 
hidden pow er, som ething lh at is playing  
tricks, as It w ere, upon tbe w ilt, and lu a 
measure thw artlog and perverting Its d es ig n s , 
and after the will has ceased to exert its 
power in any given direction, taking thiDgs 
in to its own bands, and keeping the poor 
victim in a  continual Jigger as loug ns he re­
mains aw ake, generally , though not a lw ays, 
granting a respite during sleep . T he disease 
comm only begins by alight tw itchiugs iu the 1 
m uscles o f the face, w Ich gradually increase 1 
in violence and variety. T he eyelids are kept 
wiukiug, the brows are corrugated, and then 
elevA led, the uoso is screwed first to the one  
side and then to the other, and the month ia 
drawn in various dirrctlooa, giving the patient 
the roost ludicrous appearance im aginable.
T b e upper extrem ities m ay he the first 
affected, or both sim ultaneously. A ll tbe 
voluntary m uscles are liable to he affected, 
those of the face rarely being exem pted.
I f  the patient attem pt to protrude the tongue 
it is accom plished with a great deal o f diffi­
culty and uncertainty. Tho hands nro kept 
rolling—first the pnlms upward, and then the 
heck*. T he shouldirs are shrugged, and the 
feet aud legs kept in perpetual m o tio n ; tho 
toes are turned in , and then ev er ted ; one foot 
is thrown across the other, and then suddenly  
withdrawu, aud, io short, every conceivab le  
altitude ami expreashm  ia assum ed, aud so  
varied aud irregular are *lhe motions gvsne 
through w ith , lhat a com plete d ocrip tiou  o f 
them would be im possible. Som etim es the  
m uscles o f the low er extrem ities are uot af­
fected , and I believe th sy  never are alont 
involved. In  cases o f  death from chorea, all 
the m uscles of the body seem  to have been  
affected, and tbe time required for recovery  
aud degree of success in treatm ent seem  to 
depend greatly upon the am ount o f muscular 
involvem ent- Ho m r e r o  refers to tw ocases in 
which the muscles o f respiration wtrg ajfected.
T he disease is geuerally  confined to child­
hood, being m ost frequont bciw eeu the ages 
of eight and fourteen years, and occurring 
ofteucr in girls than in hoys. D u fo s s e  and 
H u f z  refer to 420 cases; 130 occurring iu 
boys aud 290 in g k ls . W atson  m entions a 
collection of 1,020 cases, of whom 733 were 
giving a proportion of ucarly 5 to 2. 
Dr. W atson  also remarks upon the disease 
being most frequcut among children of dark  
com plex.on, w hile the two authorities just 
alluded to, D u ro ex s  and H u f z , givo as their 
opinion that it is m ost frequent in children o f 
light hair. In every  case viaittng the otinica
Figure 3 The front page from George Huntington's paper “On Chorea", April 1872
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1.2.3 Tracing the Origins o f Huntington *s Disease
The dominant hereditary nature o f Huntington’s disease allows for genealogical studies 
to  be carried out with comparative ease. The well-known genealogical studies were 
conducted before the locus o f the affected gene had been pinpointed (see 1.3), that is 
to  say, before precise genetic testing for Huntington’s disease existed. W hat has 
become clear since then is that in a surprising number o f cases, HD arises as the result 
o f new mutation. However, at the time genealogies were being elucidated it was 
believed that very few new mutations occurred. Stevens ( 1976) estimated that in his 
study one percent o f  affected individuals resulted from new mutations. Family 
histories can be very difficult to  obtain, especially if there has been an attempt to  
conceal the disease, and so it was very easy for those spending their time tracing the 
timeline to  dismiss negative family histories, especially when they could always 
question paternity.
The first o f such studies began in the US, fittingly with the descendants and 
ancestors o f the patients o f Drs Huntington. The origins o f the mutations passed 
through this genetic line have been traced back as far as seventeenth century Britain. 
This was a time o f great religious persecution and oppression, meaning that anyone 
behaving "abnormally” was not well-regarded. Many Britons, especially those under 
such persecution emigrated, with America a popular choice o f new homeland. The 
emigrants o f this time included three men: Jeffers, Nicolas (Nichols) and Wilkes 
(Wilkie), as well as one Simon Huntington, all of whom left within three years o f each 
other from East Anglia. It is something o f an historical twist o f fate that the three 
earliest known affected individuals and the ancestor o f the man whose name the 
disease know bears should follow the same journey (Critchley 1973).
It is possible that these three men fled to  America to  escape ‘family burdens’ at 
home. If their family had a history o f the disease and had been persecuted for dancing 
the “Devil’s dance”, perhaps they believed they could escape such persecution by 
fleeing. Alternatively, they may have been sent to  N ew  England because o f their 
family history. Either way, the views concerning ‘unnatural behaviour’ were not limited 
to  England.
The seventeenth century saw a great fear o f witchcraft: the first anti-witchcraft laws 
were passed in 1642 in N ew  England, and fear continued to  grow culminating in the 
Salem witch hunts o f 1692. The appropriate punishment for a witch/warlock was 
death. It was believed that a witch’s power was contained in the blood, hence the 
appropriate means o f execution became burning alive. Seven o f the female 
descendents o f the three men were regarded as witches. O f the men themselves, it is 
known that each one had problems with the law. Their sociopathic traits, combined 
the labelling o f their female descendents as witches suggests they had been suffering 
from Huntington’s Disease (Maltsbepger 19 6 1).
Similar genealogical studies have since been carried out across the globe and 
have been used to  suggest a spread o f the HD mutation around the world from a 
source or sources somewhere in Northwest Europe, in particular France, Germany 
and/or Holland. Whilst it seems the genealogical history o f the New  England patients 
is true, at least in part, it is doubtful as to  whether the stories o f the rest o f the world 
hold up to  te st Odd cases in more remote parts have been put down to  ‘actions’ of 
colonial seamen. But it is more likely that these cases, and many others arose 
independently as a result o f new mutation.
Since the discovery o f the affected locus genetic screening has been possible. 
Studies since have indicated that there is a higher number o f new mutations 
responsible than at first thought Two such studies (Nance et al. 1996; Siesling et al. 
2000) have yielded similar results from different groups o f patients. Ignoring patients 
with unknown or suspect histories, Siesling et al. found eight out o f 126 patients with 
an HD gene in the disease range had negative family histories (6.3%). The Nance 
group suggest between 4.5 and 7.5% o f cases occur with a negative family history. 
Generally such patients have fewer CAG repeats (see 1.3.3) and a lower age of onset 
supporting the idea o f a recent expansion. Such a high number o f novel mutations 
casts doubt on the reliability o f the genealogical data. Whilst it is unlikely that the East 
Anglia to  Eastern America data are all coincidence, many other appearances o f the 
disease may have been spontaneous.
1.3 The Genetic Basis
13.1 The Venezuela Search
A NUMBER o f investigators examined Huntington’s disease pedigrees in search of a marker linked to the disease; a difficult task given the late age of onset of 
the disorder. Initial investigations used classical antigen and enzyme polymorphisms in 
attempts to  find a correlate with HD (Pericak-Vance 1979; Volkers 1980). Whilst 
they were unsuccessful in finding a marker, they did exclude approximately 20% of the 
genome as possible locations for the HD gene.
The identification o f stretches o f DNA which show high variability between 
individuals: restriction fragment length polymorphisms (RFLP), allowed for a more 
detailed exploration o f the genome, including those parts which do not code for 
proteins. However, even with this technique, the success o f any study depends largely 
on the quantity and quality o f pedigree material available.
The Huntington’s Disease Collaborative Research Group were successful in 
identifying the locus, and later the gene, primarily because they had access to  such a 
large pedigree. Along the shores o f Lake Maracaibo, Venezuela lives the largest 
known concentration of HD carriers, some 3000 since the early nineteenth century, all 
interrelated and, it would appear, stemming from one common ancestor. Nancy 
W exler and colleagues obtained pedigree information, blood samples, and 
neurological diagnoses from these inhabitants. Given the late onset, it is difficult to  
identify all HD carriers, and some patients were examined over three years to  confirm 
the presence o f HD. From the blood samples, James Gusella et al. established 
Epstein-Barr virus-transformed lymphoblastoid cell lines, so as to  provide a permanent 
source o f genetic material. In the RFLP analysis a number o f DNA probes were used 
to  label fragments on the Southern blots, but only one suggested a polymorphism 
inherited with HD: the G8 probe. In fact, the G8 locus and the HD gene are very 
close together indeed, 0 -10 centiMorgans (99% confidence) (Gusella et al. 1983).
Using a Southern blot analysis o f human-mouse somatic cell hybrids, Gusella et al. 
showed that the probe corresponds to  a region o f  chromosome 4. Furthermore, 
other probes used in the initial RFLP analysis corresponded to  different regions on 
chromosome 4, with varying degrees o f co-segregation, thus allowing a substantial 
portion of chromosome 4 to  be eliminated as a locus for the HD gene.
N ot only did a marker for HD now exist, facilitating pre-symptomatic genetic 
testing, but the possible location o f the gene had been narrowed to  a relatively small 
portion of the genome. Over the next ten years the locus was steadily refined until 
the candidate region reached 500kb, whereupon exon amplification was used to  
identify coding sequences and thus the gene (Huntington's Disease Collaborative 
Research Group 1993).
1.3.2 Huntingtin
The affected gene, IT 15 (Interesting Transcript 15), spans approximately 2IOkb within 
the 4p 16.3 locus. Its 67 exons code for a protein 348kDa in size, named huntingtin 
(htt). The function o f normal htt remains unclear. Huntingtin mRNA is expressed 
throughout the foetal and adult body, in peripheral tissues as well as the brain 
(Ambrose et al. 1994); and exists in tw o forms originating from the one gene, a 
10.3kb and a 13.7kb transcript resulting from differential 3' polyadenylation (Lin et al.
1993). It is suggested that this is a form o f regulation o f expression. Both transcripts 
are present in most tissues, although the 13.7kb form is more abundant in brain (Lin et 
al. 2 0 0 1; Strong et al. 1993).
Studies investigating the protein rather than the mRNA have yielded similar 
results: huntingtin is expressed in most tissues - and at higher levels in the brain, which 
is perhaps due to  the predominance o f the highly polyadenylated transcript, which 
persists for longer. Only one study has suggested an hetrogenous expression o f  
protein within the brain. Ferrante et al. state they found a greater expression in the 
medium spiny neurons o f the striatum, which would provide a possible explanation for 
selective degeneration, but the data have not been replicated (Ferrante et al. 1997).
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Cell fractionation experiments indicate that the protein is cytoplasmic and, as revealed 
by immunostaining, is found throughout the cell bodies, dendrites, axons and terminals 
of neurons (DiFiglia et al. 1995). Immunofluorescence studies have shown that htt co- 
localises with the transferrin receptor, coated vesicles and the multivesicular bodies 
associated with the endosome-lysosome pathway. For these reasons it has been 
suggested that htt may have a role in vesicle trafficking in the secretory and endocytic 
pathways (DiFiglia et al. 1995; Sapp etal. 1997; Velier etal. 1998).
W hatever the role o f normal huntingtin, it is o f great importance. 
Identification o f the murine homologue o f huntingtin, Hdh (Barnes et al. 1994) allowed 
for manipulative experiments to  be performed on the native m ouse gene. 
Homozygous knockout o f Hdh is lethal in the early embryonic stage, during 
gastrulation, before the onset o f neurolation (Nasir et al. 1995; Duyao et al. 1995)*. 
Heterozygous knockout has no distinguishable effect Likewise, in humans loss o f one 
htt allele does not produce HD pathology. There exists a disorder, Wolf-Hirschhom 
syndrome, which is caused by a large deletion o f the tip o f chromosome 4, including 
IT 15. Whilst individuals with Wolf-Hirschhom exhibit a number o f abnormalities they 
do not exhibit HD-like neuropathology (Gottfried et al. 1981).
Such embryonic lethality suggests that htt has a crucial role in development a 
role which seems unaffected by the loss o f one allele or the presence o f a mutant 
form o f the gene. Furthermore, the generation o f  mice homozygous for Hdh  
containing an expanded polyglutamine tract (see 1.3.3) has shown that the HD-causing 
mutation does not affect the normal function o f the protein (White et al. 1997). The 
existence o f humans homozygous for the HD mutation in Venezuela supports the 
case for this being true in human HD. Therefore, the dominant effects o f mutant htt 
act not through loss o f the normal function o f the gene product
*  It should be noted  th e  Nasir e t  al. study w as n ot a com p lete inactivation o f  th e  Hdh gen e as 
in th e  D uyao e t  al. study, rather a disruption -  precisely, a prem ature term ination. Exons I -4  
w ere still expressed. H ow ever, this w as sufficient t o  cause em bryonic lethality.
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1.3.3 The Pofyghitamine Tract
In cloning the gene, the aetiology o f HD immediately became apparent Contained 
within exon I o f htt is a stretch o f nucleotide repeats. The codon CAG, coding for 
the amino acid glutamine, is repeated many times. The exact number varies widely 
from as few as 6 to  as many as 250 times. However, patients with HD always have a 
larger number. There is a threshold, somewhere between 34 and 37 repeats, at 
which the disease appears. Most normal individuals have between 11 and 35 CAG 
repeats, with most HD patients having greater that 35. In the original 75 Venezuelan 
families studied, 98% o f unaffected individuals had fewer than 24 CAG repeats, whilst 
100% o f HD patients had greater than 42 (Huntington's Disease Collaborative 
Research Group 1993). However, there is a ‘grey area’ between 35 and 40 repeats. 
There are cases o f HD in patients with 36 repeats, and yet there are also apparently 
healthy elderly individuals with 36-39 repeats. There has yet to  be a case o f HD with 
fewer that 36 repeats (Rubinsztein et al. 1996).
There is an inverse correlation between age o f  onset (and severity o f  
symptoms) and CAG repeat length (figure 4). However, patients with identical repeat 
lengths can differ in their ages at on set It seems there are a number o f modifiers 
which can either delay or promote onset o f the disease. One such factor was found 
in 1998. Vuillaume et al. demonstrated that the presence o f a glutamic acid 
polymorphism adjacent to  the CAG repeat reduces the age at onset (Vuillaume et al.
1998). Current estimates suggest that CAG repeat length alone accounts for up to  
74% o f  factors determining age at onset in HD (MacDonald et al. 1999). 
Furthermore, the fewer the number o f repeats the less they determine age o f onset. 
Figure 5 represents the same data used for figure 4  but with the variance at each 
repeat length added into the graphic. It is evident that as repeat size increases, variance 
is reduced. Also added is the number o f individuals in these studies at each repeat 
length. Less than 10% o f HD cases have a repeat size greater than 60, when this 
fraction o f the sample is removed from the calculation, CAG repeat length accounts 
for less than half o f the variability in age o f onset (Myers et al. 1998). It is reasonable 
to  assume that as CAG length increases the effects o f the expanded polyglutamine
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Figure 4 Relationship between CAG repeat sequence length and age at 
onset of HD symptoms. Data compiled form several published studies. 
There is an inverse correlation between the num ber of CAG codons and 
age at onset
A dapted from  J.F. Gusella e t al. Huntington's Disease in Cold Spring H arbor 
Symposia on Q uantitative Biology, Volum e LXI:
Function & Dysfunction o f  the Nervous System  
Cold Spring H arbor Laboratory Press 1996
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CAG Repeat Length
Figure 5 There is a greater variation among ages at onset with lower repeat 
sizes. As repeat size increases the effects of any modifiers are negated, thus 
repeat size alone becom es the major determining factor. The blue area 
indicates the number of HD individuals at any given repeat size. More than 
90% of cases are below 60 repeats.
A dapted  from  J.F. Gusella e t al. Huntington's Disease in Cold Spring H arbor 
Symposia on Q uantitative Biology, Volume LXI:
Function & Dysfunction o f the Nen/ous System  
Cold Spring H arbor Laboratory Press 1996
tract alone becom e greater thus negating the actions o f any modifiers (Stine et al.
1993; Brinkman et al. 1997).
13 A Instability and Anticipation
N ot only is there a variation between individuals within a particular generation, repeat 
lengths also vary from generation to  generation. The polyglutamine tract exhibits 
intergenerational instability, undergoing both expansions and contractions. However, 
there is a general tendency for the size to  increase (Gusella et al. 1993). This 
phenomenon is called anticipation, and is influenced both by the sex o f transmitting 
parent and the original length o f the repeat When transmitted from mother to  child 
the repeat length expands or contracts by around 4 CAG repeats, with a mild bias 
towards expansion. In the case o f paternal transmission the tendency for expansion is 
very much greater than that for contraction (Zuhlke et al. 1993). The degree of 
expansion is also size-dependent with the largest increases occurring during vertical 
transmission from males with the largest repeat length. It has been known for repeat 
length to  double from around Q 100 to  Q200 in this scenario (Ranen et al. 1995; 
Trotti e re ta l. 1995).
Marcy MacDonald et al. took four sets o f monozygotic twins and measured 
their repeat lengths; they were identical for each pair (MacDonald et al. 1993). They 
also measured repeat lengths in the same individual using brain, blood and lymphoblast 
DNA and found no variation. These results suggest that expansion occurs during 
gametogenesis, or very early on in embryonic life. In support o f this, they analysed the 
repeats in sperm from HD patients and found a remarkable amount o f variation. The 
apparent startling instability during spermatogenesis explains why paternal transmission 
o f  the faulty gene tends so greatly towards an increase. It also explains why in all 
documented cases o f  new expansions -  that is, patients with no previous family 
history o f HD -  the father has been found to have an intermediate length repeat In 
these cases, during spermatogenesis a repeat length just below the threshold for 
disease is expanded into the disease range and an apparently ‘sporadic’ case emerges.
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This also explains the global variation in the prevalence o f HD: African and Asian 
populations have fewer repeats, thus it is less likely for an expansion above threshold 
level to  occur. Furthermore, as expansion is size-dependent it is likely that any 
expansions that do occur will be o f fewer repeats than those seen in European or 
American individuals.
One group (Telenius eta l. 1994) reported mosaicism in all tissues found 
during a human post-mortem study, with the strongest variations found in brain and 
sperm. Within the brain the greatest variation was found in the basal ganglia, the 
focus for HD degeneration. These results have yet to  be replicated and subsequent 
human studies have found limited mosaicism in the somatic tissues o f HD patients 
(Benitez et al. 1995; De Rooij et al. 1995; Giovannone et al. 1997). However, 
evidence o f somatic instability has been found in the mouse models o f the disease. 
Both in the exon I transgenic mice, and the Hdh knock-in mice (see 2 .1 and 2.2) there 
exists somatic instability which mirrors the Telenius results: the greatest variation being 
found in the striatum. Certainly in the mouse models at least, somatic instability may 
play a role in the selective neurodegeneration (Kennedy and Shelboume 2000; 
Mangiarini et al. 1997).
Later work on model mice added to  this tale with the suggestion that the 
gender o f the embryo contributes to  polyQ variation. In the R6 mouse models (see 
2 .1) expansions are also predominantly through the paternal line, but there is a 
skewed variation between male and female progeny from the one father (Kovtun et al.
2000). Furthermore, the repeat distribution in the progeny does not reflect the 
repeat distribution in the sperm o f the father. Expansion does occur during 
spermatogenesis, but it seems male offspring may then undergo further expansion of 
the CAG repeat Due to  the variation in the sperm repeat lengths to  begin with, such 
an analysis is only possible with very lange numbers o f offspring. As a result w e do not 
know if this is true for human transmission.
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1.4 The Repeat Expansion Diseases
1.4.1 Polyglutamine Repeat Diseases
TINGTON’S disease is but one o f a number o f disorders caused by
ansion o f repetitive stretches o f DNA (see figure 6). In the case of HD
and (currently) nine other disorders the repeated sequence is CAG, which codes for 
the amino acid glutamine. In each disease the [CAG]n sequence is found within a 
different protein, and yet the effect is similar, the formation o f aggregates and 
degeneration o f a specific population o f neurons. Each o f the proteins shows no 
homology to  the others outside o f the polyglutamine tract, and yet the thresholds for 
the dominantly inherited diseases are similar: 30 to  40 glutamines*.
The fact that the native protein has little effect on the pathology supports the 
notion that the polyQ region confers a novel property on the protein: the toxic gain- 
of-function. Furthermore, in animal models, overexpression o f polyQ tracts in 
proteins not previously associated with disease, or the insertion of an elongated polyQ 
tract into proteins normally free from them produces neurological disorders 
concomitant with polyQ aggregates (Lin et al. 1999; Satyal et al. 2000; Warrick et al. 
1998).
Each o f the polyQ diseases also exhibits the properties explained earlier, 
including: somatic and germline instability tending towards exapansion; anticipation is 
greatest on paternal transmission; and increased repeat length is associated with a 
decreased age o f onset, together with increased severity o f symptoms. There is, 
however, a variation in the populations o f neurons affected. There is no explanation 
as to  why neurons in particular are affected in polyglutamine expansion disease, 
especially as the patterns o f expression include many non-neural tissues. Perhaps the 
novel property gained by expansion interacts with substrates found only in neurons. 
On the other hand it could be that the neuron is simply less able to  deal with the
* SCA6 in the exception, with a disease threshold slightly lower than the polyglutamine repeat 
disorders. SCA6 patients tend to  have between 20 and 30 CAG repeats.
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mutant protein. It would appear that extended polyglutamine tracts cause 
neunodegenerative disease, whilst the protein context confers the regional specificity. 
The functions of some o f the disease-affected gene products are known (see figure 6), 
and in one case at least can explain some o f the symptoms. The affected protein in 
spinal and bulbar muscular atrophy (SBMA) is the androgen receptor. Whilst the 
primary pathology in SBMA is motor neuron degeneration, androgen insensitivity is 
also seen, most ostensibly seen as breast development. In this case, loss o f function 
plays a small part in the disease as SBMA is X-linked. It may well be that loss of 
function has a phenotypic role in some o f the other disorders, but it is clear that the 
overriding cause of pathology, and thus the most important area o f study, is the gain of 
function conferred upon the mutant protein.
1.4.2 Non-Coding Repeat Expansion Diseases
There are (currently) nine known neurodegerenative diseases cause by expansions o f  
repeat sequences that are not located in coding segments o f the gene. Only one of 
these disorders is caused by polyglutamine, and three are caused by repeats of 
sequences greater than three nucleotides (see figure 6). These diseases tend to  have 
lapge and variable expansions, with a much larger threshold for disease. At the 
extreme, the pathogenic threshold for SCAIO requires 750 repeats o f the sequence 
ATTCT. Progressive myoclonic epilepsy type I (EPMI) has a threshold similar to  the 
expressed polyQ diseases -  30 -  but it must be taken into account that the repeated 
sequence is twelve amino acids in length (CCCCGCCCCGCG) and the normal 
population has only 2 or 3 repeats. Each o f these diseases results in multiple tissue 
dysfunction and degeneration. The specific pathology varies from diseases to  disease, 
and is dependent on the particular nucleotide sequence, its location within the gene, 
and the function o f the normal protein.
In the cases o f Fragile X  syndrome and Freidreich’s ataxia, the expansion o f the 
non-coding sequence leads to  a reduction or loss o f the normal protein. Both types
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HD Huntingtin 4p16.3 CAG PolyQ 6-35 36-121
SCA1 SCA1/ATX-1 6p23 CAG PolyQ 6-38 39-83
SCA2 SCA2 12q24 CAG PolyQ 14-31 32-77
SCA3 MJD 14q21 CAG PolyQ 12-40 54-86
SCA6 CACNA1A 19p13 CAG PolyQ 4-19 20-30
SCA7 SCA7 3p21.1-p12 CAG PolyQ 4-35 37-200
SCA17 TBP 6q27 CAG PolyQ 29-42 47-63
DRPLA Atrophin-1 12p13.31 CAG PolyQ 3-35 49-88
SBMA Androgen
receptor
Xq11-12 CAG PolyQ 9-36 38-62
HDL2 Junctophilin-3 16q23 CTG PolyL/PolyA 7-26 44-57
SCA12 PPP2R2B 5q31-33 CAG 5 ’ UTR 7-28 66-78
SCA8 SCA8 13q21 CTG UTR 16-91 107-127
SCA10 SCA10 22q13 ATTCT Intron 10-22 750-4500
EPM1 Crystatin B 21q22.3 CCCCGCCCCGCG 5 ’ flanking 2-3 30-75
DM1 DMPK 19q13.3 CTG 3 ’ UTR 4-37 50-4000
DM2 ZNF9 3q21 CCTG Intron «s26 75-11,000
Friedreich’s
ataxia
Frataxin 9q13 GAA Intron 8-22 120-1700
FRAXA FMR1 Xq27.3 CGG 5 ’ UTR 6-54 >230
FRAXE FMR2 Xq28 GCC Promoter 6-25 >200
Figure 6 T h e  re p e a t  ex p an sio n  d iso rd e rs  (see pp. 13-14 for abbreviations)
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o f Fragile X  syndrome (FRAXA and FRAXE) involve an expansion o f an untranslated 
trinucleotide sequence which results in hypermethylation and silencing o f the gene 
(Fu et al. 1991; Knight et al. 1993; Verkerk eta l. 1991). However, in Freidreich’s 
ataxia the disease arises from a [GAA.TTC]n expansion within intron I o f the gene 
(Frataxin). This expansion gives rise to  “sticky DNA” which inhibits transcription by 
sequestering RNA polymerases within the complex DNA structure (Sakamoto et al.
2 0 0 1). As these disorders result in the reduction or loss o f normal protein function 
they are inherited in a recessive manner. However, there is another group o f  
disorders all o f which exhibit a dominant inheritance pattern in spite o f the expansions 
being in untranslated regions.
Myotonic dystrophy (types I and 2), SCA8, SCA10, SCA12 and EMPI involve 
a variety o f  nucleotide repeats, each in a transcribed but untranslated region o f the 
associated gene. The pattern emerging is that novel gain-of-function properties are 
not confined to  proteins, rather mRNA molecules can act in a similar manner to  the 
polyglutamine-containing proteins discussed earlier. O f these disorders, the greatest 
amount o f work has been the investigating o f myotonic dystrophy. DM I results from 
an expansion o f a CTG region in the 3’ UTR of the DMPK (dystrophia myotonica- 
protein kinase) gene (Brook et al. 1992). Whilst not translated, the CTG region is 
transcribed and the [CUG]„-containing mRNA product is seen to  accumulate in 
nuclear foci. This alone would result in a loss o f the DMPK protein and a recessively 
inherited disease, but it has also been shown that these foci alter the regulation o f a 
number o f  CUG-binding proteins such as CUG-BPI, CUG-BP2 (Timchenko et al.
1996a; Timchenko et al. 1996b) and musdeblind (Miller et al. 2000). These nuclear 
factors are thought to  interact aberrantly with the CUG tract when it reaches a certain 
length due to  the extended CUG repeat sequence forming RNA hairpins which bind 
such factors (Miller et al. 2000). As a result o f the sequestration, the RNA splicing of 
several other genes is affected, including cardiac troponin T (Philips et al. 1998) and 
the insulin receptor (Savkur et al. 2 0 0 1), which may explain the cardiac defects and 
propensity for diabetes seem in DM I patients. The CCTG repeat in DM2 also 
produces foci of mRNA which also bind musdeblind (Mankodi et al. 2001), which may 
explain the similar phenotypes from tw o very different affected genes.
1.4.2 Huntingtons Disease-Like 2
Huntington’s Disease-Like 2 (HDL2) is a recently characterised disorder that has a 
very similar clinical presentation to  HD, and likewise, is an autosomal dominant 
condition (Mapgolis et al. 2001). However, it arises from a different expansion in a 
different gene: a CTG repeat sequence, within the JPH3 gene. JPH3 codes for 
Junctophilin-3, a protein involved in the formation o f junctional membrane structures, 
anchoring the plasma membrane to the endoplasmic reticulum. HDL2 has a similar 
repeat threshold to  HD (6-27 repeats in unaffected individuals and 50-60 in disease 
patients) and the repeat expansion is located within a translated region, but the 
genetics are more complicated than the other disorders. The [CTG]n sequence is 
located in a variably spliced exon o f the gene and, depending on splicing, the sequence 
can be translated or not translated. It is also read in more than one reading frame, 
producing either a polyleucine or polyalanine polypeptide chain (Holmes et al. 2001).
Given the similarity to  HD, it may be that the pathology results merely from 
the accumulation o f the polyL/polyA-containing protein. However, w e currently 
cannot rule out the possibility that HDL2 represents a mix o f pathogenic mechanisms 
involving toxic RNA effects as well as toxic protein effects.
1.4.4 A  Unified Pathogenesis?
It is possible that many codon repeat sequences, translated or not can cause disease 
once a threshold has been reached. The variety o f sequences seen in the non-coding 
repeat expansion disease suggests this might be the case. In these disorders the 
number o f repeats required to  cause pathogenesis also varies widely, from 50 (DM I) 
to  750 (SCA 10), which stands in contrast to  the limited range seen in the 
polyglutamine diseases. The high number o f diseases involving CAG repeats may 
reflect a particular property seen at its highest in glutamine, thus requiring the fewest 
repeats for pathogenesis.
1.5 Degradation, Aggregation and Inclusion Formation
1.5.1 Chaperones
DURING protein synthesis, RNA transcripts are translated to  yield a linear array of peptides. The polypeptide chain forms the primary structure of the protein, 
which then forms structural motifs producing the secondary structure. Such motifs 
include a-helices and p-sheets, which tend to  form unaided and in approximately the 
correct spatial relationship. However, at this stage the structure is unusually open and 
flexible: the molten globule. Conversion to  the correct tertiary structure normally 
requires the aid o f molecular chaperones to  adjust incorrectly folded side-chains (Ptrtsyn 
19 9 1; Christensen and Pain 19 9 1).
Molecular chaperones were first identified in £  coli as proteins whose 
expression is greatly increased following mild heat shock, hence they were termed 
heat shock proteins: hsp60 and hsp70. Upon exposure to  high temperatures proteins 
can become denatured, that is the (quaternary and) tertiary structure is altered and 
protein functionality is lost The purpose o f the hsps was believed to  be in aiding the 
refolding o f  proteins to  the correct confirmation (Visick and Clarke 1995). It is now  
apparent that they have a more constitutive role in protein folding (Craig et al. 1993; 
Agashe and Hartl 2000).
Eukaryotic cells have families o f chaperones related to  the bacterial heat shock 
proteins, with different family members particular to  cell organelles. During protein 
synthesis the polypeptide chain is exposed to  the cytosol and the possibility exists that 
certain residues will interact with cell components. The chaperones have an affinity 
for exposed hydrophobic residues on incompletely folded proteins. The term 
chaperone came into use as it was believed the components became bound to  
hydrophobic residues to  prevent unwanted, or premature reactions. It now seems 
that the chaperones play a more intimate role with nascent proteins, manipulating 
certain regions likely to  be incorrectly folded such that the protein is more likely to
incorrectly folded 
protein
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c o r re c tly  fo ld e d  
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Figure 7 Chaperone-mediated protein folding. As the polypeptide chain emerges form 
the ribosome members of the hsp70  family bind to  strings of hydrophobic residues 
preventing interaction with cytosolic components. If the protein remains incorrectly 
folded, or a previously folded protein loses tertiary structure, the hsp60 family, forming 
large barrel-like structures, isolates the protein from the cytosol until the protein is 
either refolded correctly or degraded by the proteasome (see 1.5.2).
A dapted from  Molecular Biology o f the Cell (3rd Ed.) Garland Press
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achieve the correct conformation (Rassow and Pfanner 1996; Becker and Craig 
1994). Figure 7 illustrates the different roles o f the hsp60-like and hsp70-like families 
o f chaperones.
1.5.2 The Ubiquitin-Proteasome System
In order to  maintain homeostasis, a dynamic equilibrium is necessary balancing 
anabolism and catabolism. Cellular components are continually made and broken 
down, the balance between these tw o is altered as circumstances demand. In both 
cases, accurate control over the specificity and rates o f reaction are needed. At the 
centre o f the degradation o f cellular components is the ubiquitin proteasome system 
(UPS). Selective proteolysis by the UPS occurs in tw o steps: firstly, the tagging o f the 
target substrate by the covalent attachment o f a 76-residue molecule, ubiquitin; 
secondly the degradation o f the tagged protein by the proteasome complex with 
subsequent release o f polypeptides and reusable ubiquitin (see figure 8).
Ubiquitination o f the target protein is mediated by a series o f enzymes. The 
ubiquitin-activating enzyme (EI) firstly activates ubiquitin by forming a high energy thiol 
ester intermediate (EI -S~ubiquitin). The activated ubiquitin is transferred via a second 
intermediate with one o f  many ubiquitin-conjugating enzymes (E2) to  a protein 
substrate bound to  a third enzyme, a member o f the large ubiquitin-protein ligase 
family (E3) which catalyses the transfer (Hershko 1983). Ubiquitin preferentially binds 
at lysine residues and ubiquitin itself contains an internal lysine residue, thus successive 
addition to  a target protein yields a polyubiquitin chain.
The polyubiquitin chain is recognised by the 26S proteasome complex, a 
multicatalytic protease that degrades proteins to  small peptides. It is comprised o f  
tw o structures, the 20S core particle and the 19S regulatory particle, which form a 
large barrel-shaped structure isolating the proteolytic subunits from the cytosol (see 
figure 9). The 20S unit contains four stacked rings, 2 outer a-rings and 2 inner (3-rings,
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Figure 8 The ubiquitin-proteasome pathway. Free ubiquitin is activated by the 
enzyme El and transferred via an E2 enzyme to  proteins recognised by a m em ber of 
the E3 family. Further ubiquitin is added forming a polyubiquitin chain which is 
recognised by the proteasome. The proteasom e unfolds the protein and degrades 
the polypeptide chain releasing peptides and free ubiquitin.
Image adapted  from  th e  MRC Hum an G enetics Unit w ebsite
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ATPases
20S core 1 19$ regulator
26S proteasome
Figure 9 Structure of the  proteasom e. The I9S regulatory unit of the 
proteasom e is com posed of a ‘lid’ recognising target proteins and a ‘base’ 
controlling entry into the catalytic core of the complex. The 20S core unit 
contains four stacked rings 2 outer (a) and 2 inner (P) rings, each com posed of 
seven subunits. Catalytic activity is localised to  subunits p I, p2 and p5 -  yielding 
six proteolytic sites in total (red).
Taken from  Kloetzel 2 0 0 1
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each (in eukaryotes) composed o f seven subunits. The catalytic activity is localised to  
three o f the P-ring subunits. The I9S unit caps either end o f the 20S unit and 
regulates the entry o f proteins into the proteolytic unit It recognises polyubiqu'rtinated 
proteins, and other substrates for the proteasome, and unfolds them for insertion into 
the 20S. The 19S is also responsible for opening the 20S, therefore restricting access 
to  the catabolic subunits when no recognition unit is in place. The unfolding of 
proteins and opening o f the 20S require energy and the 19S contains six different 
ATPase subunits (Zwickl et al. 1999).
Specificity in the system is determined by the ubiquitin-protein ligase family 
members and other ancillary proteins. In some cases either the E3 or the protein 
must be modified in some way before recognition occurs, phosphorylation or binding 
to  other proteins, for example. Phosphorylation can have opposite effects (preventing 
UPS recognition or enabling it) depending on the substrate, such that the activity o f a 
single kinase can increase the presence o f some proteins, whilst causing the loss of 
others. This provides another level o f control o f the turnover rates o f different 
proteins (Glickman and Ciechanover 2002).
Quite surprisingly, it is estimated that between 30% and 50% of polypeptide 
chains are degraded cotranslationally (Turner and Varshavsky 2000; Schubert et al. 
2000). It is suggested that the these nascent proteins contain errors in either coding 
or folding. As discussed, wrongly folding proteins are recognised by the molecular 
chaperones, but it is possible that the 19S unit interacts directly with these proteins. 
The proteasome itself can, in vitro at least function as a chaperone. The 19S has been 
shown to  bind certain unfolded proteins, accelerate their refolding and then release 
them in their native forms (Strickland et al. 2000; Braun et al. 1999). Increasingly, it 
seems that chaperones and the proteasome are linked in function. Not only does the 
I9S possess intrinsic chaperone properties, but chaperones have been shown to  
copurify with the pnoteasome.(Montel et al. 1999; Wagner and Margolis 1995) and in 
yeast overexpression o f Hsp70 can suppress growth defects associated with mutant 
20S subunits (Ohba 1997). It is probable that when chaperones fail to  restore the 
tertiary structure o f a misfolded protein they shuttle them to  the proteasome for
degradation, thereby limiting the effects o f any inappropriate properties the misfolded 
protein may possess.
1.5.3 The Neuronal Intranuclear Inclusion
When the Huntington’s disease gene was characterised in 1993 (Huntington’s Disease 
Collaborative Research Group 1993) the polyglutamine repeat aetiology became 
apparent Whilst it seems clear that pathology arises from a dominant gain o f function 
(see 1.3) the exact novel physical property underlying this change remains elusive. 
Given the extensive cellular machinery that exists to deal with misfolded or incorrectly 
translated proteins, it is reasonable to  assume that cells expressing mutant or 
abnormal protein would mount a response against their effects. In studying the 
degradation o f abnormal proteins in neurological disease, li etal. (1997) examined 
structures known to  be ubiqurtinated in neurological disease (AD, PD) and the elderly. 
They found colocalisation o f proteasome components in certain structures but not in 
others. For example, in Alzheimer’s disease both the dystrophic neurites and 
neurofibrillary tangle are ubiqurtinated, but the proteasome is only found the former. 
Davies et al. (Davies et al. 1997) conducted similar studies on transgenic mouse 
models o f Huntington’s disease (see 2 .1). Using antibodies raised against the N- 
terminal o f huntingtin, they examined three lines o f mice transgenic for exon I o f the 
human htt gene with an expanded polyglutamine repeat. In control brains the 
distribution was similar to  that seen in adult human brains with labelling o f the entire 
grey matter, localised to  the cytoplasm of neurons along with the axons and dendrites. 
In the transgenic mice, however, in addition to  the staining seen in the control a 
‘densely stained circular inclusion’ is seen within neuronal nuclei. The Davies et al. 
study also used anti-ubiquitin antibodies and found the newly named neuronal 
intranuclear inclusion (Nil) also stained for ubiquitin (see figure 10). Subsequent analysis 
has also revealed many other components o f the pathways discussed in 1.5 .1 and 
1.5.2 colocalise to the Nil in mouse and cell culture as well human tissue, including
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Figure 10 Huntingtin (A.C) and ubiquitin (B,D) immunoreactivity in the stnatum 
of the R6/2 mouse (see 2 .1). Nuclear inclusion are evident throughout the 
striatum (A,B). DAB reaction product is seen together with a discreet structure 
an the electron microscope level (C,D). Scale bar for (C) and (D) 500nm.
A dapted from Davies e t al. 1997
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chaperones Hsp70, Hsp40, BiP & HDJ-2 and proteasome components 20S, 19S & 
11S (Waelter et al. 2 0 0 1; Davies et al. 1999). These results suggest that the neuron 
attempts to  contain the mutant protein via the chaperone response and as the protein 
cannot be folded correctly it is degraded, or at least an attempt is made, by the 
proteasom e. W hy the mutant protein, together with the chaperone/UPS  
components, forms inclusions is another unresolved issue. However, they now appear 
to  be the hallmark o f Huntington’s disease.
Since their discovery in transgenic mice, neuronal intranculear inclusions have 
been identified also in human HD post-mortem tissue (Becher et al. 1998; DiFiglia et 
al. 1997). It has also become apparent that although not named as such, the Nil was 
discovered in human HD biopsy tissue in 1979 by Roizin et al. (Roizin et al. 1979). 
Furthermore, studies on human HD show that not only is the mutation localised to  
exon I but that the huntingtin that forms the inclusions is a truncated form from the 
N-terminus. It is probable that the neuron makes an attempt at proteolysis but 
cannot degrade the polyglutamine, thus leaving the N-terminal truncated forms to  
aggregate.
1.5.4 Neurite Inclusions
The Neuronal Intranuclear Inclusion is not the only aggregate seen in Huntington’s 
disease. With techniques similar to  those used in the identification of the Nil, one can 
identify intensely staining structures outside the neuronal nucleus. In human biopsy 
material as well as the mouse models it is apparent that dystrophic neurites also 
contain inclusions composed o f ubiquitinated N-terminal huntingtin (DiFiglia et al.
1997). In cell culture models o f HD, aggregation o f mutant huntingtin occurs both in 
the nucleus and the cytoplasm (Cooper et al. 1998) and is probable that such 
cytoplasmic aggregation underlies the neuritic degeneration.
1.5.5 Aggregation
The mechanism by which mutant huntingtin, together with the many components also 
recruited, form inclusions remains unclear. The late Max Perutz postulated that the 
expansion of a polyglutamine stretch beyond a certain length would lead to  a phase 
change from random coils to  hydrogen-bonded hairpins. These would naturally tend 
to  associate with each other and form highly stable p-sheets: the polar zipper model 
(Perutz 1996). In vitro, N-terminal huntingtin with expanded polyglutamine stretches 
can indeed form aggregates* rather like the beta-amyloid fibrils seen in Alzheimer’s 
disease (Scherzinger et al. 1997).
A second model states that aggregation results from the activity o f tissue 
transglutaminase (tTG). It has been shown in cell culture that protein polyglutamine 
stretches are substrates for tTG, with longer stretches resulting in greater tTG activity. 
Furthermore, the addition o f tTG inhibitors reduces the degree o f aggregate 
formation. As a result it has been suggested that it is this activity that leads to  the 
formation o f aggregates via the creation o f isopeptide bonds which crosslink polyQ- 
containing proteins (Kahlem et al. 1998). There is some support for this occuring in 
vivo as elevated tTG levels and activity can be found in HD brains (Karpuj et al. 2002), 
however the areas o f increased tTG activity do not correlate well the the distribution 
o f  Nils (Vonsattel and DiFiglia 1998) and increasing tTG levels does not affect 
aggregate formation (Chun et al. 2 0 0 1).
Wyttenback et al. treated transfected cells with heat shock and lactacystin (a 
proteasome inhibitor) and found that both increased the amount of htt exon I found 
in the inclusions (Wyttenbach et al. 2000). They suggest that inclusions form when 
the chaperone/proteasome system cannot cope with the mutant protein. This can be 
interpreted as the chaperone/proteasome system binding to  the mutant protein 
preventing p-sheet formation and/or transglutamination.
* Under very non-physiological conditions.
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1.5.6 Inclusions and Disease
The discovery o f the Nil and neurite inclusions in Huntington’s disease means that HD 
joins a growing number o f  neurological diseases associated with the formation o f 
aggregates. There are a number o f  different structures, som e characteristic o f a 
particular disorder, others occurring in many diseases, each with a different protein 
constitution (see figure 11). What is clear is that aggregation is a common event in 
many diseases involving many proteins, which suggests that either cells are particularly 
vulnerable to  the accumulation o f protein, or that a cellular response exists which 
purposefully aggregates harmful protein. There is evidence to  suggest that formation 
o f the inclusion is beneficial to  the cell (see 1.6.3), providing support for the evolution 
of a cellular response to  aggregate harmful protein.
W hether the neuronal intranuclear inclusion is the underlying cause o f  
pathology in HD, or whether it is simply a symptom o f the mutant protein load 
remains under debate.
Inclusions Disease Components Cell Type
cytoplasmic
Ballooned neurons Pick’s, CBD, AD, CJD, 
ALS
Neurofilaments Neurons
Dystrophic neurites AD, PD, DLBD, MND, 
CBD
a-synuclein,
proteasomes
Neurites
Granulovascular bodies AD, normal ageing Neurofiliaments and 
tau
Neurons (vacuoles)
Lewy bodies PD, DLBD a-synuclein, a - 
crystallin, proteasome
Neurons
Lewy body-like ALS Neurofilaments Motomeunons
Neurofibrillary tangles AD Paired helical filaments, 
HSPs
Penkarya
Pick bodies Pick’s disease PHF with tau Neurons
Rosenthal fibres Alexander's disease a-crystallin, 
intermediate filaments
Astrocytes
Endosomal/lysosomal
Lysosome-nelated structures TSE, AD Pnon protein, HSP70 Neurons
Bunina bodies ALS Vimentin, HSP70 Neurons
nuclear
Intranuclear inclusion CAG repeat diseases Gene products, HSPs, 
proteasome, a -  
synuclein
Neurons
Figure I I The variety of inclusions seen in neurological disease (se e p p  13-14 for abbreviations)
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1.6 The Nature of the Inclusion
1.6.1 The Neurotoxic Nature o f Inclusions
IN adult HD brains, Nils are found in the striatum and cortex, but rarely in the hippocampus, red nucleus and cerebellum, which correlates well with the 
degeneration seen in adult HD (Becher et al. 1998; Sieradzan and Mann 2001). 
Furthermore, in the juvenile form o f HD the cerebellum also degenerates and in this 
case, inclusions are found in the cerebellar Purkinje cells. Whilst one cannot rule out 
the possibility that the inclusion is merely another symptom o f degeneration, these 
data have led many to  suggest a causal relationship between inclusion formation and 
neuronal degeneration
Various N-terminal fragments o f  mutant huntingtin have been shown to  form 
aggregates in vitro and in vivo. In general, the propensity for aggregation increases with 
increasing polyglutamine length and decreasing non-glutamine content (Martindale et 
al. 1998; Li and Li 1998). This suggests that polyglutamine stretches tend to  aggregate 
naturally, arguing against a cellular mechanism for aggregation. In this case, the 
variation in inclusion distribution may arise from the ability o f the cell to  degrade the 
protein before it aggregates. In a Drosophila model o f HD, aggregation has been 
limited through the expression o f an artificial huntingtin-binding polypeptide. Inclusion 
appearance was limited as were both neuronal degeneration and death (Kazantsev et 
al. 2002) further suggesting a relationship between the formation o f inclusions and 
degeneration.
Bucciantini et al. expanded the issue o f aggregate formation by showing that 
many proteins are capable o f  aggregating into defined structures, and that these 
structures have an inherent toxicity (Bucciantini et al. 2002). Under certain conditions 
Bucciantini et al. caused tw o proteins not previously associated with disease to  
aggregate; the SH3 domain from bovine phosphotidyl-inositol-S’-kinase and the N- 
terminal o f £. coli HypF protein. The addition o f these aggregates (at certain stages of
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aggregation) to  cell culture media proved cytotoxic whereas the native proteins did 
n ot suggesting that protein aggregates in general are toxic to  cells.
1.6.2 The Toxic Fragment Hypothesis
Huntingtin was the first neuronal protein to  be shown to  be a caspase substrate 
(Goldbepg et al 1996). It has since been established that the protein contains cleavage 
sites for caspases 2, 3 and 6 (see 1.7.4). Caspase neoepitopes* have been detected in 
both normal and HD brains (Wellington et al. 2002). Other proteases are presumed 
to  cleave huntingtin as multiple fragments o f N- and C-termini have been detected 
with varying amounts according to  region and HD status (Mende-Mueller et al. 2001), 
however the studies referenced in 1.6.2 were able to  prevent aggregate formation by 
preventing the cleavage o f huntingtin using caspase inhibitors. Likewise, Wellington et 
al. have generated yeast artificial chromosome mouse models o f HD, including a 
model with huntingtin lacking caspase 3 and 6 cleavage sites. In these mice, aggregate 
formation and toxicity is also reduced (Wellington et al. 2000). The R6/2 mouse 
model (see 2 .1) is widely used as it exhibits the most aggressive phenotype. In this 
model huntingtin is already in a truncated form.
The toxic fragment hypothesis centres around the cleavage o f huntingtin as the 
key event The N-terminus alone is sufficient to  cause neurodegeneration (Mangiarini 
et al. 1996), and proteins with fewer nonglutamine residues flanking the repeat 
sequence are o f greater toxicity (Martindale et al. 1998). The generation o f N- 
terminal fragments is believed to  bring about the entry o f the cell into a vicious circle. 
Caspase cleavage o f htt generates the N-terminal fragments, the inherent toxicity of 
which causes apoptotic caspase activation, which in turn causes more htt cleavage 
(Hackam et al. 1998; Cooper et al. 1998; Saudou et al. 1998). There is little doubt
* Epitopes produced only when a protein is cleaved a t a particular site, in this case the  caspase 
cleavage sites
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that the N-terminal fragment is more toxic that full length mutant protein, but 
whether this vicious circle exists in vivo remains to  be seen.
1.6.3 The Newroprotective Nature of Inclusions
It is clear that the accumulation o f mutant N-terminal huntingtin leads to  dysfunction 
and death, but some argue that the aggregate ameliorates this effect The studies 
listed above prevent aggregate formation by preventing cleavage o f huntingtin. 
According to  the toxic fragment hypothesis, this alone will reduce toxicity. 
Furthermore, suppression o f Nil formation between the stages o f cleavage and 
aggregation proves more toxic to cultured cells transfected with mutant htt (Saudou 
etal. 1998).
Nuclear inclusions also form in SCAI. The mutant protein, ataxin I, contains a 
self-association region which promotes aggregation on top o f the polyglutamine 
effects. Transgenic mice have been generated with a deletion in this region (Klement 
et al. 1998). Whilst aggregation is significantly reduced, and Nils are not observed, 
degeneration o f the Purkinje cells still occurs.
Closer analysis o f inclusions in human post-mortem brain has found that 
distribution in terms o f cell type, rather than region, does not correlate with HD 
pathology. Nils are more frequent in the cortex yet most degeneration occurs in the 
striatum (Gutekunst et al. 1999). Furthermore, Nils are found in striatal intemeurons, 
which are completely spared in HD (Kuemmerle et al. 1999). Many of the studies 
purporting a link between aggregate formation and cell death in vitro relate amount of  
apoptotic activity to  amount o f aggregate formation, but one study analysing sensitivity 
to  apoptotic stimuli in N-htt transfected cells compared distribution o f Nils to  caspase 
activity. Whilst in general the mutant htt tranfected cells were more susceptible to  
apoptosis, there was no correlation between Nil formation and such apoptotic 
sensitivity (Chun et al. 2002).
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The Bucciantini et al. study mentioned in 1.6.1 (Bucciantini et al. 2002) shows that 
under the right conditions many proteins can form aggregates. In the case of the Hyp- 
F-N induced aggregation, the structure changed over time. Within minutes of being 
placed in a pH5.5 solution the protein formed amorphous aggregates with p-sheet 
properties. Over time, up to  20 days, these structures organised themselves into 
protofibrils and then fibrils in a manner similar to  p-amyloid (Walsh et al. 1999). 
Extracts taken at later times and added to  cell culture media prove less and less toxic. 
As the protein changes from amorphous aggregate to  regular fibrillar structure toxicity 
lessens. A similar pattern has been shown for p-amyloid itself and a-synuclein; the 
prefibrillar structures are more cytotoxic in both cultured cells and transgenic mice 
(Conway et al. 2000; Hartley et al. 1999; Pillot et al. 1999).
The toxicity o f prefibrillar structures is likely to  arise as hydrophobic sidechains, 
and other regions, are much more exposed. In other words, the fully formed fibrils 
are less likely to  cause abnormal protein-protein interactions. This would imply that 
the Nil is rather a benign structure. Given the apparent toxic nature o f the 
polyglutamine-containing fragments, such aggregation as is observed can be considered 
a beneficial effect
1.6.4 InteractioTis
Huntingtin has been shown to  interact with a large number o f other proteins. Many 
o f these have also been shown to  vary according to  polyglutmaine length. One can 
therefore conclude that mutant htt interacts abnormally with cellular proteins. 
Huntingtin interacting proteins include:
Glyceraldehyde-3-phosphate dehyrogenase (GAPDH)
Calmodulin
Huntingtin-inteacting protein I (HIPI)
Huntingtin-interacting protein 2 (HIP2)
Huntingtin-associated protein I (HAP I)
Huntingtin-associated protein 40 (HAP40)
W W  domain proteins
Cystathionine 0-synthase
SH3-containing Grb-like protein 3 (SH3GL3)
GAPDH has been shown to  interact directly with the polyQ tract and interacts more 
strongly with smaller fragments (Burke et al. 1996). It has been suggested that this 
interaction results in impaired glycolysis in HD, perhaps underlying som e o f the  
dysfunction. However, studies on human HD post-mortem tissue have found normal 
GAPDH activity (Kish et al. 1998).
Huntingtin from HD brains has been shown to  bind calmodulin in the 
presence o f calcium more avidly than wild-type huntingtin (Bao et al. 1996). 
Calmodulin is small regulatory protein which binds calcium. With calcium bound it 
interacts with many target proteins, with either inhibitory or stimulatory roles, thus 
providing a multi-target mediator in calcium signalling. Once again, this preferential 
interaction with expanded huntingtin may have some bearing on cell dysfunction.
Huntingtin-interacting protein I (HIPI) was identified through its altered 
interaction with mutant htt. The interaction with htt becom es weaker as 
polyglutamine length increases. Its function was unknown at the time, but 
overexpression resulted in caspase 3-mediated cell death (Hackam et al. 2000). HIP I 
contains a death effector domain (DED) (see 1.7.5) the overexpression o f which 
alone is sufficient to  induce the caspase 3-mediated cell death seen. If the DED is 
mutated out o f HIP I the toxicity is eliminated entirely (Hackam et al. 2000). Thus, the 
greater the polyglutamine length the more free HIP I (and DEDs) there is. It has since 
been shown that HIP I is involved in dathrin-mediated endocytosis. It is found to  be 
enriched on coated vesicles where it binds to  adapter protein 2 (AP2) and the dathrin 
heavy chain. Furthermore, expression o f truncated HIP I blocks clathrin-mediated 
endocytosis (Metzler et al. 2001). Its interaction with huntingtin is therefore very 
interesting given the suggested roles o f htt in vesicle trafficking.
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Huntingtin-interacting protein 2 (HIP2) has been identified as the ubiquitin-conjugating 
enzyme hE2-25K (a member o f  the E2 family; see 1.5.2). HIP2 in expressed 
throughout the body, but a slightly larger version is expressed in brain, most probably 
resulting from alternate splicing. The interaction o f HIP2 with huntingtin does not vary 
with polyglutamine length, casting doubt on this interaction underlying the  
ubiquitination o f mutant htt, or the interaction being part o f a chaperone response, 
nevertheless it may have an ancillary role in the processing o f mutant huntingtin 
(Kalchman et al. 1996).
Huntingtin-associate protein I (HAPI) is another huntingtin interacting protein 
with a role in vesicle function. It is predominantly a membrane-associated protein 
enriched, much like huntingtin, on synaptic vesicles (Li et al. 1995). It has also been 
suggested that HAP I, in its tw o isoforms, is involved in the formation o f the stigmoid 
body through self-association (Li et al. 1998) Mice have been generated with 
disruption to  the HAP I gene. These mice die in the early postnatal period due to  
depressed feeding behaviour. With the exception o f starvation-associated changes, 
there appears to  be little change on post-mortem examination (Chan et al. 2002). 
The interaction o f HAP I with huntingtin is the reverse situation to  HIP I, namely as 
polyglutamine length increases as does the affinity with HAP I. It is possible that the 
self-associative nature o f HAP I aids the aggregation o f  huntingtin. Furthermore, as 
disruption o f HAP I can produce profound behavioural changes in the absence of 
gross pathology, it is possible that the sequestration o f HAP I by mutant huntingtin is
the cause o f some o f the psychological changes seen in HD.
Huntingtin-associated protein 40 (HAP40) is so called as it is a 40kDa protein 
which interacts with normal huntingtin. HAP40 is encoded within intron 22 o f  the 
Factor VIII gene. Normal huntingtin appears to  anchor HAP40 to  the cytoplasm of a 
cell, without this normal action, HAP40 is actively translocated to  the nucleus (Peters 
et al. 2002). The implications o f this are unclear, but it may indicate a role in the 
normal function o f huntingtin which is disrupted in the disease state.
The W W  domain proteins consist o f  three proteins that interact with
huntingtin N-terminus, both wild type and mutant via the same region: the W W  
domain. These proteins, HYPA, HYPB and HYPC interact with the proline-rich region
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adjacent to  the polyglutamine region o f huntingtin. The interaction is enhanced as the 
polyglutamine tract lengthens (Faber et al. 1998). HYPA is known to  be involved in 
spliceosome function, and HYPC has since been shown to  have a similar function. 
HYPB has also been identified as a transcription factor, thus it is suggested that altered 
mRNA production and maturation may play a role in HD pathogenesis (Passani et al. 
2000).
Cystathionine P-synthase binds to  huntingtin but no other polyglutamine- 
containing proteins. Furthermore, this interaction is independent o f polyglutamine 
length, suggesting an interaction with a region outside o f the N-terminus (Boutell et al.
1998). Cystathionine p-synthase is a key enzyme in the conversion o f methionine to  
cysteine. The condition homocysteinuria is an autosomal recessive disorder resulting 
from the absence o f cystathionine p-synthase, which leads to  a build-up o f  
homocystein, one o f the substrates o f the enzyme. Symptoms include severe mental 
retardation, seizures and psychiatric disorders. Tw o oxidation products o f  
homocysteine, homocysteate and homocysteine sulphate, are potent NMDA receptor 
agonists. It is suggested that an accumulation o f huntingtin may hinder the normal 
function o f the enzyme resulting in a build-up o f the homocystein oxidation products 
and promotion o f excitotoxic damage (see 1.8.1).
SH3-containing Grb-like protein 3 (SH3GL3) preferentially binds the N- 
terminal fragment o f huntingtin with an expanded polyglutamine tract Furthermore, 
transfection o f mutant htt-expressing cells with SH3GL3 promotes aggregate 
formation (Sittler et al. 1998). SH3GL3 is preferentially expressed in brain and testis, 
hence it may have an effect on inclusion formation in vivo. There is a further link 
between huntingtin and vesicle function as SH3GL3 plays a major role in the 
regulation o f the exo/endocytic cycle o f synaptic vesicles (McPherson 1999).
As has been established, huntingtin interacts with a variety o f proteins, and in 
some cases there is a preferential interaction with mutant huntingtin. In the course of 
Huntington’s disease, with both free huntingtin and the Nil-contained htt it would be 
foolish to  believe that events are limited to  the direct effects o f the huntingtin 
mutation per se.
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1.7 Apoptosis
1.7.1 The Physiological Role o f Apoptosis
^tfOPTOSIS, the Greek word describing the “falling o ff’ of leaves from a tree, was 
f  \  used in 1972 by Kerr, Wyllie and Currie to  describe a “mechanism of 
controlled cell deletion, which appears to  play a complimentary but opposite role to  
mitosis in the regulation of animal cell populations” (Kerr et al. 1972).
Apoptosis is a fundamentally important process in all multicellular organisms, 
essential for the development and, in vertebrates at least the maintenance o f the 
organism. During metazoan development numerous structures are formed which are 
removed by apoptosis at a later stage (Jacobson et al. 1997). This affords a greater 
degree o f flexibility as primordial structures can be remoulded or removed for 
different functions at later stages in life, or sex. For example, the Mullerian duct which 
forms the uterus and oviduct in females is removed apoptotically in males. On the 
other hand, the Wolffian duct which forms the male reproductive origans is removed 
in females. Likewise, there are many structures which form during development that 
are evolutionary hold-overs, structures which produce functioning tissues in lower 
organisms but which are no longer needed, these too  need deleting. The apoptotic 
pathways also act as a check mechanism for the developing organism, correcting many 
errors which may occur. For example, Drosophila dosed with extra bicoid (bed), a 
morphogen, initially develop severely mispattemed anterior regions, but the apoptotic 
checking means these develop into relatively normal adults (Namba et al. 1997).
The ability to  induce rapid and selective suicide in supernumerary, misplaced or 
dysfunctional cells is thus o f vital importance to  the development and survival o f the 
organism. This is further exemplified by the large number o f diseases which result 
from a dysregulation o f apoptosis with consequences including tumorigenesis, 
autoimmunity, neurodegenerative disease, hematopoietic deficiencies and infertility
58
1.7.2 Identifying the Apoptotic Machinery
The initial work on the molecular machinery underlying apoptosis was carried out on 
the nematode worm C. elegans, which is particularly useful for such development 
studies as its developmental programme never varies. The fate o f each cell in the 
development o f the C. elegans adult worm has been mapped from start to  finish. 
Sulston and Horvitz noted that during development 13 1 o f the 1090 somatic cells of 
C elegans are removed apoptotically (Sulston and Horvitz 1977). Genetic screens for 
mutants defective in this development revealed a number of genes responsible for the 
regulation and execution o f apoptosis. The four crucial genes for C. elegans cellular 
demise are egf-l, ced-3, ced-4 and ced-9. Loss o f function o f either egl-l, ced-3 or ced- 
4 results in survival o f all 131 cells which are normally removed. In contrast loss o f  
ced-9 function results in massive, lethal, cell death early in development. As over­
expression o f ced-9 leads to  survival o f the 13 1 cells, it is clear that ced-9 is a 
suppressor o f apoptosis (Horvitz et al. 1983). These proteins are highly conserved 
throughout evolution, illustrating the importance o f the apoptotic machinery, and each 
o f the C. elegans death proteins has a homologue in human apoptosis.
1.7.3 The Morphology o f Apoptosis
The original definition o f apoptosis by Kerr, Wyllie and Currie in 1972 was based on 
morphological descriptions alone. It was defined as occurring in tw o discrete stages. 
Firstly, the dying cell undergoes nuclear and cytoplasmic condensation and fragments 
into membrane-enclosed, ultrastructually well-preserved fragments (apoptotic bodies). 
The second stage involves the engulfment o f the apoptotic remnants by other cells 
where they are degraded (illustrated in figure 12) (Kerr et al. 1972).
The earliest changes identified in the original work involve the condensation 
and aggregation of nuclear chromatin beneath the nuclear envelope. This is followed 
by shrinkage, both nuclear and cytoplasmic, and nuclear fragmentation (figure 13A).
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Figure 12 An illustrative summary of apoptosis. The dying cell undergoes a series of 
changes beginning with nuclear and cytoplasmic condensation. Chromatin condenses 
whilst the nuclear membrane initially remains intact. The plasma membrane “blebs” 
eventually leading to  fragmentation of the cell into membrane-bound, ultrastructurally 
well-preserved fragments (apoptotic bodies). These apoptotic remnants are engulfed 
by other cells whereupon they are degraded lysosomally.
Image adapted  from  Kerr & Harman: Definition and Incidence o f  Apoptosis: An Historical 
Perspective -  In Apoptosis: The Molecular Basis o f  Cell Death 
Cold Spring H arbor Press
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Figure 13 Electron micrographs of the 
stages of apoptosis. (A ) Condensation 
of chromatin (vacuolation varies 
according to cell type). (B) Formation of 
apoptotic bodies (note that whilst this 
the cell fragment is highly condensed the 
ultrastructure is still well-preserved). (C) 
Recognition and engulfment by 
phagocytes.
Scale bars A  5 (am B.C I (am.
A -  Cultured cell o f unknown type. Taken 
from Molecular Biology o f the Cell. Alberts et 
al. 4 th Ed.
B -  M ouse spinal cord, P4.5. C ourtesy of 
Elizabeth Slavik-Smith 
C -  Cerebral apoptotic death in th e  macular 
m utant mouse, Courtesy o f D r O hno  
(O hno et al. 2002)
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The cell surface also undergoes changes in the form o f the development o f  
protuberances, a process since labeled “blebbing”, which eventually separate off 
forming apoptotic bodies. The bodies themselves are o f greatly varying size, though all 
compact, and are structurally well-preserved containing closely packed organelles 
which may themselves be condensed, but which are believed to  be chemically and 
structurally intact (figure 13,B).
In ail o f the tissues studied in the original work, the majority o f apoptotic 
bodies were found within the cytoplasm o f intact cells, suggesting they are very rapidly 
phagocytosed. It was postulated (and has since been proven) that this results from 
changes to  the cell surface o f the apoptotic cell which are recognised and contacted 
by phagocytic cells (figure 13,C). Once phagocytosed, the bodies begin to  degrade in 
a process that is “ultrastructurally very similar to  ischemic coagulative necrosis and in 
vitro autolysis” (Kerr et al. 1972). In essence, the bodies begin to  lose their structural 
integrity and it was suggested that this results merely from their inability to  maintain 
homeostasis within the phagocytosing cell. The bodies are then further degraded by 
lysosomal enzymes from the engulfing cell and are rapidly reduced to  electron-dense 
lysosomal bodies.
The apoptotic journey is over fairly quickly. The entire process, from the initial 
changes in chromatin and cell condensation through to  the complete degradation of 
apoptotic bodies within phagosomes, was said to  be completed within twenty-four 
hours (Kerr et al. 1972). N o work has yet contradicted this statement
Since 1972 the field o f apoptosis research has continued to  expand. The 
identification o f the genetics and proteins involved in apoptosis led to  an explosion of 
interest in programmed cell death, and as a result the number o f publications on 
apoptosis each year has risen almost exponentially since the early nineties (figure 14).
The field o f apoptosis research is now phenomenally large, which brings with it 
both complication and confusion. To describe all the known apoptotic processes and 
cellular machinery would make this discourse too  large and confusing; therefore an 
overview o f the key elements will be presented here and a discussion o f some o f the 
confusions and errors that have arisen in the field can be found in chapter 5.
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Figure 14 The number of publications on apoptosis each year since 1972, the year in which the term  was 
coined. The identification of the molecular mechanisms throughout the early nineties led to  an explosion of 
work in the field.
D ata gathered from  Pubm ed searches using "apopt*" O R  “program * cell death" as term s.
Thirty years after its denomination w e have a far greater understanding o f apoptosis, 
particularly the molecular mechanisms behind the process. Today w e divide the 
process into three broad stages: the initiation phase, the execution phase and the 
degradation phase. Each involves what is generally considered the most important 
family o f proteins in cell death, the caspases.
1.7.4 Caspases
The caspases are a family o f  homologous proteases highly conserved throughout 
evolution. Each and every caspase possesses an active-site cysteine and cleaves 
substrates after aspartic acid (Asp) residues. Beyond this, the specificity o f  each 
protease is determined by the four amino acids to  the N-terminal side o f the Asp-Xxx 
cleavage site (Nicholson and Thomberry 1997; Thomberry et al. 1997). The caspases 
cleave a restricted set o f target proteins, usually at very few positions, making them  
“surgical tools” rather than general proteases. Around one hundred substrates have 
so far been identified, and more are continually being found. It is unlikely that all of 
these are involved in the death pathway, rather there are many ‘bystanders’ cleaved 
for no specific purpose other than general degradation o f cellular components. In the 
majority o f cases caspase cleavage o f a protein causes its inactivation, but there are 
cases whereby caspase cleavage activates proteins, either directly, by cleaving off a 
regulatory domain o f the target protein, or indirectly, by inactivating a repressing 
regulatory subunit (Nicholson 1999; Eamshaw eta/. 1999).
Like many enzymes, caspases are synthesised as inactive precursors 
(zymogens), the procaspase precursor being composed o f three domains: an N- 
terminal pro-domain, a p20 domain and p 10 domain (figure 15). Activation o f the 
enzym e can occur in th ree  ways. M ost com m only, th ey  are 
activated by another caspase. The tw o cleavage sites between each o f the three 
domains are Asp-Xxx sites, thus making caspases themselves targets for caspase- 
mediated proteolysis. Hence the term, caspase cascade; activation o f any o f the
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Figure 15 Caspases are synthesised as inactive zymogens consisting of th ree 
domains: plO domain, p20 domain and a prodomain of varying length (long for 
upstream caspases, short for downstream). Activation occurs through cleavage -  
by either another active caspase o r induced proximity with another procaspase -  
between the plO and p20 domains (blue arrow) and usually also between the p20 
and prodomains (green arrow). The active enzyme is a hetero tetram er of tw o 
p20 and tw o plO domains containing tw o active sites (AS). The exception is 
caspase-9 which is activated by the formation of a holoenzyme with Apaf-I and 
cytochrome c.
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caspases results in cleavage and activation o f others in a self-propagating manner. The 
mature caspase enzyme is a heterotetramer consisting o f tw o p20 and tw o plO 
domains, thereby yielding tw o active sites (figure 15).
The procaspase zymogens are not completely enzymatically inactive, rather 
they are o f limited efficacy. The second method o f activation utilises this fact, and is 
described in 1.7.5 in terms o f Fas-mediated activation o f apoptosis. By recruiting 
procaspases into limited regions -  induced proximity -  the reduced autocatalytic 
properties of the zymogens are sufficient to  cause cleavage and activation.
The third method o f activation does not involve cleavage at all. In the case of  
procaspase-9, association with the regulatory subunits o f apoptosome (Apaf-1 and 
cytochrome c) alters the protein confirmation in such a way as to  confer full efficacy 
on the active site, making it a holoenzyme (Rodriguez and Lazebnik 1999). Indeed, 
proteolytic cleavage o f procaspase-9 yields only a minor increase in catalytic activity 
(Stennicke et al. 1999).
Generally, caspases activated via their association with other units are the 
upstream caspases (such as caspase-9, caspase-2, caspase-8 and caspase-10) and have 
long prodomains to  accommodate the various elements underlying the interactions, 
such as the DED and CARD described in 1.7.5, whereas the downstream caspases 
(including caspase-3, caspase-6 and caspase-7) have short prodomains and are 
activated by proteolysis.
1.75 Initiation
The initiation o f apoptosis can be divided into tw o pathways: intrinsically- and 
extrinsically-signalled apoptosis. Intrinsic activation can result from a number o f  
factors, including DNA damage, serum starvation and the actions o f some steroid 
hormones and drugs (chemotherapy). In the case o f hormones, serum starvation and 
som e drugs, apoptosis is initiated via the alteration o f gene expression, tipping the 
balance o f pro- and anti-apoptotic factors in favour of the former (see 1.7.6). DNA
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damage, o f chemical, physical, drug-induced or spontaneous origin leads to  the 
activation o f the protein p53. Activation of p53 leads to  the release o f cytochrome c 
from the mitochondria, although the exact mechanism remains unclear. p53 is a 
transcription factor and thus is was suggested that p53 activation leads to  upregulated 
expression o f pro-apoptotic factors, in particular the protein Bax (see 1.7.6). 
However, it has since been demonstrated that the Bax-activation properties o f p53 
are independent o f  the nuclear localisation and transcriptional regulation domains of 
the protein. It appears there is a transcription-independent mechanism by which p53 
causes the relocalisation o f Bax to  the mitochondria (Goldstein et al. 2000; Schuler et 
al. 2000). The mechanisms o f Bax action are discussed in 1.7.6 , the result being the 
release of factors including cytochrome c and AIF (apoptosis initiation factor) from the 
mitochondria. In the cytosol, cytochrome c forms a complex with Apaf-1 (apoptosis 
protease activating factor-1) and procaspase-9, known as the ‘apoptosome’, which 
functions as a multisubstrate protease initiating the caspase activation cascade and 
moving the cell into the execution phase o f apoptotic death.
In physiologic cell death, such as described in 1.7.1 the apoptosis programme is 
activated extrinsically, via cell surface receptors. All cells require trophic support in 
order to  survive. In the case o f developing neurons, trophic support is derived from 
their targets. Only those neurons which make correct synaptic contacts with their 
targets will survive: the neurotrophin hypothesis. Those neurons which lose out in the 
competition for target-derived trophin support die by apoptosis. In this case, loss of 
trophic support leads to  an increase in levels o f the transcription factor c-Jun and its 
N-terminal kinase JNK. Phosphorylated c-Jun upregulates the transcription of many 
target genes, including the pro-apoptotic members o f the Bcl-2 family. Interestingly, 
the neurotrophin hypothesis applies mainly to  development alone. The addition o f 
neurotrophins to  fully differentiated, adult neurons can in fact induce apoptosis. 
Likewise, apoptosis can be activated extrinsically by the binding o f ligands to  ‘death 
receptors’. For example, as part o f the immune response T-lymphocytes and Natural 
Killer (NK) cells can induce the death o f  an infected cell through Fas-mediated 
apoptosis (figure 16). The Fas receptor (otherwise known as CD95) is a surface 
protein of the TNF family (tumor necrosis factor) expressed by most mammalian cells.
FAS (CD95)
FADD
Procaspase-8
P10 p20 i m d
FASL (CD95L)
DISC
Caspase-8
Figure 16 Formation of a DISC (death inducing signalling complex) involving the 
Fas (CD95) receptor. Ligation with FasL causes clustering of the receptor, the 
cytoplasmic domain of which contains a Death Domain (DD) which interacts with 
the adaptor molecule FADD (Fas-associated death domain protein). FADD 
contains a Death Effector Domain (DED) through which it interacts with the DED 
of procaspase-8. The induced proximity of procaspase-8 proteins causes 
autocatalytic actibation and release of the mature enzyme.
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The cytoplasmic portion o f  the receptor, and indeed all o f the ‘death receptors’, 
contains a ‘death domain’ (DD) through which the receptor interacts with a number 
o f other cytoplasmic proteins. The receptor ligand, FasL, (CD95L) is expressed 
predominantly on the surface o f activated T-lymphocytes and NK cells as a trimer. 
The binding o f  FasL to  the Fas receptor brings many Fas receptors into close 
proximity, resulting from both the trimeric nature o f the ligand and the expression of a 
number o f FasL proteins locally on the surface o f the T-/NK cell. The complex which 
is formed is known as the death-inducing signaling complex (DISC). Through the DDs 
o f the death receptors a number o f other DD-containing proteins are also recruited 
to  the DISC, including the adaptor molecules FADD (Fas-associated death domain), 
RIP (receptor interacting protein) and RAIDD (RIP-associated ICH-l/CED-3 
homologous protein with a death domain). RIP and RAIDD appear to  stabilise each 
other's localisation to  the DISC, and the latter contains a CARD (caspase activation 
and recruitment domain) which recruits procaspase-2 into the complex. Similarly, 
FADD contains a DED (death effector domain) which recruits the DED-containing 
procaspase-8. The result is an activation o f  caspase-8 and/or caspase-2 and, once 
again, entry into the caspase cascade.
1.7.6 Regulation
Given the autocatalytic properties o f the procaspases and the cascade nature o f the 
apoptotic executioners, it should be no surprise to  leam that there is a large and ever­
growing array o f proteins involved in the regulation o f apoptotic activation and 
execution, the more important o f which are summarised in figure 17.
The Bd-2 family o f proteins play a crucial role is the initiation and transduction 
o f apoptotic signaling. The family is divided into three groups according to  the 
repetition o f Bd-2 homology domains (BH-domains). Group I proteins, including Bd-2 
(the mammalian homologue o f ced9 [see 1.7.2]) and Bcl-xl possess 4  BH domains and 
are anti-apoptotic; groups II and III are both pro-apoptotic and possess 3 BH domains 
(Bax and Bak) and I BH domain (Bid and Bad) respectively. The major anti-apoptotic
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Apoptosome
CD951
FADD
Procaspase-8
DNA damage
Truncated bid
Procaspase-3
Cytochrome c
Caspase-3
Apaf-1
Procaspase-9
Caspase-8
Smac/DIABLO
Apoptotic substrates
Figure 17 Summary of the initiation and regulation of apoptosis. Initiation 
occurs either intrinsically - for example DNA damage leading to  p53 activation - 
o r extrinsiclally, - ligation of receptors such as CD95. Both pathways lead to  
release of cytochrome c, AIF (apoptosis initiation factor) and regulatory proteins 
such as Smac/DIABLO from mitochondria. O nce activated (directly in 
extrinsically-signalled, via apoptosom e formation for intrinsically-signalled 
apoptosis), caspases en te r into a self-perpetuating cascade of activating each 
other as well as cleaving the many death substrates.
Taken from  H engartner 2000
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proteins, Bd-2 and Bd-x, are localized to  the mitochondrial outer membrane and the 
endoplasmic reticulum. It has been shown that over-expression o f Bd-2 alone can 
support the survival o f sympathetic neurons following NGF withdrawal (Garcia et al. 
1992), whilst transgenic mice over-expressing Bd-2 are protected against neuronal 
death during development (Martinou et al. 1994). The expression o f Bd-2 is high in 
the central nervous system during development and is subsequently down-regulated 
after birth. In contrast, Bcl-2 expression in the peripheral nervous system is 
maintained throughout life (Merry and Korsmeyer 1997). Bd-2 knockout mice develop 
normally, but show subsequent loss o f motor, sensory and sympathetic neurons after 
birth (Veis et al. 1993; Michaelidis et al. 1996) suggesting that Bd-2 is crucial for cell 
survival. Bcl-x, is expressed during developm ent also, but in contrast to  Bcl-2 
expression continues into adulthood.
Many members o f  the Bel family can dimerise, but they can also form 
heterodimers with either pro- or anti-apoptotic results. The key function o f this family 
o f proteins appears to  be in regulating the release o f apoptotic initiating factors, in 
particular the release o f cytochrome c from the mitochondria. It is not fully known 
how cytochrome c manages to  cross the mitochondrial outer membrane, but it is 
clear that the Bcl-2 family is involved. Addition o f pro-apoptotic family members to  
isolated mitochondria induces cytochrome c release, whilst addition o f anti-apoptotic 
members prevents it There are three models for the action o f the Bcl-2 family: 
channel formation by protein members; channel formation induced by protein 
members; and membrane rupture. In support o f the first notion, Bcl-2 proteins have 
been shown to  oligomerise and form channels in synthetic bilayers. However, Bcl-2 
proteins have been shown to  interact with a lar^ ge number o f other proteins, and it 
may be that in vivo the Bcl-2 oligomers recruit proteins which generate a pore. Such 
interactions may also support the third idea, that the Bcl-2 family disturbs homeostasis 
and causes disintegration o f at least part o f the mitochondria. Indeed, Bcl-2 proteins 
have been shown to interact with the mitochondrial proteins voltage-dependent anion 
channel (VDAC) and adenosine nucleotide transporter (ANT) thus they may upset 
mitochondrial homeostasis.
The heat shock proteins (see 1.5 .1) have also been implicated in the regulation o f  
apoptosis. A pool o f Hsp27 spins down with mitochondria in heat-treated cells 
(Samali et al. 2 0 0 1) and in vitro studies have shown an interaction between Hsp27 and 
cytochrome c (Bruey et al. 2000; Concannon et al. 2 0 0 1). It may be that one role o f  
heat shock proteins is to  restrict the activation o f apoptosis. Furthermore, Hsp27 has 
been shown to  interact with procaspase-3 (Concannon et al. 2003; Pandey et al. 
2000a) which may suggest a role in preventing caspase activation. Indeed, Hsp70 and 
Hsp90 have been reported in inhibit apoptosis by preventing caspase activation. 
Hsp70 interacts with Apaf-1 preventing the recruitment o f procaspase-9, and similarly 
Hsp90 inhibits Apaf-1 oligomerisation, thus preventing formation o f the apoptosome 
(Beene et al. 2000; Pandey et al. 2000b).
Two further proteins have been identified which have an antagonistic action 
on apoptosis initiation through death receptor pathways. Usurpin contains a DED 
homologue which com petes with procaspase-8 for recruitment into the death 
inducing signaling complex (Rasper et al. 1998). Similarly, the protein cFLIP (cellular 
FLICE [FADD-like interleukin-1 converting enzyme] inhibitory protein) also contains a 
DED homolgoue, reducing or preventing caspase-8 activation via the DISC (Scaffidi et 
al. 1999).
Caspase activation is further inhibited by the inhibitor-of-apoptosis proteins 
(lAPs), a family o f eight (in mammals) proteins which appear to  have a number o f  
constitutive roles including the regulation of cell cycle progression and the modulation 
o f receptor-mediated signal transduction. lAPs contain a RING finger domain similar 
to  E3 proteins (see 1.5.2) and thus it has also been suggested that lAPs possess 
ubiquitin ligase activity. lAPs inhibit apoptosis via their binding to  activated caspases, in 
particular caspases-3 -7 and -9, thereby negating their activity (Deveraux and Reed 
1999). It is reasonable to  assume that lAPs serve to  quell inappropriately activated 
caspases, which can be produced spontaneously due to  their auto-catalytic properties. 
Upon activation o f apoptosis certain lAPs have been shown to  be ubiquitinated and 
degraded, thereby removing the brake from the caspase cascade (Yang and Li 2000).
Further removal o f caspase inhibition occurs upon apoptotic initiation. Upon 
stimulation o f apoptosis the mitochondrial protein Smac (second mitochondrial-
derived activator o f caspases), also known as DIABLO (direct lAP-binding protein with 
low pi) is proteolytically processed and released from the intermembrane space and 
the cytosol along with other pro-apoptotic factors such as cytochrome c and AIF. 
Smac/DIABLO interacts directly with multiple lAPs neutralising their caspase- 
interacting properties, thus removing lAP-mediated caspase inhibition (Springs et al. 
2002; Verhagen et al. 2000; Chai et al. 2000). Interestingly, Smac/DIABLO knockout 
mice appear to  develop normally, unlike many other apoptosis-deficient mice, and 
respond normally to  apoptotic stimuli (Okada et al. 2002). This suggests a 
redundancy, which should not be surprising given the complexity and the ever­
growing number o f protein components in the system.
1.7.7 Execution
As mentioned in 1.7.4, caspases can be divided into tw o  groups: upstream and 
downstream. The downstream caspases are considered the “central executioners” of 
apoptosis and are activated via proteolytic cleavage by an upstream caspase. Many of 
the upstream events can be buffered halting apoptosis midway, but once the 
downstream, executioner caspases are activated, a point-of-no-retum is passed. This 
exact moment, at which a cell becomes “committed to  die” remains under debate, 
but just as Smac/DIABLO perpetuate the apoptotic cascade by negating the effects of 
the inhibitors o f apoptosis, the downstream caspases cleave and inactivate those 
proteins which would act to  repair the ‘damage’ caused by apoptosis.
The targets o f activated caspases-3, -6 and -7 are too  numerous to  list in their 
entirety. The key events, which also illustrate the self-perpetuation principle, include 
the cleavage o f DFF45 (DNA fragmentation factor 45) which is normally bound to  
DFF40. Upon cleavage o f DFF45 by caspase-3 DFF40, a DNAse, is released and 
translocates to  the nucleus whereupon it begins cleaving the chromatin. Within the 
nucleus resides PARP (poly-ADP ribose polymerase), the normal function o f which is 
to  repair damaged DNA. PARP is also a substrate for caspase-3, thus in apoptosis it is
73
cleaved and inactivated preventing it from repairing the fragmenting chromatin. 
Certainly, once repair proteins are inactivated there is no stopping the deconstruction 
o f apoptosis; the ‘committar point has been passed.
Many other caspase targets are involved in DNA repair and regulation o f the 
cell cycle, including pRb, DNA-PK and NuMA; as well as proteins involved in 
transcription and translation, including SREBPs, hnRNPs and snRNPs; and proteins 
essential to  cell regulation including kinases. Furthermore, the toss o f structure seen in 
apoptosis can be accounted for by the cleavage o f structural proteins including lamin 
A, lamin B and G-actin by caspases.
In summary, the activation o f downstream caspases leads to  a series o f  
proteolytic events causing the systematic degradation o f  both those molecules 
essential for maintenance o f cell function and structure, together with those proteins 
responsible for the repair o f such degradation.
1.7.8 Removal
The original definition o f apoptosis by Kerr, Wylie and Currie included a description of 
the means by which apoptotic bodies are removed from the biological system. 
Indeed, the title o f a more recent paper makes the claim that “corpse clearance 
defines the meaning o f cell death” (Savill and Fadok 2000). O f course, clearance o f  
the apoptotic remnants is as important as the process o f degradation itself seeing as 
the aim is to  prevent the leakage o f cell contents and an inflammatory response. In 
som e cases apoptotic bodies can simply be shed from epithelial-lined surfaces, for 
example figure I from the seminal paper illustrates the shedding o f apoptotic bodies 
from human glandular epithelium into the lumen (Kerr et al. 1972). W here shedding 
is not possible, apoptotic bodies are seen to  be taken up by other cells and digested. 
Whilst many cells appear to  be capable o f ingesting apoptotic bodies, in mammals 
corpse clearance is normally carried out by professional phagocytes: granulocytes and 
cells o f the macrophage lineage (including microglia in the CNS).
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Successful engulfment requires the display o f so-called ‘eat-m e’ signals on the 
apoptotic cell surface and the recognition o f such by phagocytes (figure 18). A 
number o f ‘eat-me’ signals have been identified, the most well-characterised, and 
perhaps the most prominent o f which is the phospholipid phosphatidylserine (PS). In 
a healthy cell, PS is localised to  the internal surface o f the plasma membrane. During 
apoptosis decreased aminophospholipid translocase activity results in extemalisation of 
PS and its presentation on the cell surface (Fadok et al. 1998a). Phagocytic cells 
interact with the exposed PS via PS receptors expressed on their surfaces. Likewise 
there are also changes in cell surface sugars which are detected by phagocyte lectins 
(Savill and Fadok 2000). It also appears that the ICAM-3 immunoglobulin family has a 
role as an ‘eat-me’ signal (Moffatt et al. 1999). Other signals require the interaction of 
‘bridging’ molecules present in the extracellular fluid, such as Cl q, a component o f the 
complement cascade. It has been noted that CI q-null mice have defective apoptotic 
cell clearance (Botto et al. 1998). There are a number o f other molecules that have 
been implicated in apoptotic clearance, as illustrated in figure 18, the exact nature and 
degree o f importance o f each has yet to  be clarified.
Once the phagocyte receptors bind the ‘eat-me’ flags, a signalling complex is 
recruited to  th e  plasma m em brane o f  th e  phagocytic cell which 
causes the activated o f a number o f GTPases which are involved in the regulation of 
the actin cytoskeleton (Conradt 2 0 0 1). Reorganisation o f the cytoskeleton brings 
about the change in cell shape underlying engulfment
The engulfed apoptotic body undergoes a series o f changes involving further 
degradation of structure, including loss of mitochondrial integrity. Kerr and colleagues 
believe that apoptotic bodies are still metabolically active until they enter the 
phagocytosing cell. Certainly, in order to  maintain plasma membrane structure -  the 
key feature o f apoptosis -  there must be some activity, and in support o f this 
mitochondria appear to  be the last organelles to  lose integrity. Kerr et al. suggest that 
this stage o f degradation arises from the body’s “inability to  maintain... homeostasis 
within phagosomes” (Kerr et al. 1972). The final degradation is mediated directly by 
the phagocytosing host, as lysosomes fuse with the phagosomes containing apoptotic 
bodies releasing hydrolases into the closed environment
A p op totic  ce ll
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Figure 18 The recognition of apoptotic cells by phagocytes. A number o f ‘eat- 
m e’ signals presented on the surface of a cell undergoing apoptosis are 
recognised by phagocyte receptors, either directly or via serum-derived bridging 
molecules. TSP, th rom bospondin; LDL, low-density lipoprotein; Cl q ,  
com ponent of the compliment cascade; PS, phosphotidylserine; SRA, class A 
scavenger receptor.
Taken from  Savill & Fadok, 2000
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The relationship between apoptotic cell and phagosomes has recently been called into 
question. It seems the role o f the phagocyte may not simply be the passive removal 
o f ‘waste’. In som e cases phagocytes seem to  induce apoptosis o f a cell before 
removal. For example, the co-culturing o f activated macrophages with mesangial cells 
induces apoptotic cell death in these cells (Duffield et al. 2000). Furthermore, in vivo 
the elimination o f macrophages in the rat eye results in the survival o f vascular 
epithelial cells which normally die by apoptosis during capillary regression (Diez-Roux 
and Lang 1997; Lang and Bishop 1993). In other cases phagocytes appear to  play a 
role in promoting the execution o f the apoptotic process. There exists a mutation in 
the C  elegans ced3 gene (the caspase-3 homologue) which only partially reduces the 
efficacy o f the enzyme. Alone, this mutation results in an average o f 1.5 o f the 16 cells 
that would die during normal development o f the anterior pharynx surviving. Loss-of- 
function mutations in any o f the seven C. elegans engulfment genes do not affect death 
o f these cells on an otherwise wild-type background. However, in combination these 
mutations result in between 5 and 6.2 extra cells in the mature anterior pharynx 
(Hoeppner et al. 2001; Reddien et al. 2001). Thus engulfment can partially rescue 
phenotype when ced-3 is compromised01, suggesting that phagocytes plays a role in 
enhancing the execution o f apoptosis, ensuring that cells committed to  die complete 
the process. It is possible that the examples o f phagocyte-induced apoptosis given 
above are actually cases o f loss o f enhancement. In the case o f the rat eye vascular 
epithelial cells, the cells may survive as the ‘apoptotic drive’ is not strong enough 
without the macrophage enhancement In the case o f the cultured mesangial cells the 
macrophages had been cytokine-activated prior to  co-culture. It is possible that such 
activation induced pathways that may normally be activated by ‘eat-me’ signals. 
Therefore, whilst the absolute toxic nature o f phagocytes may be in question, in seems 
apparent that these cells, at least in some cases, are part o f a feedback loop enhancing 
apoptosis.
The relationship between phagocyte and apoptotic cell deepens further. The 
uptake o f  apoptotic cells by macrophages actively suppresses the secretion o f
a Complete inactivation o f ced-3 results in survival o f all cells irrespective o f engulfment
”7  “7/ /
proinflammatory cytokines such as TNFa. Thus, the apoptotic mechanism is doubly 
protective against inflammation: not only does it prevent the release o f cell contents 
but also has a ‘calming’ effect on inflammatory cells, resetting activated macrophages 
(see figure 19). The effect appears to  result as a side-effect o f ligation o f receptors 
associated with engulfment, in particular C D 36, throm bospondin and 
phosphatidylserine (Fadok et al. 1998b; Voll etol. 1997).
Presentation of peptides
o
Early exposure of 
‘ea t m e’ flags Degradation and processing
*  R em oval of cell corpses
* Prevention o f leakage of 
contents from dying cells
Altered secretion
*  Suppression  of inflammation
* Modulation of cell killing
Figure 19 Summary of the relationship between phagocyte and apoptotic cell. In 
the early stages of apoptosis the dying cell displays various ‘eat-m e’ signals on its 
surface which are recognised by phagocyte receptors triggering the engulfment 
and subsequent degradation of the apoptotic body. It has recently becom e 
apparent that as well as waste removal, the phagocyte functions as an enhancer of 
cell death. Furthermore, engulfment of an apoptotic body ‘deactivates’ the 
phagocyte, suppressing inflammation.
Adapted from Savill & Fadok 2000
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1.8 Neuronal Death in Huntington’s Disease
1.8.1 Introduction
THE cause and nature of cell death in Huntington's disease are the main areas this thesis seeks to  address. Throughout the past few decades a number o f theories 
have been put forward in attempts to  answer these questions. The theory in vogue at 
the moment is that the accumulation o f mutant huntingtin begins to  exceed to  
neuron’s ability to  buffer any damaging effects, at which point apoptosis is initiated 
resulting in cell death. The finer points o f apoptosis are discussed in 1.7, and further 
discussion on its role in HD, and the evidence presented herein, can be found in 4.1. 
In order to  provide some introduction there follows a brief summary o f the apparent 
evidence for an apoptotic response along with a discussion on the previous theory de 
mode: excitotoxicity.
1.8.2 Apoptosis
Human HD is dominated by cell death throughout the caudate, putamen and cortex 
(see 1.1.3). The cell death seen is certainly not necrotic. There is no clear 
imflammatory response and ultrastructurally, degenerating neurons are generally well- 
preserved (Vonsattel and DiFiglia 1998). Coupled with the naive notion that death 
always presents as one o f tw o extremes, this evidence alone is sufficient to  convince 
some that neuronal death in HD is an apoptotic process.
There is a wealth o f evidence to  support a role for apoptotic components in 
the pathology o f HD. In human post-mortem tissue, a subset o f neurons and glia in 
the striatum have been shown to  stain positive with TUNEL (terminal transferase- 
mediated d-UTP-biotin nick-end labelling) indicating the presence o f double-stranded 
DNA breaks suggested to  be the result o f apoptotic DNAse activity (Dragunow et al.
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1995; Thomas et al. 1995). Furthermore, one group identified the activated form of 
caspase-8 in the insoluble fractions o f human post-mortem brain areas affected in HD 
(Sanchez et al. 1999). Using a cell model based around the expression o f an ataxin3 
Q 79 construct, the same group showed caspase-8 recruited to  the Q79 aggregate. 
Blocking caspase-8 recruitment and subsequent activation in this system prevented cell 
death. Likewise, Miyashita et al. identified activation o f caspase-8, and subsequently, 
caspase-3 in an inducible cell model o f polyglutamine disease (Miyashita et al. 1999). 
Subsequent work by this group found a redistribution o f caspase-8 upon induction of  
extended glutamine expression and aggregate formation. Indeed, activated caspase-8 
was only found in association with the polyQ aggregate. Immunopnecipitation 
experiments revealed a selective interaction between polyQ and caspase-8, however, 
in vitro binding assays show that for any polyQ length this interaction does not occur 
directly (U et al. 2 0 0 1). Rather an adaptor molecule, or molecules must exist
Conversely, it has been suggested that activation o f caspase-8 occurs not as a 
result o f recruitment to  the aggregates, but as a result o f loss o f a function o f normal 
huntingtin. The huntingtin-interacting protein I (HIP-1) was identified through its 
weaker interaction with mutant huntingtin compared to  wild type protein (Wanker et 
al. 1997). Overexpression o f HIP-1 has been shown to  induce rapid caspase-3- 
dependent cell death (Hackam et al. 2000). More recently a partner to  Hip-1 was 
identified, Hippi, which forms a complex with free Hip-1 and caspase-8. Both HIP-1 
and Hippi contain proteins similar to  the death-effector domain (DED) o f caspase-8 
(see 1.7.5) and it is believed that the interaction o f these domains underlies the 
formation o f the complex and its toxicity. As the interaction between HIP-1 and 
huntingtin is inversely proportional to  polyQ length, in HD there is a greater amount 
o f free HIP-1 available to  dimerise with Hippi and recruit and activate caspase-8 
(Gervais et al. 2002).
Caspase-9 enzymatic activity is induced as part o f the apoptotic process, but it 
has also been suggested to  play role in the pathogenesis o f HD by one group studying 
CNS-derived cells. Rigamonti et al. identify cytochrome c release and activation of 
caspases -9 and -3 as part o f the death process, and find that over-expression o f wild- 
type huntingtin prevents caspase-9 and -3 activation whilst having no effect on
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cytochrome c release. The implication being that the anti-apoptotic effects o f wild- 
type huntingtin are mediated at the level between cytochrome c release and caspase- 
9 activation (Rigamonti et al. 2 0 0 1). In other words, by preventing apoptosome 
formation.
(Li et al. 2000) report that in their cell culture model intranuclear mutant 
huntingtin increases the activity o f caspase-1 which promotes cytochrome c release, 
leading to  caspase-3 activation. Cytochrome c release is also reported by the 
Rigamonti group discussed earlier, and by Jana et al. who found that after expressing 
expanded polyQ in neuro2a cells for three days, isolated mitochondria contained a 
reduced amount o f cytochrome c ()ana et al. 2 0 0 1). Support for a role for caspase-1 
in vivo comes from work on R6/2 mice showing that inhibition o f caspase-1 (or 
crossing onto ca sp a se -1 m ice) seems to  delay onset o f symptoms and prolong 
survival in the R6/2 mouse model o f HD (Ona et al. 1999). Other groups have also 
reported the rescue o f transfected cells using anti-apoptotic compounds such as BclX, 
or caspase inhibitors (Hackam et al. 2000; Saudou et al. 1998).
It may not be that huntingtin directly induces apoptosis, rather that apoptosis 
occurs more readily. As described in 1.7, there exists a balance between pro- and 
anti-apoptotic drives in the resting cell, the aggregation o f mutant huntingtin, and the 
sequestration o f those proteins with which it interacts may alter this balance in favour 
of the pro-apoptotic mediators. Several groups report an increased sensitivity to  
stressful, or apoptotic stimuli in cells transfected with mutant htt
1.8.3 Exdtotoxicity
Exictotoxicity was identified in 1957 when D.R. Lucas and J.P. Newhouse found that 
feeding infant mice sodium glutamate destroyed retinal neurons (Lucas and Newhouse 
1957). The term, exdtotoxicity was coined later by J.W. Olney, who identified the 
pattern and nature of the death; namely, that death is restricted to  post-synaptic cells
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and is dependent on excitatory mechanisms similar to  those employed in glutamate 
signaling (Olney 1969; Olney et al. 19 7 1).
During normal synaptic transmission levels o f glutamate in the synaptic cleft 
rise to  high levels, but only for a matter o f milliseconds before re-uptake or removal 
by astrocytes. Accumulation o f glutamate occurs in conditions when removal from 
the cleft is impaired, most notably in times o f metabolic impairment such as occurs 
during ischemia. Accumulation can also occur as a result o f hyperstimulation o f the 
presynaptic neuron. Such accumulation causes as influx o f calcium ions through the 
glutamate NMDA receptors, which, to  a certain extent can be removed from the 
cytosol by calcium pumps at the plasma and ER membranes. Neurons also possess a 
calcium-sodium ion exchanger to  further buffer the effects o f calcium influx. If the 
calcium influx cannot be buffered a number o f changes occur in the neuron, most 
notably impairment o f  mitochondrial function and activation o f a group o f calcium- 
dependent proteases, the calpains. Calpains are essentially inactive under basal 
conditions, but when bound to  calcium they cleave a large variety o f substrates in a 
manner similar, but more general, to  caspases (Reverter et al. 2 0 0 1). Inhibition o f the 
proteolytic activity o f calpains rescues neurons from glutamate-induced excitotoxic 
death (Brorson et al. 1995; Rami et al. 1997).
The damage caused by calcium influx includes metabolic impairment, thereby 
hindering the function o f  the calcium pumps/exchanger, thus potentiating the problem. 
Similar to  the process o f apoptosis, there is a threshold beyond which the death-signal 
cannot be buffered. Likewise, as the cell begins to  destroy that machinery which 
would otherwise repair the damage being caused, a point-of-no-retum is passed and 
death is inevitable.
Excitotoxicity has long been implicated in the pathogenesis o f Huntington’s 
disease. The earliest models o f the disease were generated using the NMDA- 
receptor agonist quinolinic acid as the resulting pattern o f cell loss was suggested to  be 
similar to  that seen in HD (Beal et al. 19 9 1; Ferrante et al. 1993; Hantraye et al. 
1990)*. The striatum receives abundant glutamatergic input from the cortex and
*  A lthough criticisms o f  th e  validity o f  excitotoxic-lesion  m odels o f  H D  existed  at th e  tim e  
(Davies & Roberts 1987).
studies have claimed that those neurons that die preferentially in HD are those that 
are the most sensitive to  glutamate excitotoxicity. It has been shown that a greater 
membrane depolarization and inward current is induced by exogenous glutamate 
receptor agonists in medium spiny neurons compared to  aspiny intemeurons 
(Calabresi et al. 1998; Cepeda et al. 2001b). Indeed, both striatal and cortical 
projection neurons are highly vulnerable to  NM DA-receptor agonists, whilst 
intemeurons are relatively spared (Figueredo-Cardenas et al. 1994). This apparent 
explanation o f cell specificity has made excitotoxicity an attractive explanation for cell 
death in HD.
The exact role, if any, mutant huntingtin plays in exitotoxicty remains under 
debate. As described in 1.3.2 and 1.6.4, huntingtin appears to  be associated with 
neuronal terminal vesicles, interacting with several exo/endocytic vesicle proteins such 
as HIP-1, HAP-1 and SH3GL3. It is therefore possible that mutant huntingtin 
interferes with the regulation o f synaptic vesicle cycling, causing a build-up o f excitatory 
neurotransmitters.
Huntingtin associates with a post-synaptic protein, PSD-95 (post-synaptic 
density 95) which binds NMDA receptors regulating NMDA-dependent long-term 
potentiation and depression. Expanded polyglutamine within htt inhibits binding to  
PSD-95 and increases the sensitivity o f NMDA receptors (Sun et al. 2 0 0 1). There is in 
vivo evidence for an increased sensitivity to  excitotoxicity in HD. Cepada et al. report 
a greater inward current and, importantly, calcium ion influx in R6/2 striatal neurons 
stimulated with quinolinic acid compared to  wild-type mice. They find a similar, yet 
smaller, increase in response in the same situation using the YAC725 mouse model 
(Cepeda et al. 2 0 0 1 a). Likewise, Zeron et al. found that injection o f QA into the 
striata o f the YAC72 mice produces a greater amount o f medium spiny neuron death 
than a similar dose in control mice. They see a similar result using NMDA/AMPA on 
cells in culture (Zeron et al. 2 0 0 1).
8 A  m odel generated  in th e  laboratories o f  Michael Hayden, possessing a yeast artificial 
ch rom osom e (YAC) expressing full-length huntingtin with 7 2  glutamine repeats (H odgson et  
al. 1999).
Whilst these data do not show conclusively that mutant huntingtin causes cells to  die 
via excitotoxicity, it does seem apparent that both the medium spiny neurons o f the 
striatum are more sensitive to  excitotoxicity than other cells, and that the presence of 
mutant huntingtin enhances this susceptibility.
1.8.4 Neurotrophins
There is also a suggested role for neurotrophins in the pathology o f Huntington’s 
disease whatever the mechanism o f cell death. As described in 1.7.5 neurotrophins 
are vital to  cell survival, particularly in the developing nervous system. It has been 
shown that the levels o f the neurotrophin BDNF (brain-derived neurotrophic factor) 
are lower in the caudate and putamen o f HD patients, in some cases almost half basal 
levels (Ferrer et al. 2000); a condition which has also been demonstrated in the 
YAC72 mouse model o f HD (Zuccato et al. 2 0 0 1). Whilst the toxicity o f mutant 
huntingtin appears to  result from a toxic gain-of-function, the laboratory o f Elena 
Cataneo believes the loss o f a beneficial property o f wild type huntingtin, namely the 
up-regulation o f BDNF transcription in cortical neurons (which is released in the 
striatum and required for survival o f striatal neurons), makes striatal neurons more 
sensitive to  cellular perturbation and more prone to  death (Reilly 2 0 0 1; Zuccato et al. 
2001).
One o f the candidate therapeutic drugs for Huntington’s disease, Riluzole has 
been shown to  increase life-span o f the R6/2 mouse (Schiefer et al. 2002) though the 
effect in human patients appears to  be transient (Seppi et al. 2 0 0 1). The actions of 
Riluzole include elevation o f levels o f BDNF, GDNF (glial-derived neurotrophic factor) 
and NGF (neuronal growth factor). Whilst these increases are a result o f actions on 
astrocytes (Mizuta et al. 2001) rather than the cortical neurons the increase in BDNF 
may offset some o f the decrease which results from huntingtin mutation. It has also 
recently been demonstrated that dietary restriction in the R6/2 mice can prolong
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survival, purportedly through upregulation o f BDNF and Hsp70 in the cortex and 
striatum (Duan et al. 2003).
The evidence firmly indicates that there is a decreased level o f BDNF within 
the striatum in Huntington’s disease. W hether this has a direct effect on pathology, 
however, is unclear. Increasing BDNF levels does seem to  slow disease progress, 
suggesting that BDNF depletion may indeed contribute to  pathology. Local 
neurotrophin depletion may make certain cell populations more susceptible to  injury 
and contribute to  disease progression. Nevertheless, I believe that these effects are 
secondary to  the toxic nature o f the huntingtin mutation.
Materials and Methods
2.1 The R6 Mouse Models of Huntington s Disease
2.1.1 Generating the Model
T HE first genetic model of polyglutamine disease was a spinocerebellar ataxia-1 (SCAI) mouse generated using a human SCAI cDNA construct, expressed 
under a Purkinje cell-specific promoter (Burright et al. 1995). Mice were generated 
with either normal or expanded CAG repeats in the construct, those expressing an 
expanded repeat exhibited Purkinje degeneration. Thus, these mice not only 
established that human glutamine repeat-expansion diseases can be modelled in mice, 
but also provided evidence for the argument that expanding CAG repeat in a protein 
is sufficient to  cause pathology.
The first polyglutamine disease models to  be created were the HD mouse 
models generated in the laboratories o f Gillian P. Bates. Originally, they attempted to  
generate a model using a yeast artificial chromosome (YAC) to  introduce the gene. 
However, these proved to  be too  unstable and furthermore, CAG repeats appear to  
be highly unstable in yeast. Instead, a transgenic model was generated using a 
construct derived from a human HD patient
A l.9kb restriction enzyme fragment (Sacl-EcoRI) was taken from the five 
prime end o f the HD gene isolated from a human patient with 130 CAG repeats. 
This fragment contains approximately I kb o f upstream elements, the entire o f exon I 
and the first 262 base pairs o f intron I (figure 20). This produces a protein 
approximately equivalent to  the first ninety amino acids of normal huntingtin (CAG21). 
To prevent the possible expression o f an unspliced transcript a stop codon was 
generated at the beginning o f intron I and indeed, northern and western blot analyses 
reveal that when the trangene is active exon I alone is transcribed and translated 
(Mangiarini et al. 1996).
Transgenic mice were generated by microinjection of the construct into single 
cells o f mouse embryos (CDAxC57BI/6 strain). Only one transgenic mouse survived: 
the R6 founder. It appears that the construct had integrated into five different regions
CAGi3o
HD E X O N  1
TGA
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Figure 20 Genetic construct used for the generation of the 
transgenic R6 lines of mice. The construct, isolated from a human 
HD patient, is com prised of approxim ately I kb of upstream  
untranslated sequence, exon I with an expanded CAG repeat 
sequence and the first 262bp of intron I. There is also an in-frame 
mutation providing a stop codon (TGA) at the 5’ end of intron I.
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of the founder genome, thus backcrosses onto wild-type C57BI/6 yielded five different 
strains o f mice: R6/0, R6/I, R6/2, R6/5 and R6/T (figure 21). Furthermore, as the  
repeat is unstable (see 1.3.4) the FI generation o f mice had variable repeat sizes, but 
all within region o f the 130 used in the construct. Lines R6/0, R6/I, and R6/T result 
from a single integration, although in the R6/T line most o f the 5’ end o f the construct 
has been deleted leaving a highly truncated, non-expressing transgene. Surprisingly, 
the R6/0 line does not express the tranSgene. Southern blotting indicates that the 
transgene has integrated adjacent to  a highly repetitive region o f the genome as a very 
large fragment is produced. It is suggested that this region somehow silences the 
surrounding genome. The R6/I line possess a single copy o f the transgene containing 
116 glutamine repeats which is expressed in all tissues tested. These mice develop a 
phenotype similar to  the R6/2 line but much less severe and with a later onset The 
R6/5 line appears to  have resulted from a four-copy integration with. The suggested 
arrangement is shown in figure 2 1, but this is speculative.
The R6/2 line resulted from a three-copy integration o f the construct into the 
founder genome, but at som e point deletions occurred at both the 5’ and 3’ ends o f  
the transgene leaving a single whole functioning copy with 144 repeats and tw o  
flanking UTR remnants.
2.1.2 Phenotype o f the R6/2 Mouse
The R6/2 line has becom e one o f  the most widely used models o f Huntington’s 
disease. Whilst the R6/I and R6/5 lines also develop a phenotype (only in the 
homozygous state in the R6/5 line) the R6/2 is the most aggressive and mice pass 
through the spectrum o f disease in a matter o f weeks rather than months. Age at 
onset has been seen to  be as low as 4 weeks, though most R6/2 mice develop overt 
symptoms between 9 and 11 weeks. Death usually occurs around 12 or 13 weeks o f  
age. The cause o f death is generally unknown, though most likely to  be a result o f  
complications arising from the symptoms.
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Figure 21 The genomic structures of the R6 lines of mice resulting from the five 
integrations of the construct into the founder mouse genome. Pale regions indicate 
deletions that are presum ed to  have occurred to  generate the  fragments tha t 
remain.
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The mice develop a motor disorder reminiscent o f HD including a resting tremor and 
the display o f choreic m ovem ent In some cases, a mild ataxia is also seen. One 
measure o f disease progression in the R6/2 mouse is the degree o f “clasping”. When  
picked up by their tails mice spread their legs in an attempt at counterbalance. The 
R6/2 mice however, clasp their feet together. As disease progresses the ability to  
release this clasping posture lessens. Handling also induces epileptic seizures in late 
R6/2 mice, which can last for several minutes. It has been suggested that this epileptic 
activity may underlie the cause o f death in at least some o f the mice.
R6/2 females are sterile and so the line has to  be maintained through the 
mating o f heterozygous males with wild-type females, which has important implications 
on the stability o f the repeat length (see 1.3.4). Further maintenance complications 
arise from the fact that males also exhibit a reduced fertility. Post-mortem analysis 
finds females with ‘miniscule ovaries and a hair-like uterus’ whilst males have small 
testes, seminal ducts and coagulation glands (Mangiarini et al. 1996).
In the presymptomatic stages, R6/2 mice are physically indistinguishable from 
littermate controls, but coincident with onset o f symptoms, the R6/2 bodyweights 
plateau and then progressively decline as the disease progresses. End-stage mice have 
been observed weighing as little as 60% of their normal littermates, in spite of the fact 
that they continue to  ea t Furthermore, post-mortem analysis reveals food in the 
stomach and faecal pellets o f the gut The situation is similar to  that seen in human 
HD patients, as documented in 1.1.1 (Mangiarini et al. 1996).
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2.2 The Hdh Knock-In Models of Huntington s Disease
22 .1  Generating the Models
A COMMON criticism of the R6 mouse models of HD is the “unphysiological” nature o f the transgenics. A foreign gene under a foreign promoter is inerted 
randomly into the mouse genome. It is clear from the differences between the R6/0, 
R6/I, R6/2 and R6/5 mice that transgene insertion point plays a pivotal role. The R6/I 
mice carried (initially) 116 CAG repeats; the R6/2 a comparable 114 repeats. Whilst 
both express the mutant protein and exhibit a phenotype, the R6/1 disease process 
occurs over months, normally beyond the lifespan o f the mouse, a stark contrast to  
the R6/2 mice, which die at around 15 weeks o f age.
It seems obvious that the most apt mouse model o f human HD would be the 
introduction o f the human mutation into the mouse homologue o f the human gene, 
Hdh. Such a model has been generated by the laboratory of Peggy F. Shelboume.
As described in Shelboume et ol. (1999), targetting vectors were constructed 
such that an expanded CAG repeat o f 72 to  80 units replaced the normal mouse Hdh 
repeat sequence. To identify transfected cells a neomycin resistance cassette, flanked 
by two loxP sites, was inserted into intron I o f  the gene. Transfected embryonic stem 
cells were used to  generate tw o lines o f mice (Hdh4/neo and Hdh6/neo), males of 
which were crossed with homozygous p-actin-cre females thereby achieving cre- 
mediated deletion o f the loxPneo sequences. Subsequent analysis confirms removal of 
the neo cassette from all cells. Therefore, the resultant founder mice have effectively 
had an extended polyglutamine tract inserted into their Hdh genes (figure 22).
The founder mice were bred to  establish tw o lines o f mice, the Hdh4/Q80  
mice with 80 CAG repeats, and the Hdh6/Q72 mice with 72 repeats. The mice used 
for generating the models were o f C57BL/6 strain. Subsequently, the models have 
been both maintained on the C57BL/6 background and crossed onto the FVB 
background strain o f mice. Both backgrounds, with identical mutations, have been 
used in this study.
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Figure 22 Generation of the Hdh knock-in mouse models. A 
restriction fragment elem ent from the mouse huntingtin gene 
homologue (green stars represent restriction enzyme sites) is 
replaced with a construct containing an expanded (72/80) 
CAG repeat sequence.
94
2.2.2 Phenotype of the Hdh Mouse
At the genetic level, the mice mimic the human disease not only in the nature o f the 
mutation but also in its behaviour. The mice exhibit germ-line instability, with a 
tendency towards anticipation, and similar sex-of-origin dependencies to  the human 
(Shelboume et al. 1999).
In the initial study mice were studied up until 18 months, during which time 
the Hdh mice showed no difference in eating or drinking behaviour and were o f  
similar body weight to  the littermate controls. In further contrast to  the R6 mice, 
fertility also remained unaffected. The only phenotype observed in the knock-in mice 
is a behavioural abnormality. The mutant mice, in particular the males, exhibit a 
chronic aggressive behaviour. Given the lack o f any other symptoms it is surprising 
that these behavioural changes can be seen as early as three months o f age. The 
degree o f aggressiveness is such that affected males have to  be housed separately.
It is suggested that these mice mirror the early changes seen in human HD. 
Psychiatric symptoms present in HD patients up to  a decade before the onset o f 
motor symptoms, such symptoms include inappropriate behaviour and aggressiveness 
(see 1.1.1).
In a manner similar to  the human disease and the R6 models, mutant 
huntingtin cam be seen to  accumulate when immunostained at the light level. Li et at. 
report the appearance o f both nuclear and neuropil aggregates in the knock-in mice. 
Whereas intranuclear inclusions appear in many areas, including those unaffected in 
HD, in the R6/2 mice, there is a preferential accumulation o f Nils in the striatum o f the 
knock-in model. Furthermore, these Nils appear to  form in the medium spiny 
projection neurones, which preferentially degenerate in HD (Li et al. 2001). 
Aggregates are reportedly seen outside o f the striatum in those regions to  which the 
striatum projects; including the lateral (and to  a lesser extent the medial) globus 
pallidus and the substania nigra, but these are neuropil aggregates rather than 
intranuclear inclusions, suggesting that their later appearance in these regions 
represents the formation o f  aggregates in the axons and dendrites o f those cells which 
are affected by intranuclear inclusions. It also appears that axons containing these
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aggregates degenerate in the later stages o f the mouse life in the absence o f any 
noticeable cell body death (Li et al. 2 0 0 1). It is suggested that the context of the full- 
length huntingtin protein, as opposed to  a truncated transgenic form, confers the 
pathological cell specificity seen in HD. It is certainly true that the knock-in model 
differs markedly from the R6 lines.
2.3 Experimental Protocols
2.3.1 Perfusion of Mice
A  LL perfusions o f R6/2 and Hdh mice used in this study were conducted by 
/  Professor Davies, under the guidelines o f his personal license. Mice were first 
anesthetised with an overdose of sodium pentobarbitone, approximately 100 mg/kg, 
delivered intraperitoneally. Once the anaesthetic had taken full effect the chest cavity 
was exposed and an incision made into the right atrium of the heart. The animals 
were then perfused through the left ventricle with either 2% PLP, for tissue to  be used 
in light microscopy, or 4% paraformaldehyde for tissue destined for the electron 
microscope, until a clear solution is continuously expelled form the breached right 
atrium. Each brain was then carefully removed from the cranium and placed in fresh 
fixative.
Tissue for light microscopy was fixed in vitro for a further six hours before 
being placed in a cryoprotectant solution o f 30% sucrose at 4°C. Tissue for electron 
microscopy was placed in a solution o f 4% paraformaldehyde also containing 0.2% 
gluteraldehyde for a minimum of 24 hours at 4°C.
2.3.2 Preparation of Tissuefor Light Microscopy
After incubation in 30% sucrose cryoprotectant brains were removed and trimmed 
with a razor blade to  provide planar surfaces at both extremes o f the sections under 
study. They were then embedded in Tissue-Tek mounting medium on the stage of a 
Leica SM2000R sledge microtome. The tissue, and mounting medium, was frozen 
with powdered carbon dioxide pellets and maintained in a frozen state by use o f the 
C 0 2(S) reservoir surrounding the stage. Coronal sections of, usually, 40mm were cut
and carefully collected using a paintbrush. Sections were deposited serially in a ‘dimple 
tile’ filled with 0 .1M TRIS buffer, which was then stored at 4°C until needed.
2.3.3 Preparation o f Tissuefor Electron Microscopy
Following post-fixation in a 4% paraformaldehyde /  0.2% gluteraldehyde solution, 
brains were removed and trimmed with a razor blade to  provide a planar surface at 
posterior extremity o f the region under study. This surface was then bonded to  the 
mounting block o f a Vibratome Series 1000 using superglue (cyanoacrylate). The 
Vibratome reservoir was filled with 0 .1M phosphate buffer and sections o f 50-200mm  
were cut and collected into ‘dimple tile’ wells containing 0 .1M phosphate buffer.
23.4 Processing for Standard Transmission Electron Microscopy
Sections were osmicated in I % osmium tetraoxide (in 0 .1M phosphate buffer) for 60 
minutes at 4°C. Sections were then washed in phosphate buffer, followed by washes 
in 0 .1M sodium acetate. They were then stained in a solution o f 2% uranyl acetate (in 
0 .1M sodium acetate) for 45 minutes at 4°C.
Following washes in sodium acetate and distilled water, sections were then 
dehydrated though a graded ethanol series (35%, 50%, 70%, 90%, 100% x4); and 
cleared through four changes o f propylene oxide (taking care not to  expose the 
sections to  the air, thereby risking osmium extraction). Sections are then incubated 
for 45 minutes in a solution o f 50% araldite resin in propylene oxide, followed by an 
overnight incubation in pure araldite resin on a rotator.
The sections are then sandwiched between tw o sheets o f Melanex and 
stacked beneath glass plates weighted down with brass weights. This stack is placed 
overnight in an oven at 60% to polymerise the araldite resin.
Areas o f interest from each section are super^glued onto blocks o f solid resin and 
sectioned using an ultramicrotome. Once the block-face has been polished to  a flat 
surface, semi-thin (0.5-1 mm) sections are collected in a well o f distilled water attached 
to  the glass knife and transferred to  slides. Once dr/, these sections are counter­
stained with toludine blue and viewed under the light microscope. From these semi- 
thin sections one can determine whether or not one is cutting enough tissue to  
warrant collection for electron microscopy. If not the block can be polished further. If 
so, sections are cut at the ultrathin level (approximately 70nm) and collected on 
copper-mesh grids.
Grid-mounted sections are counterstained in lead citrate for 3 minutes, 
washed in distilled water, and allowed to  dry before being viewed in a JEOL 1010 
transmission electron microscope.
2.3.5 EM-levelImmunohzstochernistry
Sections are incubated in primary antibody, diluted to  the appropriate concentration in 
primary antibody buffer, for 72 hours at 4°C. Sections are then washed in buffer 
before being incubated in the appropriate secondary antibody, according to  which 
species the primary antibody was raised in and the type o f label to be used.
Immunohistochemically-stained sections can be visualised at EM using either 
the HRP-DAB reaction product as used in light sections or by using secondary 
antibodies conjugated to  gold particles. For the processing method for the former see 
2.3.6, adapted only in that sections are not mounted onto slides.
For immunogold, primary-labelled sections are washed before being incubated 
in immunogold secondary antibodies, usual concentration 1:200 in phosphate buffer, 
overnight at 4°C. Sections are then washed and further fixed in 0.1% gluteraldehyde 
for 10 minutes at room temperature. Immunogold secondary antibodies conjugated 
to  large gold particles ( I Onm) can be viewed without enhancement, but small particles 
are usually enhanced with silver staining.
Sections to  be silver-enhanced are washed first in phosphate buffer then in sodium 
acetate, before being placed in constituted Nanoprobes HQ Silver Enhancement Kit in 
the dark for between I and 5 minutes. The reaction if stopped by transferring 
sections to  acetate buffer. Sections are then washed in acetate followed by phosphate 
buffers and processed for EM.
Processing o f immunogold sections for EM involves a shorter osmication time 
as the silver enhancement reaction product dissolved in the osmium solution. 
Sections are osmicated in I % osmium tetraoxide (in 0 .1M phosphate buffer) for only 
7 minutes at 4°C; they are then washed and dehydrated as for standard tEM (see 
2.3.4). Similarly, sections stained with DAB are processed in I % osmium tetraoxide 
for only 30 minutes at 4°C. Neither process involves en-bloc staining with uranyl 
acetate, although individual sections can be stained in a manner similar to lead citrate 
staining in standard tEM processing.
2.3.6 LM-LevelImimmohhtorJiemistryProcessing
Sections are incubated in primary antibody, diluted to  the appropriate concentration in 
primary antibody buffer, for 72 hours at 4°C. They are then washed thoroughly in 
0 .1M TRIS before being incubated in appropriate biotinylated secondary antibody 
(raised against the species o f primary antibody and conjugated with biotin), usually at a 
concentration o f 1:200, for tw o hours at room temperature. Sections are then 
washed in 0 .1 TRIS before being transferred into a 1: 100 dilution o f VectorLabs ABC 
solution for 90 minutes at room temperature. ABC consists o f avidin, which binds 
biotin, including the biotin conjugated to  the secondary antibody, and biotinylated 
horseradish peroxidase (HRP); thus forming an amplifying complex linking many HRP 
molecules to  each biotinylated secondary antibody.
Following ABC sections are washed in TRIS before being developed using a 
diaminobenzidine/hydrogen peroxide solution (DAB). Sections are developed in DAB 
for up to  30 minutes depending on the rapidity o f staining development. Once
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enough reaction product has been produces, cells are washed in 0 .1M TRIS and 
mounted onto gelatinised slides.
The slide-mounted sections are allowed to  air dry before being dehydrated 
though an ascending ethanol series (70%, 80%, 95%, 100% x2) and cleared in tw o  
changes o f Histoclear. Slides are then coverslipped using DPX mountant, which is 
allowed to  harden before viewing.
2.3.7 Immunofluoresence
Sections for immunofluoresence are incubated for 72 hours in primary antibody as 
with the other labelling protocols, however, if multiple-labelling is the aim, each 
primary antibody must have been raised in a different host species as this is the basis 
for differentiation between labels.
Following incubation in primary antibody/antibodies and washing in 0 .1M TRIS, 
sections are incubated fluorophore-linked secondary antibody (usual concentration 
1:200 in 0 .1M TRIS) for tw o hours in the dark Sections are then washed in 0 .1M TRIS 
in the dark and then if there are multiple labels, the secondary antibody labelling is 
repeated with each secondary. To achieve good multiple labelling each o f the 
secondary fluorophore-linked antibodies must m eet the following criteria: they must 
be raised in the same host species; they must be raised in a species not used to  raise 
any o f the primary antibodies; and they must be conjugated with fluorophores in such 
a combination as to  give maximum separation o f absorbance and emission spectra. 
For these reasons, a series o f secondary antibodies all raised in donkey and conjugated 
to  a variety o f fluorophores were used.
Following secondary antibody labelling sections are washed in 0 .1M TRIS and 
mounted onto slides. Before the sections dry, the slides are coated with Vectashield 
DAPI mounting medium, which contains the nucleic acid-counterstaining fluorophore 
DAPI, coverslipped and sealed with a small rim o f clear nail varnish.
Sections were viewed using a Leica confocal microscope.
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2.3.8 TUNELLabelling
TUNEL (terminal transferase-mediated b-UTP nick-end labelling) incorporates 
biotinylated UTP molecules to  the free ends o f double-stranded DNA. Hence its use 
as a marker for double stranded DNA breakages.
Tissue is sectioned as for light immunohistochemistry and incubated in 
Boeringer-Manheim TUNEL mix for 90 minutes at 37°C. The reaction is stopped with 
cold 0 .1M phosphate buffer and sections are washed thoroughly.
The biotin conjugated to  the UTP molecules is revealed in an identical manner 
to  staining for biotinylated secondary antibodies: incubation in ABC and development 
with DAB. Sections are them washed and mounted on gelatinised slides.
2.3.9 Western Blotting
In order to  achieve maximum separation o f proteins in the expected range, brain 
region homogenates (and markers) were electrophoretically separated on a 15% SDS- 
polyacrylamide gel. The separated proteins were then electrically blotted form the gel 
to  PVDF membranes using cooled Bio-Rad blotting tanks overnight. Gels were 
stained with Coomassie Blue to  confirm clean protein separation. Membranes were 
immunolabelled, the labelling revealed using chemiluminescence detected by exposure 
to  photographic film.
2.3.10 Image Analysis
Counts o f cell number, measurement o f brain region cross-sectional areas and nuclear 
size were carried out using Improvisioris OpenLab software (v2.2.5) capturing data from 
a Roper Scientific Photometries CoolSnap CCD camera attached to  a Leica microscope.
Cross-sectional areas were calculated by drawing around the areas o f interest after 
calibrating the software for each magnification using a captured image o f a graticule. 
Cell counts were conducted by ‘density slicing’ a captured image. A number o f  
‘regions o f interest’ (ROIs) are defined by the user and the properties o f each ROI 
analysed by the software. The software then selects all regions it calculates to  be 
similar to  these ROIs. This is fine-tuned by the user until they are confident the 
system is selecting all Tt should be and no more. OpenLab then ‘slices’ the captured 
image creating a representation o f all appropriate regions and their properties 
(number, area, perimeter etc.).
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2.4 Methods Employed
2.4.1 Immunohistochemistry
A  LL adult tissue for immunohistochemistry was prepared according to  the 
protocols described in 2.3, sectioned at 40(jm. The juvenile wild-type mice, 
both unadulterated and X-irradiated, were sectioned at greater thicknesses so as to  
maintain as much structural integrity as possible. Accurate details o f section thickness 
cannot be given as each brain, and areas within, were sectioned in an ad hoc manner.
The primary antibody incubation time o f 72 hours at 4°C was never varied; 
rather the only variable factor was antibody dilution. The ubiquitin, N-terminal 
huntingtin and GFAP antibodies (see 6.3) have been used previously by members of  
our group and have been shown to  work well under these conditions at a dilution of 
1: 1000; therefore, this concentration was always used for these antibodies.
The antibodies to  the various factors involved in apoptosis were new to  the 
laboratory. Furthermore, given the nature o f the experimental work -  searching for a 
factor which may not be present -  it was necessary to  use a range o f dilutions for 
these antibodies. Such dilutions ranged from 1:50 to  1:1000.
Likewise, the processing o f primary antibody labeling, and preparation for 
viewing, was never varied from the protocol given in 2.3.6.
2.4.2 TUNEL
Sections for TUNEL were usually taken from brains cut for immunohistochemisty, and 
thus all adult sections were 40pm in thickness. The juvenile mice were sectioned at 
greater thicknesses in an ad hoc manner similar to those for immunohistochemistry.
TUNEL labeling was conducted by following the instructions provided with the 
kit as described in 2.3.8. The recommended time for incubation (at 37°C) with the
constituted TUNEL mix is 90 minutes. However, during these experiments, to  ensure 
and reaction that could take place would take place, incubation times were increased 
up to  three hours.
2.4.3 X-irradiation
The juvenile mice used as positive controls had areas o f apoptosis induced by X- 
irradiation. Dr John Scholes, o f  the UCL Department of Anatomy, routinely uses X- 
irradiation in a manner similar to  radiotherapy. Indeed, the very principle o f  
radiotherapy is that dividing cells are more susceptible to  apoptosis induced by 
radiation damage, thus destroying more o f a growing tumor than healthy post-mitotic 
tissue. In a similar vein, cells in the developing mouse that have not yet exited the cell 
cycle can persuaded to  die apoptotically.
An X-irradiator, once used for medical radiography was used as a source. 
Pups were placed in a small, thin cardboard box with lid and the entire package placed 
under the field o f X-irradiation. They were exposed for one minute to  a middling 
does o f radiation. Following exposure they were left for four hours, for the nudear- 
led apoptotic events to  exert their effects, before being perfused.
2.4.4 Western Blotting
13 week-old R6/2 and LMC brains were dissected and sections o f frontal cortex, 
striatum and cerebellum removed. These regions were homogenised and protein 
content assayed. Samples were loaded such that 20pg o f  protein (denatured in 
sample buffer) from each region were run in each lane o f the gel. Primary antibodies 
for caspase-1 were used at a dilution o f 1:1000 (others, not presented here, were 
used at lower concentrations). Secondary (anti-rabbit) antibody was used at a
concentration o f 1: 15,000; a dilution found in preliminary experiments to  produce the 
best balance between noise and signal.
2.4.5 Striatal Oligodendrocyte Counts
The counts o f striatal oligodendrocytes were conducted using semi-thin (0.5 pm) 
sections from tissue processed according to  the EM preparation documented in 2.3.4. 
Semi-thin sections were taken from R6/2 mice o f 4, 6, 8, 10, 12 and 17 weeks o f age, 
and littermate control mice o f 17 weeks o f age. Sections were stained with toludine 
blue and viewed under the standard light microscope.
Oligodendrocytes were identified according to  their morphology and counted 
manually. By using a microscope connected to  the OpenLab imaging system one can 
scan through defined strips o f the striatum without the possibility o f overlap or 
separation that would undermine counts conducted when viewing the microscope 
image directly. Individually, oligodendrocytes are ‘flagged’ and counted by the 
computer as the entire striatum is scanned. The section is then viewed using a low 
power lens and the striatum outlined by the user. The cross-sectional area thus 
provides a means o f calculating density o f oligodendrocytes within each section of 
striatum.
To minimise effects from sampling different areas o f the striatum, three 
sections were taken from each of seven mice through the region where the striatum is 
largest in cross-sectional area
The average for each mouse was calculated and compared to  each o f  the 
others using the students t-test (n=7).
2.4.6 Corpus Callosum. Oligodendrocyte Counts
Counting oligodendrocytes within the corpus callosum is somewhat easier than in the 
striatum as one can be fairly certain that all cell somata within the region belong to  
oligodendrocytes.
Thionin-stained 40pm sections from R6/2 and LMC mice from I to  12-weeks 
o f age (n=2 for each time-point) were viewed using the OpenLab software as 
described above, such that the corpus callosum filled the entire field o f view analysed 
by the software. Several nuclei were defined as ROIs and density slices (see 2.3.9) 
were taken throughout the corpus callosum. Similar to  the striatal counts, the cross- 
sectional area o f the corpus callosum was then measured to  yield densities.
It should be noted that the measurements from striatum and corpus callosum 
are not directly comparable as they were conducted using different sectioning 
methods. There will be far more cells contained within any given region o f a 40pm  
section than there are in the corresponding 0.5pm section.
2.4.7 F36larigitudiiialStudy
Anticipation (see 1.3.4) means that repeat sizes are gradually increasing in each 
subsequent generation o f R6/2 mice. The original construct contained 150 CAG 
repeats, but current generations have repeat lengths closer to  200. Thus, in order to  
conduct an accurate study into the timing o f inclusion and degeneration events, I 
decided to  take a single generation of mice, the F36 generation, and take littermates 
(transgenic and control) at 4, 6, 8, 10 and 12 weeks o f  age. There is also the 
possibility o f variation from one sibling to  the next, and so I took sections for 
immunohistochemistry and sections for standard electron microscopy from each 
individual brain. Therefore, in contrast to  the protocols given in 2.3, mice for this 
study were perfused with 4% paraformaldehyde without gluteraldehyde. Furthermore, 
sections for light microscopy were cut on the Vibratome alongside the sections for EM.
Two sections o f 50pm followed by one section o f 200pm were cut in series through 
the brain. The 200pm sections were post-fixed in 0.2% gluteraldehyde for one hour 
before being processed for EM as normal. The 50pm sections were processed for 
immunohistochemistry according to  the protocol given in 2.3.6.
2.4.8 ImmunoEM
This study has used the DAKO anti-ubiquitin and Santa Cruz anti-huntingtin n-terminus 
antibodies for immunocytochemical labelling at the EM level. Both o f these antibodies 
have been thoroughly characterised and have been shown to  possess sufficient affinity 
for their target proteins that they can be used on tissue fixed with 4% 
paraformaldehyde without significant loss o f signal. Thus, tissue for immunoEM was 
taken from standard EM-fixed tissue.
Results
3.1 Degeneration in the R6/2 Mouse
3.1.1 Introduction
REGULATIONS now stipulate that R6/2 mice are to  be culled no later than 13 weeks o f ages. In mice o f this age, symptoms are very apparent (one reason 
for the current restriction) and so whatever underlies the neurological dysfunction 
seen in HD must also be apparent at this age. For analyses o f degeneration I have 
therefore used mice o f 12 to  13 weeks of age. Previous material collected before the 
onset o f this particular project has also been kindly made available by Mark Turmaine; 
this material, in the form o f tissue prepared for electron microscopy, includes sections 
from mice up to  17 weeks old.
3.1.2 Inclusion Formation and Distribution
Davies et al. identified the neuronal intranuclear inclusion in the R6/2 mouse in 1997, 
and claimed the formation o f this body ‘underlies the neurological dysfunction’ seen 
this model. As discussed in 1.5, such aggregates are seen in all polyglutamine diseases, 
however the toxicity o f the aggregate remains under debate. In order to  address this 
question myself, I have analysed the distribution o f inclusions and compared it to  the 
pattern o f pathology.
The inclusion can be identified at the level o f light microscopy by labelling with 
either anti-huntingtin N-terminus (httn) or anti-ubiquitin antibodies (see 2.2 for details). 
Figure 23 is an example o f the staining seen with anti-httn illustrating the presence of 
both intranuclear and neurite inclusions. Anti-ubiquitin staining yields a similar image 
as both ubiquitin and htt„ co-localise to  the inclusion, as illustrated in figure 24.
Labelling o f late-stage R6/2 mice with anti-httn readily highlights inclusions, 
visible even at low magnification. The nuclei o f such mice also appear to  contain non-
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Figure 23 Cortical section from a 10 w eek old R6/2 mouse immunolabelled for 
N-terminal huntingtin. N ote the dark nuclei containing inclusions (arrows) and the 
neuropil aggregates (arrowheads). Scale bar = 10pm
Figure 24 A confocal micrograph showing the co-localisation of ubiquitin and 
N-terminal huntingtin to  the inclusions of striatal neurons. The nucleus is 
stained with DAPI (blue); ubiquitin and huntingtin are stained green and red 
respectively, but when co-localised in this merged image, they are shown as 
yellow. Scale bar = I Opm.
aggregated huntingtin, whereas in littermate controls, huntingtin is predominantly 
found in the cytoplasm (figure 25).
The rate at which inclusions appear varies according to  cell type/brain region. 
It is conceivable that this variation may underlie some o f the specificity seen in HD. In 
order to  address this I have analysed the formation o f inclusions and degree of 
degeneration in the R6/2 mice. As most change in repeat size occurs on vertical 
transmission this analysis was limited to  one generation o f mice. Transgenic and wild- 
type mice were culled at 4, 6, 8, 10 and 12  weeks o f age. The httn antibody is 
extrem ely effective, so much so  that tissue can be fixed for EM (4% 
paraformaldehyde) without significant loss o f signed. Therefore, mice were perfused 
with 4% paraformaldehyde and vibratome sections were cut in a repeating series of  
four 50mm sections for immunohistochemistry followed by a single 200mm section, 
which was fixed further in 0 .1 % gluteraldehyde, for processing to  the semi- and ultra- 
thin level. This permits a direct comparison between htt,, staining and ultrastructural 
appearance.
Work on previous generations o f  mice shows inclusions are most apparent 
throughout the cortex, striatum and hippocampus, therefore I chose to  focus on four 
areas o f cortex: the cingulate, motor, somatosensory and pyriform cortices; the CAI 
and CA3 fields o f the hippocampus, the dentate gyrus and the anterior striatum (see 
figure 26).
At four weeks o f age, nuclear inclusions are already apparent in some areas, to  
w it the somatosensory cortex, striatum and CAI field of the hippocampus (see figures 
27 and 28). These inclusions are relatively small, the largest being the CAI inclusions. 
In the striatum not all cells show inclusions, suggesting that the striatum is at a 
threshold point around four weeks o f age. Cells which do not yet possess inclusions 
can often be seen to  contain small foci o f htt ,^ likewise, in the cingulate, motor and 
pyriform cortices, the nuclei stain rather prominently for http and small foci can often 
be seen, yet inclusions are absent from the upper layers and rare in the deep layers of  
these cortices. It is interesting that the inclusions are common in the somatosensory 
cortex at this age and yet rare in the other cortical areas. Furthermore, within the 
hippocampus, the CA I neurons possess the largest inclusions seen at this age, whilst
Figure 25 Striatal sections from 12 week old wild-type (A, C) and R6/2 (B, D) mice immunolabelled for N-terminal 
huntingtin. Scale bar I Opm (C,D)
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Figure 26 Topography of the mouse brain. Areas under discussion are highlighted. 
CG: cingulate cortex. M: m otor cortex. SS: somatosensory cortex. Pyri: pyriform 
cortex. Str. striatum. DG: dentate gyrus (GC: granule cells). Hippocampal areas 
CA I, CA2 and CA3.
I 15
ss
Figure 27 Sections from a 4 week old R6/2 mouse immunolabelled for N- 
terminal huntingtin. Cingulate cortex (eg), m otor cortex (m), somatosensory 
cortex (ss) and pyriform cortex (pyr), Scale bar = I Opm
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Figure 28 Sections from a 4 w eek old R6/2 mouse immunolabelled for N- 
terminal huntingtin. Striatum (str), dentate gyrus (dg), hippocampal CAI field 
(CAI) and hippocampal CA3 field (CA3), Scale bar = IOpm
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Figure 29 Sections from a 6 week old R6/2 mouse immunolabelled for N- 
terminal huntingtin. Cingulate cortex (eg), m otor cortex (m), somatosensory 
cortex (ss) and pyriform cortex (pyr), Scale bar = I Opm
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Figure 30 Sections from a 6 w eek old R6/2 mouse immunolabelled for N- 
terminal huntingtin. Striatum (str), dentate gyrus (dg), hippocampal CAI field 
(CAI) and hippocampal CA3 field (CA3), Scale bar = 10pm
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the CA3 cells are completely devoid o f aggregates, either inclusions and foci o f htt^ 
Indeed, the CA3 fields seem to  have very little htt„ within the nucleus, rather their 
staining suggests a concentration o f http at the cytoplasmic face o f the nuclear 
membrane. It is likely this indicates an early stage in the evolution o f inclusions in 
which http is processed to  the nucleus before aggregating into foci and then the 
inclusion.
At six weeks o f age, inclusions are evident in all areas under study 
(see figures 29 and 30). The cingulate and m otor cortices now resemble the 
somatosensory cortex and the pyriform cortex shows prominent inclusions. All 
neurons in the striatum show inclusions and the dentate gyrus and CA3 neurons have 
progressed from showing no inclusions to  a widespread distribution. Furthermore, the 
intense staining at the nuclear periphery o f the CA3 cells has disappeared, to  be 
replaced by a pan-neuronal staining with either multiple focal aggregates or an 
inclusion; this furthers the notion that the perinuclear staining indicated a phase of 
translocation o f N-terminal huntingtin to  the nucleus.
By eight weeks o f age, nuclear inclusions are very apparent and neurtte 
inclusions have become evident (see figures 3 1 and 32). At this point the inclusions of 
the pyramidal cells in the pyriform cortex, which were among the last to  show  
inclusions, have now become among the largest inclusions o f the cortex; indeed, they 
appear as large as the inclusions o f the somatosensory cortex which were the first to  
appear in the cortex. Likewise, the dentate gyrus and hippocampal CA3 neurons, 
which were among the last to  develop inclusions, now posses very evident aggregates. 
The largest inclusions, however, remain in the CA I neurons.
Figure 37 is an illustration o f the suggested process o f inclusion formation. I 
have used an idealised hippocampal CA3 neuron, as in this study, beginning at week  
four, I see the earliest changes only in these neurons. The earliest stage, before four 
weeks, is an extrapolated state based on the appearance o f control mouse neurons 
stained for http. In summary, http is targeted from the cytoplasm to  the nucleus, which 
results in an accumulation at the nuclear membrane whilst proteins are being 
translocated. This accumulation disappears once the nucleus has been filled with htt^ 
The six-week stage in figure 37 is based on the most immature cells rather than a
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Figure 31 Sections from an 8 w eek old R6/2 mouse immunolabelled for N- 
terminal huntingtin. Cingulate cortex (eg), m otor cortex (m), somatosensory 
cortex (ss) and pyriform cortex (pyr). Scale bar = I Opm
# #
4'
#
p ip
m
9 *
- •
str
.
dg s'" * 1
mw »*r l*** 
. . . »
•  * L *h
* •M ••mL * * L iL # ■# *#
r  * * 7 *
* . •
CA1 , .  •_ CA3 _
Figure 32 Sections from an 8 week old R6/2 mouse immunolabelled for N- 
terminal huntingtin. Striatum (str), dentate gyrus (dg), hippocampal CAI field 
(CA I) and hippocampal CA3 field (CA3). Scale bar = I Opm
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Figure 33 Sections from a 10 w eek old R6/2 mouse immunolabelled for N- 
terminal huntingtin. Cingulate cortex (eg), m otor cortex (m), somatosensory 
cortex (ss) and pyriform cortex (pyr). Scale bar = 10pm
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Figure 34 Sections from a 10 week old R6/2 mouse immunolabelled for N- 
terminal huntingtin. Striatum (str), dentate gyrus (dg), hippocampal CAI field 
(CAI) and hippocampal CA3 field (CA3). Scale bar = IOpm
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Figure 35 Sections from a 12 w eek old R6/2 mouse immunolabelled for N- 
terminal huntingtin. Cingulate cortex (eg), m otor cortex (m), somatosensory 
cortex (ss) and pyriform cortex (pyr). Scale bar = I Opm
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Figure 36 Sections from a 12 w eek old R6/2 mouse immunolabelled for N- 
terminal huntingtin. Striatum (str), dentate gyrus (dg), hippocampal CAI field 
(CAI) and hippocampal CA3 field (CA3). Scale b a r=  I Opm
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representative sample seen in the six week sections studied. Therefore, I interpolate 
that some time before six weeks the now-nuclear httn begins to  aggregate forming 
multiple foci against the background o f a nucleus filled with httn. Between six and 
eight weeks these foci disappear to  be replaced by the familiar intranuclear inclusion. 
It is logical to assume that the inclusion results from the seeding effect o f one of the 
foci. If the other foci move in and coalesce with the nascent inclusion, it is surprising 
that neither myself nor any o f my colleagues have observed a stage o f coalescence; 
presumably a ‘raspberry-like’ structure. The inclusion continues to  grow between 
eight and ten weeks, presumably by the addition o f more now-nuclear http to  the 
inclusion surface. However, growth then slows such that comparatively little occurs 
between ten and twelve weeks. However, whilst the Nils slow in their growth, 
neurite inclusions become more apparent It may be that as the nucleus becomes 
“saturated” with http, the process o f aggregation occurs before nuclear translocation 
can occur. However, the question o f why non-neuronal aggregates are found in the 
neuronal processes and not in the soma remains a mystery.
It is shown that inclusions appear at differing ages in each brain region, and that 
inclusions increase in size over time. However, it appears that whilst inclusions 
increase in size rapidly at first, this growth reaches a threshold size at which growth 
rate declines considerably, or may even stop. The inclusions o f the dentate gyrus are 
amongst the last to  appear, but by eight weeks o f age they seem to  have reached their 
maximum size (compare figures 32, 34 and 36). Furthermore, at four weeks inclusions 
are present in the CAI neurons of the hippocampus, whilst huntingtin has yet to  fill 
the nucleus of the CA3 neurons (see figure 28). By ten weeks of age, the inclusions of 
the CA3 nuclei are indistinguishable from those o f the CA I cells. Indeed, between 
eight and ten weeks all cells appear to  reach a point whereby inclusion growth slows 
dramatically. In terms of Nil size, sections from a 10-week old R6/2 mouse are almost 
indistinguishable from those o f a 12-week R6/2 mouse. This is an important 
observation when one is considering the relationship between inclusions and 
degeneration. Whilst inclusion growth appears to  plateau, phenotype progressively 
worsens. It may be that the cell cannot continue to  sequester mutant huntingtin to  
the inclusion indefinitely, thus its effects are no longer buffered and phenotype
<4wk ~4wk
Figure 37 An illustrative summary of inclusion formation. Ages 
based on the inclusion formation within a hippocampal CA3 neuron.
worsens. If true, this supports the notion that the formation o f the inclusion is a 
beneficial response by the affected cell. It also counters the idea that the inclusion is 
the underlying cause o f disease phenotype.
3.1.3 Patterns o f Degeneration
Tissue processed for electron microscopy is taken first to  the toludine blue-stained 
(to l blue’) semi-thin stage: 0.5 to  I mm sections are cut on an ultramicrotome, 
mounted on glass slides and stained with toludine blue. These sections are viewed 
through the light microscope and areas o f degeneration are apparent even at low 
magnifications. Figure 38 is a micrograph of a tol blue taken through the cingulate and 
motor cortices o f a twelve week R6/2 brain. The nuclei o f healthy neurons appear 
pale in contrast to the neuropil, whilst certain glial and degenerating cells stain darker 
than the surround. This dark nature o f the degenerating neurons is what led Mark 
Turmaine to  label this type o f death dark cell degeneration. Degenerating cells and 
healthy glia can be distinguished by morphology; at the simplest level o f identification, 
dying cells show a more irregular profile, as illustrated in figure 39A, a high powered 
section o f the cingulate cortex highlighted in figure 38. The dying neurons (arrows) 
are considerably darker than the relatively healthy neurons in the same area, exhibiting 
both nuclear and cytoplasmic condensation. Figure 39A also shows a cell in the early 
stages o f this process (asterisk): this cell is mildly darker than the other healthy neurons 
and the nuclear and plasma membranes are becoming irregular in appearance. Figure 
39B is a similar section labelled with anti-ubiquitin, revealed with DAB stain (yellow), 
clearly illustrating the presence o f nuclear inclusions (red arrows), though staining is 
hard to  distinguish in the condensed cells.
When studying the degeneration in the R6/2 mice it became clear that the 
cells appear completely healthy long after inclusion formation. I have documented 
inclusion formation at four weeks o f age, but the earliest observable changes in micro­
morphology do not occur before ten weeks o f age. Figures 40 and 4 1 are tol blues 
though the areas studied in 3.1.2 o f a ten week old R6/2. In most areas, cells appear
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Figure 38 I pm section through the cingulate and m otor cortices of a 12 w eek old R6/2 mouse. 
Degenerating neurons are identifiable by their darkened appearance. Highlighted section is magnified in 
figure 39. Scale bar = 100pm
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Figure 39 Toludine blue-stained semi-thin (I pm) sections through the cingulate 
cortex of a 12 w eek old R6/2 mouse. A: unlabelled section. Degenerating 
neurons in early (asterisk) and late (arrows) stages. B: immunolabelled for N- 
terminal huntingtin. Inclusions identifiable by the presence of DAB staining (red 
arrows). Scale bar = I Opm
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Figure 40 Toludine blue-stained semi-thin (I pm) sections through the cortical 
regions of a 10 week old R6/2 mouse. Cingulate cortex (eg), m otor cortex (m), 
somatosensory cortex (ss) and pyriform cortex (pyr). Inclusions are visible in 
many neurons (arrowheads) and some cells show early signs of degeneration 
(arrows). Scale bar = 10pm
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Figure 41 Toludine blue-stained semi-thin (I pm) sections through the 
subcortica! regions of a 10 w eek old R6/2 mouse, Striatum (str), dentate 
gyrus (dg), hippocampal CAI field (CAI) and hippocampal CA3 field (CA3),. 
Inclusions are visible in each region (arrowheads), but degenerative changes 
are only observable in striatal neurons (arrows). Scale bar = 10pm
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normal, with the exception o f the inclusion, which can be seen, unlabelled, at this level 
o f examination (arrowheads). I have included micrographs o f the cingulate & motor 
cortices and anterior striatum, which illustrate early condensation in isolated cells 
(arrows), but these are not representative samples. A representative sample o f each 
area would should all neurons with large pale nuclei; rather these images represent 
extremes which are difficult to  locate. Nevertheless, it can be said that whilst rare, 
these are the earliest changes seen in the R6/2 mouse.
At twelve weeks o f age the situation is dramatically different, dark cells are 
abundant in the cingulate & motor cortices and frequent in the striatum. Rarely, they 
can also be found in the somatosensory cortex. Figures 42 and 43 are representative 
o f that which is seen in these areas. Inclusions are visible unlabelled (arrowheads), and 
can be clearly seen within the neurons o f the hippocampus and dentate gyrus in the 
complete absence o f any degenerative changes.
3.1.4 Inclusions and Degeneration
Figure 44 presents a simplified summary o f the results seen in this longitudinal study. It 
seems clear that the relationship between inclusion formation and degeneration is not 
absolutely causative. At the extreme, the largest inclusions are seen in the 
hippocampus, and yet within the lifespan o f the R6/2 mouse, no hippocampal 
degeneration is seen. Within the cortex, inclusions are first apparent in the 
somatosensory cortex. Furthermore, the inclusions o f the somatosensory cortex 
remain larger than those o f the cingulate and motor cortices, and yet the bias of 
degeneration is heavily weighted towards these latter areas.
It must also be taken into account that the inclusions exist for many weeks 
before degeneration occurs. Indeed, there seems to  be a sudden increase in the 
degree o f degeneration in the last tw o weeks o f the study. All cell types contain 
sizeable inclusions by six weeks o f age, and yet the vast majority remain healthy in 
appearance until 10-12 weeks o f age. As inclusion growth slows towards this time 
point it could be that the cell loses its ability to  isolate mutant h tt to  the inclusion. As
Figure 42 Toludine blue-stained semi-thin (I pm) sections through the cortical 
regions of a 12 week old R6/2 mouse. Cingulate cortex (eg), m otor cortex (m), 
somatosensory cortex (ss) and pyriform cortex (pyr). The cingulate and m otor 
cortices show degenerating neurons (arrows). Scale bar = I Opm
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Figure 43 Toludine blue-stained semi-thin (I pm) sections through the cortical 
regions of a 12 week old R6/2 mouse. Striatum (str), dentate gyrus (dg), 
hippocampal CAI field (CAI) and hippocampal CA3 field (CA3). Inclusions are 
evident in each section (arrowheads) but only the striatum exhibits degenerating 
neurons (arrows). Scale bar = I Opm
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M H N H
A g e  (w k) e g m s s pyr str dg CAI CA3
A Inclusions ✓
✓ ✓✓ ✓ ✓✓ ✓ ✓✓ -
4
Degen. - - - - - - - -
6
Inclusions ✓✓ ✓✓ ✓✓ ✓✓ ✓✓ ✓✓ ✓✓✓ ✓✓
Degen. - - - - - - - -
8
Inclusions ✓✓✓ ✓✓✓ ✓✓✓ ✓✓✓ ✓✓ ✓✓ ✓✓✓ ✓ ✓
Degen. - - - - - - - -
10
Inclusions ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Degen.
* * - - * - - -
12 Inclusions
✓✓✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓✓ ✓✓ ✓✓✓ ✓ ✓ ✓
Degen.
* * * * * * * - * * - - -
Figure 44 Table correlating inclusion formation and dark cell degeneration within cortical and subcortical areas. Inclusions 
refer to  neuronal intranuclear inclusions and frequency & size are scored 0-3, 0 (-) representing no Nil formation, 3 ( / /  / )  
representing the maximum seen. Degeneration is similarly rated, 0 (-) representing no dark neurons, 3 (***) representing 
the maximum concentration of dark cells observed.
LO
mentioned previously, this correlates with the increased appearance o f neurite 
inclusions. Two possible conclusions can be drawn: that the Nil is protective and the 
neurite aggregate is the toxic species; or that as the cell loses its ability to  sequester 
http, in either form o f protective inclusion, the non-aggregated species is free to exert 
toxic effects.
3.1.5 The Ultrastrvctiiral Appearance o f Apoptosis
The current theories on the nature o f cell death in Huntington’s disease are 
summarised in 1.8 and are discussed further, in light o f this study, in Chapter 4. In 
short the prevailing theories argue for an apoptotic mode o f cell death in Huntington’s 
disease. As apoptosis was first defined using morphological criteria (see 1.7) it seems 
appropriate to  examine the morphological details o f degeneration first
Comparing results from the R6/2 mouse to  published micrographs o f ‘classical 
apoptosis’ is fraught with problems. For example, differences in preparation 
techniques may produce artefacts which are interpreted as real differences between 
accepted norms and results observed. Therefore, before beginning a detailed analysis 
of the ultrastructural changes o f the R6/2 mouse, I sought to  obtain images, prepared 
using identical techniques to  those used for preparing R6/2 tissue, o f classical 
apoptosis.
Apoptosis can be induced in a variety o f ways, chemical or physical, and 
indeed, I have used X-ray induction o f apoptosis in parts o f this study. However, as 
these techniques are by definition harmful, one has no guarantee that the methods 
preserve the “natural” profile o f death. Therefore, in order to  obtain reliable 
ultrastructural data of classical apoptosis in vivo, I took what I considered to  be the only 
viable approach: to  locate developmental cell death (the original definition o f  
apoptosis) in the mouse brain.
The overwhelming amount o f  developmental cell death in the mouse occurs 
pre-natally. Furthermore, as I wanted to  prepare developmental tissue using identical 
methods to  those used for adult R6/2 brain, sections had to  be cut using a Vibratome.
This made it extremely difficult to  prepare tissue from mice younger than 7 days old 
(P7). However, I successfully managed to  cut several P5 and P6 brains and process 
the sections (200-300mm) for electron microscopy.
N ot only is developmental cell death at this age rare in the mouse, but one 
must also take into consideration the fact that classical apoptosis is reported to  be 
completed within a matter o f hours. Thus, cells undergoing apoptosis are extremely 
difficult to  find. P5/P6 sections were therefore first processed to  the semi-thin stage 
and toludine blue revealed any pyknotic cells within each plane. As expected, for the 
majority o f semi-thin sections there were no visible dying cells. However, very rarely, 
a darkened profile could be seen and the subsequent section was cut at the ultrathin 
level and viewed in the electron microscope.
Figures 45 through 48 represent the results seen in the P5/P6 wild-type mice, 
which correlate well with the published accounts on the appearance o f apoptosis. 
Figures 45 and 46 illustrate the appearance of the majority o f the (very few) cells seen. 
The cell is shrunken in size; and both the cytoplasm and nucleoplasm are condensed. 
In each figure the appearance o f cytoplasm (and in fig. 45, nucleoplasm) in a healthy 
cell can be seen towards the periphery (black arrow). Chromatin (c) is seen to  be 
condensed into large bodies, which are found against the nuclear periphery. The 
plasma membrane, conclusively in figure 45, has a ‘scalloped’ appearance, possibly 
corresponding to  an early stage o f the ‘membrane blebbing’ described as a feature of 
apoptosis. In the earlier stages, figures 45-47, the nuclear membrane is seen intact, 
and appears to  remain so until quite late in the process.
The nucleolus in these cells appears to  gradually fragment whilst the individual 
fragments themselves condense. Figure 47 shows an early stage o f nucleolar 
fragmentation. The nucleolus (white arrowhead) mostly retains its traditional 
‘raspberry-like’ structure, but the components o f this structure appear considerably 
darker than those of the nucleolus o f a healthy cell. Dissociated nucleolar fragments 
are also visible in figures 45 and 46 (white arrowheads) those in these cases the 
overall structure cannot be seen, possibly due to  a greater degree o f fragmentation. 
Certainly, by the very latest stages observed in these mice (figure 48) there is no 
identifiable nucleolus, however certain dark fragments are evident distributed widely
Figure 45 Electron micropgraph of an apoptotic cell in the brain of a P6 
wild-type m ouse. N o te  th e  ruffling o f the  plasma m em brane, the  
condensation o f th e  chromatin (C) and th e  loss of nucleolar structure 
(arrowhead). The degree of condensation of the cell is noted by compahson 
to  the cytoplasm and nucleoplasm of a healthy cell (arrow).
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Figure 46 Electron micropgraph of an apoptotic cell in the brain of a P6 
wild-type mouse. N ote the condensation of the chromatin (c) and the loss of 
nucleolar structure (white arrowheads). The degree of condensation of the 
cell is most notable by comparison to  the cytoplasm of a healthy cell (black 
arrow). Autophagic activity is evidenced by the  presence of autophagic 
vacuoles (white arrow) and multivesicular bodies (black arrowhead).
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Figure 47  Electron micropgraph of an apoptotic cell in the brain of a P5 
wild-type mouse. N ote the  loss of nucleolar structure (white arrowhead). 
Autophagic activity is evidenced by the  presence of autophagic vacuoles 
(white arrow).
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Figure 48 Electron micropgraph of an apoptotic body in the brain of a P5 
wild-type mouse. N ote the marginated chromatin clumps (c). The degree of 
codensation is noted by compahson to  a healthy cell (arrow).
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across the cell; even if these are nucleolar fragments it suggests a complete 
disintegration o f the nucleolus. This latest stage also illustrates the persistence o f the 
chromatin condensations (c) within a highly condensed structure possessing no 
nuclear membrane: the distinctive “apoptotic bodies” o f programmed cell death. 
According to  other reports o f classical apoptosis, including the seminal paper, 
apoptotic bodies are said to  be ultrastructurally well-preserved. However, the body in 
figure 48 has little identifiable internal structure. There appears to  be some sort of 
membrane-bound organelle, or remnants thereof, in the centre o f the body, but in 
contrast to  previous reports one cannot locate any preserved mitochondria, for 
example.
O ne important feature to  com e out o f this analysis is the evidence o f  
autophagic activity within apoptotic cell death. In figures 46 and 47 one can see 
double membrane-bound structures containing other cellular constituents (white 
arrows); one can also identify multivesicular bodies (black arrowheads), both 
structures being associated with the endosome-lysosome pathway and autophagy. As 
discussed in 4.2, it is becoming clear than autophagy and apoptosis are not entirely 
distinct processes. This evidence supports the notion that autophagic degradation o f  
cellular components is involved in the apoptotic break-down o f a doomed cell.
It is thus confirmed that apoptosis within the mouse brain produces an 
ultrastructural profile similar to  those reported in other studies, particularly those that 
seek to  define the nature o f the process. Furthermore, as the EM preparation 
protocols within this study are unvaried, one can conclude that the preparation of 
tissue does not significantly alter the ultrastructural profile, rather that if classical 
apoptosis is occurring, these procedures are able to  identify it
3.1.6 The Ultrastructural Appearance o f Degeneration
The most apparent ultrastructural feature o f the R6/2 mouse central neurons is the 
intranuclear inclusion. They are visible without immunolabelling at relatively low  
magnifications due to  their unique texture, which stands out against the background of
the nucleoplasm (figure 49, A). Needless to  say, such inclusions are never found in 
tissue from control animals (figure 49, B). In the older mice in particular, the inclusion 
fills a remarkable percentage o f the nuclear volume; correlating well with the 
immunohistochemistry presented in 3.1.2. Figure 49, A also illustrates the second 
most evident feature seen in the R6/2, the invagination o f the nuclear membrane 
(arrowhead). Within the cortex it is difficult to  attribute nuclear membrane 
invagination to  pathology as certain cortical neurons often show invaginations in 
control mice, however within the healthy striatum, cells exhibit a well-rounded nuclear 
profile (figure 49, B), thereby permitting the attribution o f invagination to  pathology. 
Figure 50 contains a striatal neuron from a 10-week R6/2 mouse exhibiting the first 
signs of change. The cell appears to  be extremely healthy -  in spite o f the presence of 
the inclusion -  with the exception o f  the first signs o f invagination o f the nuclear 
membrane (arrows).
As the pathological processes continue to  exert their effects, the most notable 
change is the condensation o f the cell. In section 3 .1.3, this condensation was used as 
the identifying characteristic o f degeneration. Figure 5 1 contains a section o f striatum 
in which tw o neurons in different stages o f degeneration can be seen. N ote that the 
Nils seen in both are o f comparable size (arrowheads) and yet the healthier cell is 
much larger and paler than the other. N ote also that there is a greater degree of 
invagination o f the nuclear membrane in the darker cell. Whilst this one image alone 
does not prove that invagination increases with time, as one can easily imagine a plane 
o f section through a highly invaginated cell which would yield an image with a rounded 
nucleus, the number o f sections viewed throughout this study (including those to be 
presented herein) allows one to  say with good confidence that as the cell becomes 
darker, the number and severity o f invaginations also increase.
Figure 52 illustrates three stages o f degeneration within the R6/2 cortex. The most 
advanced neuron includes the apical dendrite and so appears larger, but if one takes 
the somata alone it is apparent that as the cell steadily darkens so too  it shrinks. It 
should be noted that the nucleoplasm and cytoplasm darken at the same rate; 
however, throughout these stages the nucleus shrinks at a faster rate than the 
cytoplasm, such that as degeneration progresses the ratio o f cytoplasm (within the
Figure 49 Electron micropgraphs of striatal neurons from a 17 week-old 
R6/2 mouse (A) and a 10 week-old wild-type mouse (B). N ote the 
intranuclear inclusions (arrow s) and invagination o f th e  nuclear 
membrane (arrowhead) in the R6/2 neurons.
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Figure 50  Electron micrograph of a striatal neurons from a 10 week-old R6/2 
mouse. The first signs of pathology, invaginations of the nuclear membrane are 
evident (arrows).
Figure 5 1 Electron micrograph of striatal neurons from a 12 week-old R6/2 mouse. 
N ote th e  neuronal intranuclear inclusions (arrow heads) which becom e less 
distinguished as cells darken (arrow).
Figure 5 2  Electron micrograph of cortical neurons from a 12 week-old R6/2 
mouse. N ote the dilation of golgi / endoplasmic reticulum, most apparent in the 
most condensed neuron (arrowheads).
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Figure 5 3  Electron micrograph o f a cortical neuron from a 13 week-old R6/2 
mouse. N ote the dilation of the endoplasmic reticulum (arrow), golgi apparatus 
(solid arrowhead), and mitochondia (open arrowhead).
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soma) to  nucleoplasm is biased to  favour the former. One explanation for this may 
be the dilation o f cytoplasmic organelles, which in figure 52 is seen most clearly in the 
darkest cell (arrowhead).
The dilation o f organelles can be seen even more strikingly in figure 53. This 
cortical neuron, from a 13-week R6/2 mouse, contains dilated endoplasmic reticulum 
(arrow), golgi apparatus (solid arrowhead) and mitochondria (white arrowheads). 
There is always the possibility that such dilatory changes are an artefact from perfusion 
and processing, however, given that it is seen as a consistent feature from each R6/2 
mouse to  the next this is unlikely. Furthermore, figure 54 is a high-power micrograph 
showing parts o f tw o adjacent cells in the R6/2 striatum, one in the latter stages of 
degeneration and the other merely showing early nuclear membrane invagination. 
Golgi apparata (arrow) in the degenerating cell are markedly dilated; the mitochondria 
(arrowheads) even more so. Indeed, many of the mitochondria o f the degenerating 
cells in both figures 53 and 54 appear not only to  be dilated but also to  be losing 
internal structural integrity. Whilst the outer membrane o f the mitochondria remains 
intact the inner membrane -  forming the cristae -  loses its defined structure and may 
in som e cases even fragment. This is also illustrated in figure 55, where the 
mitochondria o f the dark cell can be compared to  those in the adjacent neuropil 
(open arrowheads). Figure 55 also illustrates another key feature o f the R6/2 neuronal 
degeneration: the involvement o f the lysosome/autophagosome and the build-up of 
lipofuscin.
In the previous section I mentioned the presence o f autophagic profiles within cells 
undergoing apoptosis. Such profiles are also evident with degenerating R6/2 neurons. 
As discussed in 4.2, the distinction between lysosomal-based cellular turnover and 
autophagy is somewhat arbitrary, but breakdown o f cellular components remains at 
the basis. There appear to  be four general types o f profile seen in these cells. The 
first is the mufti-vesicular body (MVB), a single membrane-bound structure containing a 
number of small vesicles, as shown in figure 56 (solid arrowheads). The second profile 
is that o f the classical lysosome; a single membrane-bound structure containing 
homogenous material, most probably resulting from the proteolysis o f the contents, as 
illustrated in figures 56 (blue arrowhead). The relationship between these first tw o
Figure 5 4  High-magnification electron micrograph of adjacent striatal neurons from 
a 13 week-old R6/2 mouse. In the dark cell, note the dilation of the golgi apparatus 
(arrow), and mitochondia (arrowheads).
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Figure 55  High-magnification electron micrograph of a cortical neuron from a 17 
week-old R6/2 mouse. The dilation of mitochondria in the degenerating neuron is 
noted by com parison o f its mitochondria with those in the neuropil (open 
arrowheads). N ote the evidence of lysosomal activity (solid arrowhead) and the 
accumulation of lipofuscin (arrows)
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Figure 5 6  Electron micrograph o f a cortical neuron from a 13 week-old R6/2 
mouse. Autophagic processing is occuring as indicated by the presence of 
multivesicular bodies (solid arrowhead), autophagic vacuoles (open arrowheads), 
lysosomes (blue arrowhead) and accumulation of membranous material (arrow).
classes o f lysomsomal/autophagic profiles and the latter tw o remains under debate. 
As will be discussed, lysosomes and MVBs exist in healthy cells; a general turnover 
mechanism without the specificity o f the ubiquitin-proteasome system. However, the 
second tw o classes are considered more to be a part of traditional autophagy rather 
that constitutive lysosomal turnover.
The third profile is the autophagic vacuole, or autophagosome: a double 
membrane-bound structure believed to  originate from the endoplasmic reticulum, 
visible in figure 56 (open arrowheads). Such structures often contain further layers of 
membrane, forming multi-lamellar bodies, though they may contain anything from 
homogenous cytoplasm to  entire mitochondria.
The final class is the most prominent the membrane whorl. This is a single 
membrane-bound structure containing an accumulation o f membranous material, and 
variable amounts o f the protein component o f lipofuscin. The size and shape o f each 
o f these structures varies, as does the degree o f condensation; but the defining 
characteristic remains the same: the laminar appearance o f the membranous 
com ponent as seen in figure 56 (arrows). Clearly visible in figure 55 is the fact that 
the lipofuscin protein component within the autophagic whorl is contained within its 
own single-membrane. This raises the possibility that as the autophagic contents are 
processed, the membrane and protein components are isolated to  distinct storage 
sites. How these structures are formed also remains under debate. It is clear that 
there is a great amount o f  membrane within each structure, suggesting an 
accumulation rather than a single processing event Figure 57 contains examples o f  
the early double-membrane structures (solid arrowhead) as well as the persistent 
membrane whorls (arrow). In support o f the formation o f autophagosomes from ER 
and Golgi, many autophagosomes are seen to  form in the vicinity o f a very prominent 
and somewhat dilated reticular network (asterisks)(see also figure 56, asterisks). The 
shape o f the labelled membrane whorl is representative o f many seen: a variable 
number o f ‘lobes’ within a single membrane-bound structure. This suggests that the 
large whorls seen result from the fusion o f a number o f smaller autophagosomes, a 
processes familiar in lysosomal processing.
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Figure 5 7  Electron micrograph of a cortical neuron from a 10 week-old R6/2 
mouse. Autophagic vacuoles have formed (arrowheads), possibly originating from 
the endoplasmic reticulum and/or Golgi apparatus (asterisk). The sequestered 
product is degraded leaving m em branous material, which, m ost probably, 
accumulates trough the fusion of product-filled autophagic vacuoles and lysosomes, 
yielding the multi-lobed structure seen here (arrow).
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Figure 57 also acts as acts as an example o f a further change seen in this form of 
degeneration. Whilst the nuclear membrane persists even unto the end stages (as 
shall be shown) following invagination, it begins to  adopt a ‘ruffled’ appearance. In 
figure 57 this is most noticeable in the outer membrane of the nuclear envelope. As 
this occurs after onset o f invagination and concomitant with nuclear shrinkage, the 
ruffling may simply be a consequence o f these events. However, Mark Turmaine has 
conducted freeze-fracture analyses o f the R6/2 nuclear membrane and has found an 
increase in the density, and presumably number, of nuclear pores (Davies et al. 1999). 
There are also reports o f mutant huntingtin being associated with the nuclear 
membrane, therefore it is possible that hrtt^  disrupts cytoplasmic-nuclear transport 
leading to  the increase in pores, membrane ruffling and invagination. Similar changes 
are also seen in the plasma membrane, particularly in the later stages o f degneration, 
though this may also simply be a consequence o f cell shrinkage.
O ne o f the changes most difficult to  characterise is the alteration o f  the 
nucleolus. Elizabeth Slavik-Smith is currently undertaking a detailed study o f the 
subnudear changes in the R6/2 mouse, including an analysis o f the molecular 
components o f each o f the nuclear bodies, including the nucleolus, and her results will 
no doubt shed considerable light on these changes. On a gross, morphologic level, I 
have observed a general loss o f definition o f the nucleolus. Figure 58 contains 
examples o f both wild-type and R6/2 nucleoli. There is a great degree o f variation in 
the appearances o f the wild-type nucleoli alone, but each seems more defined than 
their R6/2 counterparts. One can more easily identify the component regions o f the 
nucleolus -  the fibrillar centres (open arrowhead) surrounded by the dense fibrillar 
component (solid arrow), the granular component (open arrow) and the perinucleolar 
cap (solid arrowhead) -  in the wild-type examples. However, the nucleolus, and often 
its substructure (particularly the fibrillar centres) remains evident in dark neurons even 
unto the most advanced stages o f degeneration (F). Furthermore, the perinucleolar 
cap appears to  be enlarged in degenerating neurons (58, D-E); though wild-type 
nucleoli can also show extremely lar^ ge perinucleolar caps (C). Importantly, the 
changes seen in the nucleoli o f the R6/2 certainly do not resemble those show to  
occur during apoptotic cell death. As illustrated in figure 47, the neuronal nucleus
Figure 5 8  Nucleoli from wild-type (A-C) and R6/2 (D-F) mice. The wild-type 
nucleolus substructure consists of the granular com ponent (open arrow), and dense  
fibrillar components (solid arrow) surrounding the fibrillar centres (open arrowhead). It 
is bordered by the perinucleolar cap  (PNC)(solid arrowhead). R6/2 neuronal nucleoli 
generally show a more diffuse, less defined structure; though the components are still 
visible (D) even unto the darkest stages (F). The PNC often appears enlarged in the 
R6/2 (E), though wild-types may also possess large PNCs (C).
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during apoptosis appears to  condense down into its individual components before 
disintegrating.
One further change observed in these mice is the relocation o f the Cajal body 
(also known as the coiled body). The Cajal body (CB) is so called as it was first 
identified by Ramon y Cajal. In spite o f long time since its identification, its function 
still remains under debate. It is currently believed to  be involved in snRNP maturation 
and/or transport (see Ogg & Lamond 2002 for review). Given its size (0 .15 to  1.5pm 
in diameter), it is rarely caught within 70nm EM preparations, but can readily be 
identified in 5 - 10pm toludine blue-stained sections, as illustrated in figures 40 (ss, 
arrowhead) and 4 1 (CA3, arrowhead). The feature to  note is that the CB is usually 
seen in association with the Nil in R6/2 mice, far too  frequently to  be a chance 
occurrence. In wild-type tissue, the CB is normally nucleolar-associated or free in the 
nucleoplasm. The relocation to  the Nil is confirmed in ultra-thin sections that do 
happen to  include the CB, such as seen in figure 59. Figure 59 indicates that the CB 
(arrowhead) associates with the Nil (arrow) even when in close proximity to  its 
normal partner, the nucleolus.
As previously described, the degenerating cells continue to  darken as the 
pathological process continues. Figure 60 is a section through a 17-week R6/2 cortex 
showing tw o cells in the late stages o f degeneration. Also in section is a relatively 
healthy cell, which shows only the presence of an Nil (open arrowhead) and a mild 
invagination o f the nuclear membrane (solid arrowhead). The differences in densities 
o f cell content are quite striking. In the dark cell at the top of the figure the Nil is still 
discernible (open arrowhead). Even at this level o f condensation, mitochondria and 
Golgi apparatus are still structurally intact although still dilated. The extent to  which 
organelles persist is even more evident in the high magnification o f the second 
degenerating cell: figure 6 1.
This cell has been sectioned towards one extreme o f the nucleus (asterisk) 
and as a result an Nil is not present. Nevertheless this section affords a relatively large 
sample o f degenerating cytoplasm. Mitochondria are still present and whilst dilated, 
given that they maintain external structure and some degree o f internal structure one 
can presume that they are functional (open arrowhead). It is also important to  note
. .  . 'V  . > •
Figure 59  Electron micrograph of a cortical neuron from a 13 week-old 
R6/2 mouse. Even at this early stage in the degenerative process the 
Cajal body (arrowhead) has becom e associated with the intranuclear 
inclusion (arrow).
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Figure 60  Electron micrograph of a section through the cortex of a 17 week-old 
R6/2 mouse. Two cells in the m ost advanced stages of dark cell degeneration are 
visible to ge ther with a cell showing the very earliest signs of change, including 
membrane invagination (solid arrowhead). Inclusions are evident at both extremes 
(open arrowheads).
Figure 61 High-magnification electron micrograph of a cortical neuron from a 17 
week-old R6/2 mouse in the end stages of degeneration. Even at this late stage, 
organelles are still discernible including mitochondria (open arrowhead) and Golgi 
apparatus (arrow). Though difficult to  distinguish in this reproduction, the nucleus 
(asterisk) has an intact membrane.
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that whilst the nuclear membrane can become extremely convoluted, it persists. The 
nuclear membrane is just visible in figure 6 1, however, as this figure indicates, it 
becom es increasingly difficult to  trace the membrane in micrographs as the cells 
darken. Nevertheless, under the electron microscope one has the advantage o f being 
able to  increase magnification and roam through the section, following the membrane. 
Such analyses suggest that in contrast to  the defined nature o f apoptosis, the nuclear 
envelope does not disintegrate.
A further contrast, marked by its absence, is the condensation o f chromatin. 
Figure 60 shows that even unto the darkest stages o f dark cell degeneration, the 
nucleus remains devoid o f the chromatin condensations associated with apoptosis (cf. 
figures 45, 46 & 48). In the earlier stages o f degeneration one can find areas of 
nucleoplasm darker than the surrounding material (for example, see figure 55), which 
may indeed correspond to  mild chromatin condensations, but these neither marginate 
nor coalesce to  form the characteristic condensations o f apoptosis.
There are suggestions o f oligodendrocyte and astrocyte involvement in the 
pathology o f HD (Myers et al. 19 9 1; Vonsattel et al. 1985). Both types o f glia have 
been said to  proliferate during the disease process. Investigations into the proliferation 
of glial cells are reported in 3 .1.9; the question addressed here is whether these glia 
have a more direct role in the degeneration o f R6/2 neurons. As described in 1.7, glial 
cells have an active role in apoptosis; indeed, the seminal paper includes the 
involvement of phagocytic glia as part o f the definition of apoptosis.
At the EM level, glia are often seen in close association with neurons; both in 
wild-type (figure 62) and R6/2 (figure 63) tissue. The majority of these glia have an 
ultrastructural profile corresponding to  oligodendrocytes: a large ovoid nucleus with 
condensations o f chromatin at the periphery, and a thin band o f relatively dense 
cytoplasm. Given the association o f these glia with neurons in the control tissue, one 
can assume that these are a feature o f the normal glial-neuronal relationship, providing 
support for the functioning o f the neuron. However, uniquely within the R6/2, glia 
that might otherwise me classified as oligodendrocytes sometimes present a 
somewhat different profile. Figure 64 contains an example o f such an instance. The 
cortical neuron (n) is in contact with a glial cell (g) that resembles an oligodendrocyte
Figure 6 2  Electron micrograph of a striatal neuron from a 10 week-old wild-type 
m ouse (n). A glial cell (g) is seen in close contact with the  neuron. The 
morphological appearance of this glial cell is indicative of an oligodendrocyte.
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Figure 63 Electron micrograph of a striatal neurons from a 13 week-old R6/2 
m ouse (n). A glial cell (g) is seen in close contact with the  neuron. The 
morphological appearance of this glial cell is indicative of an oligodendrocyte.
Figure 6 4  Electron micrograph of a cortical neuron from a 13 week-old R6/2 
mouse (n). A glial cell (g) is seen in close contact with the neuron. The 
morphological appearance of this glial cell is unusual, thus its nature cannot easily be 
defined.
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but for the small degree o f marginated chromatin and the invaginated nucleus. 
Furthermore, the cytoplasm appears relatively large and pale in comparison to  
‘classical’ oligodendrocytes. The nature o f these glia remains under question. As 
explained below, glia within the R6/2 brain may be directly affected by the HD 
mutation.
Within the R6/2 one can also frequently find associations between neurons 
and another type o f glial cell. Figure 65 contains contact between a neuron and a glial 
cell with an astrocytic profile: a large, spherical pale nucleus within a large, tenuous 
cytoplasm. Such contact between these astrocyte-like glia and neurons can be found 
at all stages o f degneration. Figure 66 contains a neuron at a later stage o f  
degeneration contacted by an astrocyte-like glial cell. This figure also raises another 
important difference between the human condition and the R6/2 model: within the 
glial nucleus is found a structure corresponding to  the Nil (arrow). As shown in 3.1.9 
these aggregates appear to  be glial inclusions similar to  those o f the neurons.
As described previously, at the light microscopy level one can identify neurtte 
aggregates using the same anti-ubiquitin and/or anti-http labelling used to  highlight the 
intranuclear inclusions. Likewise, at the EM level, the neurtte aggregates can also be 
identified without labelling due to  their structure. Figure 67 contains an R6/2 cortical 
neuron in the early stages o f degeneration, but it also contains a visible neurtte 
aggregate, enlarged in the insert (arrow). Using standard electron microscopy it is 
impossible to  establish from which cell this process originates, but given the ubiquity of  
Nils within the R6/2 model, one can safely assume that the soma from which this 
neurtte stems also contains a nucleus with an inclusion. What effects the presence of  
aggregates within the processes exert remains unknown. It is clear that certain cells 
within a population degenerate more rapidly than others and this may relate to  
differing pathogenicities o f inclusions within the nucleus and neurite.
W hether a consequence o f the somal degradation, or an effect caused by the 
presence o f extra-nuclear aggregates, degeneration is also seen with the processes. 
Darkened processes can be seen in the R6/2 mouse, which most likely correspond to  
cytoplasmic condensation. However, within axons a different mechanism o f  
degeneration has been seen. Figure 68 contains a section through a striatal fascicle
Figure 65 Electron micrograph of 17 week-old R6/2 cortex. There is a 
darkened cell which is most probably a neuron (n), containing an inclusion 
(arrow), which is closely contact by a glial cell (g). The morphological 
appearance of this glial cell suggests that it is an astrocyte.
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Figure 66 Electron micrograph o f a degenerating 17 week-old R6/2 
cortical neuron (n), which is closely contact by a glial cell of astrocytic 
morphology (a). Both cells contain intranuclear aggregates (arrows).
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Figure 67  Electron micrograph of a cortical neuron from a 13 week-old R6/2 
mouse. W ithin th e  surrounding neuropil, a neurite aggregate is found. 
Highlighted and enlarged in inset (open arrow).
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Figure 68  Electron micrograph of an axon bundle in a 17 week-old R6/2 
mouse. The axon shown appears to  be degenerating via autophagy; as 
indicated by the dominance of membrane whorls (arrows)
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from an R6/2 mouse. Within the axon are numerous membrane whorls indicative of 
autophagic degeneration, from open, early whorls to  late, darkened bodies (arrows). 
As seen in figure 67, the neurite aggregate occupies most o f the cross-sectional area of 
the process; therefore, it may be that the presence o f the aggregate isolates the 
process -  distal to  the aggregate -  and induces an autophagic ‘dismantling’ o f the 
contents. One important caveat, however, is that degeneration and the presence of 
an inclusion have not been seen together within a single process; thus, a causative 
relationship cannot be confirmed.
3.1.7 The Appearance o f Inclusions
The structural elements underlying the formation o f the inclusion remain under 
debate. As described in 1.5.5, the prevailing theory for the formation o f the inclusion 
is the polar zipper model, which involves the formation o f 13-pleated seats. Such a 
mechanism o f aggregation would produce fibrous structures akin to  those seen in 
Alzheimer’s and Parkinson’s disease (see 4.4). However, as mentioned previously, the 
Nil presents as a roughly spherical, homogenous structure with little discernible 
structure. Figure 69 contains representative examples of Nils from a variety o f R6/2 
mice. There is som e variation between each, but the overall appearance is o f a 
roughly spherical, granular structure. Occasionally, within Nils one may find structural 
elements that one may define as fibrous, but these are relatively rare (arrowheads).
The neurite aggregates present with a rather different ultrastructural 
appearance. Their shape appears to  be defined by the shape o f the process. A 
process with a large circular cross-sectional area will allow the formation o f an 
inclusion with a roughly circular cross-section akin to  those o f the nucleus (figure 70). 
However, a process with a smaller oval cross-section will possess oval aggregates 
(figure 7 1) suggesting that the inclusion increases in size to  fill the available space, 
supporting the suggestion earlier that the neurite aggregate may block and isolate the 
distal dendrite.
Figure 69  Electron micrograph of inclusions from R6/2 mice of varying 
ages. N ote the dominating granular appearance of each, with occasional 
elements which may be interpreted as fibrous (arrowheads).
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Figure 70 High-magnification electron micrograph of neurite inclusions 
from 17 week-old R6/2 mice. These aggregates resemble intranuclear 
inclusions but show m ore elem ents which may be considered fibrous 
(arrowheads).
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Figure 71 High-magnification electron micrograph of neurite inclusions from 17 
week-old R6/2 mice. These aggregates further dem onstrate the  presence of 
elem ents which may be considered fibrous (arrowheads), but exhibit an oval 
morphology.
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The important feature to  note is the structure o f the neurite aggregates. Figures 70 
and 71 contain representative neurite inclusions within which one can identify 
structural elements (arrowheads). Whilst there is no regular structure to  the degree 
of the Lewy Body o f Parkinson’s disease (see 4.4), many fibrous elements appear to  be 
present within the aggregate, considerably more than seen in the neuronal intranuclear 
inclusion. As there is a structural difference between the neuronal inclusion and the 
neurite inclusion, there may also be a functional difference. The subcellular localisation 
o f  the mutant protein, and its aggregates, may have important pathological 
consequences. Conversely, given that fibrous elements are rare with the Nil it is 
unlikely they are required for inclusion formation. They may develop as a secondary 
consequence o f inclusion formation. As it has been shown that polyglutamine 
stretches tend toward fibrilisation, induced increases in concentration are likely to  
increase the likelihood o f such events occuring. As discussed in 4.4, the fewer 
structural elements in the Nil may in fact indicate a greater rather than simpler 
complexity.
3.1.8 The Biochemical Profile o f Degeneration
Since the identification o f the molecular machinery behind apoptosis (see 1.7), it has 
become common practice to  define mode o f cell death through involvement o f this 
machinery. Indeed, much o f the evidence supporting an apoptotic mode of cell death 
in HD originates from the identification of ‘markers’ o f apoptosis in various models. 
Often, the identification o f only one player in the plethora o f proteins involved in 
apoptosis has led some groups to  hail apoptosis as the answer.
As shown above, whilst the neuronal intranuclear inclusion appears early on in 
the lifespan o f the R6/2 mouse, indeed before the onset o f symptoms, cellular 
degeneration does not occur until the last weeks o f the mouse’s life. Before twelve 
weeks o f age there is little readily identifiable cellular pathology in the R6/2 mouse. 
The beginnings o f nuclear condensation can rarely be detected in mice as young as ten
weeks, but the later pathological events are only found in mice older than twelve 
weeks (see previous section).
In order to  be certain that markers being sought after are in areas where they 
would be found if present, I have limited the results presented here to  the cingulate 
and motor cortices. I have previously shown that degeneration is most prevalent in 
these areas, therefore there is a greater chance o f identifying activated apoptotic 
machinery in these areas. During my investigation I have examined all areas o f the 
brain for evidence o f apoptosis, and I can confidently say that the cortical results are 
representative o f all areas studied. Nevertheless, in order to  provide the most 
convincing evidence, sections through the motor and cingulate cortices are shown 
here.
The micrographs presented in this section are all taken from tw o (consecutive) 
generations o f mice, transgenic and wild type, culled at either 12 weeks 4 days or 12 
weeks 5 days of age. The degree o f degeneration in the cingulate and motor cortices 
o f the R6/2 mouse at this age is illustrated in figure 72A, a semi-thin toludine blue- 
stained section. Dark profiles are evident throughout the region. Figure 72B is a 
corresponding section o f R6/2 brain labelled with anti-cleaved caspase-3 and 
processed for DAB.
Caspase-3 is generally considered to  be the central component o f the 
apoptotic pathway. It sits at the crux o f the pathways linking the initiation events to  
the execution events o f apoptosis. As explained in chapter 1.7 once caspase-3 is 
activated there is little hope o f redemption for a cell.
There appears to  be no staining above background in the regions one would 
expect to  find cell death. Figure 72C is a high magnification image o f the section 
shown in B. Some cells appear to  have stained slightly darker than others, but as the 
littermate control section in D shows, this is part of the normal variation.
The other common marker for apoptotic cell death in the use o f TUN EL 
which labels double-stranded DNA  breaks (see 2.3.x) such as occur as a result o f  
DNAse activation in apoptosis. Figure 73 illustrates the staining of the cingulate/motor 
cortex o f the R6/2 (A&C) and LMC (B&D) mice. There is no evidence o f  DNA
Figure 72 A: Toludine blue-stained semi-thin section of cingulate and m otor cortices from a 12 week-old 
R62 mouse. B: Corresponding section immunolabelled for activated caspase-3. C: Sample high power 
section from B. D: Corresponding image from a littermate control mouse. Scale bar for C and D = I Opm
Figure 73 Corresponding sections of cingulate and m otor cortices in 12 week-old R6/2 (A) and littermate control (B) mice 
after TUNEL processing. High magnification images of A and B presented in C and D. Scale bar for C and D = I Opm
breakage using TUNEL labelling in the R6/2 mouse. Indeed, the neuronal nuclei 
appear to  be the clearest parts o f the section.
Figures 74-77 illustrate the staining patterns obtained using the ABC-DAB 
method for processing labelling with other apoptotic indicators.
Apoptosis Initiation Factor (AIF) is normally localised to  the mitochondrion and 
is released upon stimulation o f apoptosis. Interpretation o f the results obtained with 
the AIF antibody is difficult, as it appears the cytoplasm o f all cells is filled with AIF. 
W hereas cytochrome c produces punctate staining corresponding to  individual 
mitochondria, AIF does not In an apoptotic cell one would expect AIF to  first fill the 
cytoplasm and then the whole o f the condensed neuron as the structural integrity of 
the nuclear membrane is lost. As shown in 3.1 .5  the nuclear membrane o f  
degenerating R6/2 neurons retains integrity throughout the measurable process o f 
degeneration, therefore even if AIF is released from the mitochondria it is unlikely one 
would ever see it fill the neuron. It is therefore difficult to  draw any conclusions about 
release o f AIF in the degeneration o f  R6/2 neurons. What can be said is that there is 
no correlation betw een areas o f  degeneration and pattern o f AIF staining. 
Furthermore, littermate control sections produce identical staining patterns.
Apoptosis activating factor-1 (Apaf-I) is normally found throughout the 
cytosol. During apoptosis it forms the apoptosom e, a holoenzyme, through 
interaction with procaspase-9 and cytochrome c released from the mitochondria. 
Interestingly, the staining pattern obtained here appears to  label the nuclei for Apaf-1 
as well as the cytoplasm. Once again it would therefore be difficult to  draw any 
conclusions about the involvement o f such a protein given that there would be little 
change upon activation o f  apoptosis. Rather, useful results are only really obtainable 
from either labelling proteins which alter their subcellular distribution or from the use 
of antibodies raised against the active forms o f the components.
The antibody used to  label cleaved DFF45 (DNA fragmentation factor 45) is 
an example o f  such. DFF45, otherwise known as ICAD (inhibitor o f CAD), is 
normally bound to  DFF40/CAD (caspase activated Dnase) inhibiting its actions. 
During apoptosis ICAD is cleaved releasing CAD. The labelling obtained does show  
some faint cytoplasmic staining, with foci occasionally visible. This suggests either an
180
Cl
ea
ve
d 
DF
F4
5/
IC
AD
 
Ap
af
-1
 
A
IF
R6/2 LMC
Figure 74 Sam ple light m icrographs 13 w eek-old R6/2 and litterm ate
control cingulate cortical neurons, immunolabelled as indicated.
Scale bar applies to  all ( I Opm).
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Figure 75 Sample light m icrographs o f 13 w eek-old R6/2 and litterm ate
control cingulate cortical neurons, immunolabelled as indicated.
Scale bar applies to  all ( I Opm).
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antibody with som e affinity for the uncleaved species, or som e degree o f tonic 
cleavage o f ICAD. Given the mild catalytic nature o f the caspase zymogen it may be 
that these occasional foci represent cleaved ICAD. In either case, there is no 
detectable difference between the R6/2 and LMC sections.
Once released from its inhibitory bondage by caspase-mediated cleavage o f  
ICAD, CAD translocates to  the nucleus whereupon it begins degrading the chromatin. 
If CAD is active in the degenerating cells o f the R6/2 brain one would expect to  see 
DAB staining in the nucleus. However, even in the areas o f known degeneration anti- 
CAD labelling fills the cytoplasm leaving the nucleus at background level.
As mentioned previously, labelling for cytochrome c normally yields a punctate 
staining o f the cytosol corresponding to  individual mitochondria. During apoptosis, the 
apoptosome forms as a result o f release o f cyt c from the mitochondria to  the 
cytoplasm. O ne would therefore expect to  diffuse labelling o f the cytosol in an 
apoptotic cell labelled for cyt c. However, as shown in 3 .1.5 whilst there is a transient 
swelling o f  mitochondria they remain intact throughout the degenerative process. 
Furthermore, as the degenerating neuron persists for a relatively long time, w e assume 
that the remaining mitochondria are functional, requiring the presence o f cyt c. 
Therefore, the staining pattern obtained is difficult to  interpret There does appear to  
be some diffuse cytoplasmic labelling along with the mitochondrial foci. In order to  
make the result more clear, I removed the coverslips from the cyt c sections and 
counterstained them with thionin. This provides enough contrast to  remove the 
background staining making the mitochondrial foci more easily identifiable. 
Furthermore, thionin staining also facilitates identification o f condensed cells. Such an 
example is included in figure 75. The cell (arrow) appears darker than the surrounding 
neurons (and larger than the oligodendrocytes [asterisk]) but cytochrome c foci are 
still visible. This supports the idea put forward in 3.1.5 that the mitochondria persist in 
a functional state, and also suggests that cytochrome c is not released into the cytosol.
Figure 76 contains tw o more examples o f activated caspase-3 labelling. The 
New England Biolabs antibody and CM I (Idun Pharmaceuticals). Each yields a slightly 
different staining pattern, the CM I producing a more punctate appearance. As with 
the anti-ICAD antibody it may be that the CM I antibody has som e affinity for
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Figure 76 Sample light m icrographs o f 13 w eek-old R6/2 and litterm ate
control cingulate cortical neurons, immunolabelled as indicated.
Scale bar applies to  all ( I Opm).
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Figure 77 Sample light m icrographs o f 13 w eek-old R6/2 and litterm ate
control cingulate cortical neurons, immunolabelled as indicated.
Scale bar applies to  all ( I Opm).
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unprocessed species, and yet neither caspase-3 antibody produces any significant 
staining. This suggests further that caspase-3, for many the major identifying factor of 
apoptotic cell death, is not activated in the degenerating R6/2 neurons.
One o f the targets o f activated caspase-3 is poly-ADP ribose polymerase 
(PARP), whose normal function is to  repair DNA damage. The cleavage o f PARP 
prevents it from repairing the breakages caused by DFF40/CAD thus reinforcing the 
catalytic efficacy o f activated caspase 3. As no evidence for either caspase-3 activation 
or DFF40/CAD translocation has been found it should be unsurprising to  report that 
there is no evidence for PARP cleavage either.
It has been suggested that caspase-8 is recruited to  the neuronal intranuclear 
inclusion in a cellular model o f polyglutamine disease (Sanchez et al. 1999). In the 
R6/2 mouse model, however, caspase 8 is seen to  be localised throughout the cell, but 
has never been seen to  colocalise with the Nil.
Caspase-9 is unique among the caspases in that it does not have to  be cleaved 
to  reach maximum efficacy. Rather, as mentioned, it functions as a holoenzyme with 
Apaf-1 and cytochrome c. Free procaspase-9 will be cleaved during apoptosis as a 
result o f the general self-activation o f  the caspase family, but is not fundamental to  the 
apoptosis process. Nevertheless, it is interesting to  find that one of the tw o antibodies 
used to  label cleaved caspase 9 produces the punctate pattern reminiscent o f other 
results. These experiments were conducted on consecutive sections, with the only 
altered variable between the tw o being the primary antibody. Therefore, it may be 
that the Cell Signalling Technologies cleaved caspase-9 antibody has a mild affinity for 
the non-activated form, as suggested for the cleaved ICAD and CM I antibodies, but it 
may also be that this pattern is the result o f some sort o f general background staining, 
seen so prominently only as the sections are processed in DAB for a relatively long 
time to  bring out any staining as might be present. However, without a positive 
control for comparison it is impossible to  say whether this signal would be developed 
in the presence o f confirmed apoptosis. Indeed, whilst the negative controls o f the 
LMC mice provide a means o f comparison for the R6/2 mice, it has yet to be shown 
whether these antibodies will actually recognise apoptosis if it is occurring.
R6/2 LMC
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Figure 78 W estern blot (chemiluminescence detection) of 13-week 
R6/2 and littemnate control brain lysates (oc cortex; str striatum; cb: 
cerebellum) immunoblotted for caspase-1. The zymogen is present 
as a 45kDa band (arrow), precursor forms appear as intermediates 
(arrowheads) in the  cortices of both mice. Activated caspase-1 
should appear as a 20kDa band.
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For the vast majority o f my analyses into the involvement o f the apoptosis players in 
dark cell degeneration, I have used immnohistochemistry, the advantage being that 
activity within individual cells can be identified. For caspase analyses, antibodies have 
been used which are engineered to  recognise only the cleaved, activated form of each. 
As caspase-1 has been reported to  be activated in R6/2 mice (Chen et al. 2000), it 
was important for me to  assess the involvement o f this factor myself. However, such 
an antibody has yet to  be made against the activated form of caspase-1. Thus, in 
order that I might distinguish between the inactive and active forms o f the enzyme I 
turned to  western blotting. Figure 78 is an example o f a blot immunolabelled for 
caspase-1, obtained form a gel on which lysates from 13-week old R6/2 and littermate 
control mice have been separated. The active form of caspase-1 should appear as a 
labelled band at approximately 20kDa. However, whilst the inactive forms o f the 
protein are labelled, including, interestingly, two precursor forms in the cortex fractions 
from both mice, the blot is clear between 15 and 30kDa. Whilst there is the strong 
possibility that levels o f activated caspase-1 are dwarfed by the inactive form in the 
greatly outnumbering non-dark cells (the very reasoning behind immunocytochemistry 
being my weapon o f choice) my results certainly do not replicate the published 
reports which use identical methods to  show considerable caspase-1 activation in the 
R6/2 mouse (ibid).
As reported in 3 .1.5 the identification o f a positive control for morphological 
analysis was fraught with difficulties. At the five and six day age cells dying by 
developmental apoptosis in the mouse are exceptionally rare. At the semi-thin tol- 
blue level one may find one or tw o dark cells which one can then centre in on for 
ultra-thin EM analysis. With 40mm frozen sections one would have no guarantee that 
dying cells are present, and it would be almost impossible to  verify this post- 
immunocytochemical analysis.
In order to  address this question I investigated the possibility o f inducing 
apoptosis, in as lar^ ge numbers o f cells as possibly, and preferably within the same 
tissue to  act as a good positive control. John Scholes o f the UCL Department o f  
Anatomy, routinely X-irradiates rodents. Cells still in the cell cycle are more 
susceptible to  radiation damage than post-mitotic cells (the basis for radiotherapy) and
therefore it was reasoned that in the P4-P6 mouse, whilst cells undergoing a natural 
apoptotic ‘pruning’ are rare, there may be many more in which apoptosis could be 
induced by X-ray damage.
The method o f X-irradiation used is described in 2.4.x. PLP-fixed tissue had to  
be cut at 80mm as at this age, it is very difficult to  keep the tissue from disintegrating. 
Sections w ere p rocessed  for either D A B-im m unocytochem istry o f  
immunofluorescence. The latter involves fewer steps and thus yielded the greater 
quality tissue at the end o f processing.
X-irradiation stimulated more than the death o f a few more isolated, 
susceptible cells. There appear to  be whole populations o f neurons that undergo 
apoptosis when X-irradiated at P4/P5; particularly the sub-ventricular zone and the 
granule cells o f the cerebellum. These areas are the last to  com plete cell 
division/maturation, and therefore posses the most cells yet to  leave the cell cycle, 
making them the most sensitive to  radiation damage. The very centres o f these areas 
labelled with, for example, anti-activated caspase-3 and developed using the ABC- 
DAB system produces areas so dark that it is difficult to  identify individual cells. 
Processing for confocal microscopy allows one to  ‘optically section’ the sample and it 
is therefore easier to  see individual cells amongst the cacophony o f labelling. Figure 79 
contains examples o f apoptotic labelling in the sub-ventricular zone (A&B) and 
cerebellar cortex (C&D). The efficacy o f the labelling is without question. Figures 
79A & B are labelled for cleaved caspase-3, using the New England Biolabs and CM I 
antibodies respectively. B is shown at high magnification such that the ultrastructure 
can be more easily distinguished. The cells in the plane o f this optical section show  
pan-cellular labelling with the exception o f one or more large circular regions which 
correspond to  the condensations o f chromatin formed in the generation o f the 
apoptotic bodies, as illustrated at the EM level is figures 45-48. Figure 79C represents 
the labelling o f cleaved DFF45/ICAD seen in the cerebellar cortex There appears to  
be a distinct population o f cells within the cortex that label for cleaved DFF45/ICAD, 
most likely the granule cells as these are the last to  mature. Figure 79D shows 
cleavage of PARP, also within the cerebellar cortex
Figure 79 Confocal microscopy immunofluorescence on x-irradiated neonates. 
A: activated caspase-3 (NEB) in the subventricular zone (cc=corpus callosum) 
B: activated caspase-3 (CM I) shown at higher magnification (c=chromatin 
condensation) C: cleaved ICAD in the cerebellar cortex D: cleaved PARP in 
the cerebellar cortex.
Scale bars in A, C  & D =  50pm ; scale bar in B =  I Opm
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Figure 80 Cells in the subventricular zone of neonates following x-irradiation. 
Immunolabelled for listed factors (both CM I and C3 are labelled for activated 
caspase-3) and processed using the ABC/DAB system. Scale bar = 10pm
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Using DAB-immunocytochemistry individual cells can be identified on the periphery of 
these apoptosis-rich areas, and these also show morphology reminiscent o f the 
apoptosis seen in the developing mouse in 3 .1.5. Figure 80 contains examples of 
cleaved caspase-3 (C3 & CM I) labelling using DAB. Though not as apparent as the 
optically sectioned confocal sections, circular DAB-free areas can be identified. 
Interesting, labelling for AIF yields no significant results, even in these areas o f high 
apoptosis. O ne can find areas o f darker staining, but neurons within these areas 
exhibit a healthy morphology with lar^ ge pale nuclei, similar to  the results seen in the 
adult R6/2 and LMC mice. Similarly, there appears to  be no difference in staining for 
Apaf-1. Once again, there are zones within the apoptotic areas that exhibit a darker 
staining, but these resemble areas seen in the adult mice (cf. figure 74).
Unfortunately, whilst I attempted to  do so several times, I did not manage to  
complete TUNEL labelling of X-irradiated sections due to  the complexity o f the 
procedure. By then end o f processing very little remained of the sections.
Nevertheless, it can be said with a good degree o f confidence that as these 
antibodies do label cells artificially induced into apoptosis in the P4-P6 brain they 
would label apoptotic cells in the adult brain if the appropriate protein species were 
present. Therefore, I believe it is reasonable to  conclude that the negative results 
gathered in this study are true negative results.
3.1.9 TheRoleofGlia
Kerr, Wylie and Currie’s original definition o f apoptosis included as the second stage 
the engulfment o f the apoptotic cell by surrounding cells. In the nervous system this 
normally falls under the purview o f the microglia: the macrophages of the CNS. In the 
case o f necrotic cell death the resultant inflammatory response in dominated by 
astrocytes.
As mentioned in 3 .1.5 glial cells are often seen juxtaposed to  degenerating 
neurons. It has also been suggested that processes from these glia penetrate the 
degenerating neurons (Mark Turmaine, personal communication). The question,
therefore, is what are these glia and what role do they have in the degeneration o f the 
R6/2 neurons?
Astrocytosis occurs as part o f HD (Vonsattel et al. 1985); there are also 
reports of an increase in density of oligodendrocytes (Myers et al. 1991). Astrocytes 
are identifiable at the electron microscope level, but at the light level, they need to  be 
labelled to  facilitate counting. Labelling with GFAP, produces highly variable staining 
patterns, not only between individual mice but between individual sections from each 
mouse. Attempts at quantifying astrocyte numbers therefore proved fruitless. 
However, since oligodendrocytes are relatively easy to  identity in tol-blue sections, this 
issue is more easily addressed.
The increase reported by Myers et al. occurs before the onset o f symptoms, 
indeed, they suggest that the increased number o f oligodendrocytes may be indicative 
of developmental changes in HD gene carriers affecting glial numbers from birth 
(redrawn from original data as figure 8 1). Using tol-blue sections o f the striatum I 
counted the number o f oligodendrocytes at each age and also measured the total 
cross-sectional area o f each striatal slice. As it cannot be guaranteed that each section 
is from an identical region o f the striatum, a comparison o f cross-sectional areas would 
not yield a reliable result, however, oligodendrocyte densities should provide more 
reliable sample data. I have expressed the data in figure 82 in a manner similar to  the 
data from Myers et al. in figure 8 1. The broad trend is similar, there is a significant 
increase in oligodendrocyte density in the diseased individuals (p<0.005). However, in 
contrast to  the suggestion from Myers et al. this increase is not congenital. It does 
occur before the onset o f overt symptoms, before eight weeks (p<0.05), but is not 
apparent at six weeks or younger. If the human data were to  include HD-carrier 
youths in its sample, the picture may be identical.
There remains, however, the possibility that the increases in oligodendrocyte 
density occur not as a result of oligodendrocyte proliferation but rather as a result of 
cell shrinkage. As previously mentioned, a comparison o f striatal cross-sectional area 
would not yield a reliable result; however, to  address the question o f neuronal 
shrinkage affecting density, one can study the corpus callosum. Given that there are 
no neuronal cell bodies within the corpus callosum the effect o f any neuronal
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Figure 81 Density of oligodendrocytes within the striatum of human HD patients throughout disease progression 
compared to  otherwise healthy individuals. A significant increase in density is seen at all stages of the human disease.
Redrawn from data published by Myers et al. ( 1991)
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Figure 82 Density of oligodendrocytes within the striatum of the R6/2 mouse model throughout disease progression 
compared to  littermate control mice of 17 weeks of age. A significant increase in density is seen at 8 weeks (* p<0.05). 
This increase becomes more significant as the disease progresses (*** p<0.0l).
Students t-test (n=7); error bars = ± I standard error.
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Figure 83 Density of oligodendrocytes within the corpus callosum of R6/2 and littermate control mice from I w eek to  
12 weeks of age. There is no statistical difference between these densities. (p>0.05, n=2; error bars = ± I std err)
shrinkage should be negligible. Furthermore, given that the only cell bodies present in 
the corpus callosum are glial, it is even easier to  count cell number. Using the 
OpenLab software, I counted thionin-stained cell nuclei within the corpus callosa o f 
R6/2 and LMC mice from one week o f age to  twelve weeks o f age (figure 83). The 
results indicate that there is no significant effect on oligodendrocytes in the R6/2 
mouse. Indeed, density decreases as the mice age suggesting that as the size o f the 
white matter increases, oligodendrocytes do not proliferate in exact proportion.
It has been reported that R6/2 exhibit a reduced growth; indeed, the average 
corpus callosum cross-sectional areas was smaller in the R6/2 mice compared to  their 
littermates. Therefore, w e would expect density values to  be higher if the same 
number o f oligodendrocytes were contained in a smaller area. Whilst the results 
show no statistical difference, if they suggest anything at all, it is that there is a decrease 
in oligodendrocyte numbers in the R6/2 corpus callosum.
It is very difficult to  say whether the R6/2 striatal oligodendrocyte counts 
indicate a true increase in absolute number. Furthermore, whilst the human data o f  
Myers et al. indicate an increase in oligodendrocytes even in presymptomatic HD 
patients, it has been noted that remarkable shrinkage can occur in patients before the 
onset of symptoms (de la Monte et al. 1988). It is therefore a distinct possibility that 
the reports o f increases in striatal oligodendrocyte numbers, including my own work, 
are an artefact resulting from neuronal shrinkage.
It is interesting to  read that Myers reports no significant astrocytosis until there 
is significant neuronal loss in the human disease. Given that there is no significant 
neuronal loss within the lifespan o f the R6/2 mouse, if the model does indeed replicate 
the glial behaviour in the disease, one would not expect to  see significant astrocytosis 
at all.
Whilst it is not possible to  accurately identify any increases in glial numbers in 
the R6/2 model, it is evident that there is some form o f glial response to  the 
degenerating neurons; glial cells are seen juxtaposed to  dying cells and ‘cuffing’ is seen 
around the blood vessels. In an attempt to  identify these neurons which contact 
degenerating cells I labelled 12 w eek R6/2 sections for the glial markers GFAP, F4/80 
and NG2; identifying astrocytes, microglia and oligodendrocytes respectively. I viewed
Figure 84 Confocal micrographs to  illustrate the staining 
patterns obtained when immunolabelling for either GFAP (A) 
o r NG2 (B). Scale bars = I Opm.
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Figure 85 An oligodendrocyte (A) and an astrocyte (B) from a 17 
week-old R6/2 mouse. Intranuclear inclusions are evident in both glia 
(arrows).
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of dopaminergic SNC neurons. Here we have shown that the JNK3 ko provides long-lasting 
protection against axotomy; moreover, JNK3 ko and c-JunAA are transiently protective 
against 6-OHDA. These findings suggest a pro-apoptotic role of JNK3 and c-Jun in degenera­
tion of dopaminergic neurons being in line with recent observations (Hunot et al., 2004). 
Moreover, c-JunAA and JNK2 revealed a non-significant tendency to improve the survival of 
SNC neurons following axotomy. Recently, SNC neurons were transiently protected against 
axotomy by c-jun antisense-oligonucleotides (Crocker et al., 2001), and JNK2 ko protected 7 
d after MPTP induced dopaminergic death whereas later time points were not investigated 
(Hunot et al., 2004). We have also found that the number of dopaminergic SNC neurons in 
JNK1 ko was significantly enhanced compared to WT1, whereas no differences were found as 
published elsewhere (Hunot et al., 2004). Previously, similar numbers of facial motoneurons
these sections using confocal microscopy, such that I could also scan vertically through 
each section. Glial cells labelled well (figure 84), but I could not find a labelled glial cell 
contacting a dark nucleus indicative o f a degenerating neuron. Thus, whilst it is difficult 
to  make conclusions using such data, it suggests that those glia seen to  contact 
degenerating neurons at the electron microscope level are neither microglia, 
oligodendrocytes or mature astrocytes. Since GFAP is present only within reactive 
astrocytes, there remains the possibility that the glia are astrocytic in lineage, but have 
yet to  mature.
In undertaking these investigations an important difference between the human 
disease and its R6/2 model became apparent. Most evident within the corpus 
callosum, it can be seen that glia in the R6/2 often contain inclusions in a manner 
similar to  the neurons. In fact at the ultrastructural level they appear similar to  the Nils 
(see figure 85). As illustrated, they are found both in oligodendrocytes (A) and in glia 
with astrocytic morphology (B). Whilst my results suggest the presence o f the 
inclusion within the oligodendrocyte appears to  affect neither its development nor its 
survival, there remains the possibility that its presence affects glial function. Given that 
glial inclusions have not been detected in the human condition, this raises the 
possibility that there may be a glial component to  the R6/2 disease, perhaps adding to  
the severity of the disease phenotype.
3.2 Degeneration in the Hdh Knock-In Mouse
3.2.1 Introduction
A  MONG the various mouse models o f Huntington’s disease (see 4.6), a number 
/ " A  have involved the ‘knocking-in’ o f the mutation that causes the human 
condition into the murine homologue o f  the IT 15 gene, Hdh (Huntington’s disease 
homologue). Whilst more complicated to  generate, one may argue that these models 
recapitulate the human condition more accurately, given that the mutation is within 
the natural mouse gene and this gene is within the correct ’genetic context’ (the 
random nature o f the integration event(s) involved in generating transgenic mice has 
the potential to  disrupt the normal genome).
Conversely, given that the human and mouse huntingtin proteins are only 90% 
similar (see 6.2), one could argue that the knock-in models replicate not the human 
condition, but the mouse equivalent N o mouse model is going to  replicate fully the 
human disease simply because they are different species. Rather the question is one 
of the ‘most appropriate’ model(s).
In order to  address this issue I have also studied the Hdh knock-in model o f Dr 
Peggy Shelboume in order to  compare it to  the R6/2 transgenic model. This Hdh 
model exists on more than one genetic background: both Black 6 and FVB mice 
strains, thus allowing me to  also investigate any differences that may occur due to  
background genetics, as each strain o f knock-in mouse expresses an identical mutant 
protein. Furthermore, a spontaneous mutation occurred in one line o f Black 6 Hdh 
mice yielding an aberrant stop codon near the 3’ end o f intron I. These mice express 
a truncated version of the mouse huntingtin containing only exon I with an expanded 
polyQ sequence, akin to  the transgenic construct expressed in the R6/2 mice. Thus 
comparing these mice permits a comparison o f the R6/2 to  its knock-in equivalent 
(albeit with different repeat sizes).
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3.2.2 Inclusion Distribution
Sections from each o f the mice, Hdh and wild type, were immunolabelled using the 
http antibody. Whilst each o f the Hdh mice showed the presence o f inclusions, the 
distribution was markedly different to  that seen in the R6/2 mice. In contrast to  the 
ubiquitous distribution seen in the R6/2, inclusions were confined to  discrete areas 
within these mice. The primary foci for inclusions were the nucleus accumbens, 
olfactory tubercle and the striatum. There was no observable difference between the 
distribution o f number o f inclusions seen in either o f the full-length strains, but in the 
striatum alone, each showed a considerably greater number o f inclusions than the 
truncated expression black 6 strain (figures 86 and 87). Both full-length strains 
exhibited many mature inclusions within the striatum, and yet these are relatively rare 
in the truncated expression knock-in. This is rather surprising given that the work of 
others suggests a greater propensity for inclusion formation in models that express 
merely the N-terminus o f huntingtin.
Each o f these mice stands in stark contrast to  the R6/2 where areas that were 
seen to  possess frequent large inclusions show no involvement at all using the knock- 
in approach; most noticeably all cortical regions. Furthermore, within each area that 
does contain inclusions, the Hdh mice exhibit a restricted distribution. Figure 88 
contains micrographs from the striata o f R6/2 and Hdh mice. Large inclusions are 
visible in both (arrowheads), and yet whereas the R6/2 shows nuclear http 
immunoreactivity in all cells, the Hdh possesses cells with nuclear http and large 
inclusions adjacent to  cells with a wild-type appearance (arrows).
Referring to  figure 37, within the striatum, the Hdh mice show profiles 
corresponding to  all stages up to  8 weeks. At this point the mice are at the end o f  
their natural lifespan and so cannot show more mature profiles. This would also 
explain why I have been unable to  locate neurite inclusions in these mice. In my R6/2 
analyses, neurite inclusions formed after numerous, large nuclear inclusions were 
evident thus it is reasonable to  assume that these mice die before neurite inclusions 
can form. The R6/2 mice also show mostly concomitant inclusion formation in 
contrast to  the single-area variation seen here. Figure 88 (Hdh) shows that adjacent
202
Striatum Nucleus Accumbens
FLB6
FLFVB
TrB6
Figure 86 N-terminal huntingtin immunolabelling in the striatum and nucleus 
accumbens of full-length Hdh black 6 (FLB6), full-length Hdh FVB (FLFVB) and 
truncated Hdh black 6 (TrB6) mice. Inclusions (arrows) are more prevalent in 
the nucleus accumbens of all animals. Within the  striatum, the  truncated- 
expression black 6 mouse shows the fewest inclusions.
Scale bar = approximately 100pm
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Figure 87 N-temninal huntingtin immunolabelling in the olfactory tubercle of 
full-length Hdh black 6 (FLB6), full-length Hdh FVB (FLFVB) and truncated Hdh 
black 6 (TrB6) mice. Inclusions are present throughout the region (arrows) at 
comparable frequencies in each animal. Scale bar = approximately 75pm
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Figure 88  Striatal sections from a 29 month-old full-length Hdh mouse and a 
12 week-old R6/2 mouse immunolabelled for N-terminal huntingtin. Inclusions 
(arrowheads) are smaller in the  Hdh.  The R6/2 also shows nuclear 
accumulation of htt in all cells, whereas the Hdh shows many neurons with 
purely cytoplasmic labelling (arrows). Scale bar = I Opm
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cells can exhibit profiles at opposite ends o f the inclusion spectrum. This limited 
variation, together with the limited distribution in the brain as a whole, may 
correspond to  the selectivity seen in HD.
3.2.3 Patterns of Degeneration
As with the R6/2 mice, the presence o f degeneration was assessed using semi-thin 
toludine-blue stained sections. Interestingly, considerable amounts o f degeneration 
were observed in many areas. Given that these mice are relatively asymptomatic, 
exhibiting only minor behavioural alterations, the amounts o f degeneration seen were 
truly surprising. However, the most startling observation was found in the controls. 
Both black 6 and FVB wild-type mice showed comparable levels o f  degeneration to  
their littermates expressing mutant huntingtin.
Sections throughout each o f  the brains were taken and the distribution o f dark 
profiles noted. As reported below, variation along the anterior-posterior (A-P) axis 
was found for each mouse at each age (thus making quantitative analyses difficult); but 
for an illustrative comparison, sections from comparable regions in mice approximately 
128 weeks old4 are presented in figures 89 to  100. As seen in the R6/2 mice, the 
cingulate cortex showed the greatest number o f degenerating cells in the Hdh mice 
(figure 89), with the majority o f cells in each layer o f this region exhibiting a darkened 
appearance (arrows). Between the controls, degenerating cells are found more 
frequently in the FVB wild-type; an interesting result as this mouse is nearly tw o  
months’ younger. In either case, degenerating cells within the cingulate cortices o f the 
controls are considerably few er than any o f  the knock-ins. Thus it appears 
degeneration in the cingulate cortex can be ascribed to  the Hdh mutation.
The secondary motor cortex (at this A-P position) shows mild degeneration in 
each mouse, with no substantial differences between each o f the mice (figure 90);
4  All black 6  m ice in this com parison w ere  29  m onths and 21 days-old, th e  o ld est surviving 
Hdh FVB m ouse w as 29  m onths and 18  days-old. Unfortunately, th e  only extant wild type  
FVB w as 28  m onths-old exactly.
FLB6
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Figure 89 Toludine blue-stained 
semi-thin sections of cingulate 
cortices from full-length black 6 
(FLB6), full-length FVB (FLFVB) and 
truncated black 6 (TrB6) Hdh mice; 
and from wild-type black 6 (WTB6) 
and  FVB m ice (W TFVB). 
Degenerating neurons exhibit a 
darkened appearance (arrows).
Scale bar applies to  all «  50pm
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Figure 90 Toludine blue-stained 
semi-thin sections of supplementary 
motor cortices from full-length black 
6 (FLB6), full-length FVB (FLFVB) 
and truncated black 6 (TrB6) Hdh  
mice; and from wild-type black 6 
(WTB6) and FVB mice (WTFVB). 
Degenerating neurons exhibit a 
darkened appearance.
Scale bar applies to  all »  50|jm
whereas the primary motor cortex shows degeneration in each o f the Hdh mice with 
few  observable changes in the controls (figure 91). Therefore it would seem that 
degeneration in the primary motor cortex is also attributable to  the mutation.
The situation is reversed in the somatosensory cortex (figure 92) where each 
o f the Hdh mice is spared degeneration in contrast to  the controls, which possess 
numerous darkened cells at various stages o f degeneration. It seems reasonable to  
assume that mutant huntingtin would act as a toxic stimulus over and above the 
degenerative effects seen with age. It is unlikely that there is an unknown beneficial 
effect o f  the mutation, delaying age-related changes, thus this situation is rather 
puzzling. Given the variation along the anterior-posterior axis it is likely that this 
situation arises as a result o f comparing slightly difference areas. In most regions, this 
variation occurs gradually as one moves through the brain, but in the somatosensory 
cortex there appears to  be a very defined, focal region o f degeneration. Thus, whilst 
these sections are as close as possible, and provide a good means o f contrast for most 
areas, they yield a misleading picture for the somatosensory cortex.
As one moves out o f this area into the insular cortex (figure 93), the contrast 
between controls and Hdh mice abruptly disappears. Mild degeneration is seen in 
each brain, with darkened profiles most frequent in each o f the full-length knock-ins. 
Similarly, within the pyriform cortex (figure 94) the truncated-expression black 6 
mouse possesses fewer darkened profiles that either o f the full-length Hdh mice, and a 
comparable number to  the wild type black 6. Once again, the wild-type FVB mouse, 
whilst younger, exhibits a greater degree o f degeneration. The preoptic area, along 
the entire o f  the anterior-posterior axis, exhibits consistently high levels o f  
degeneration (figure 95).
The striatum is the focus o f degeneration in the human condition, and it has 
been shown that httn accumulates in the nuclei o f striatal neurons in each Hdh mouse, 
with lar^ ge inclusions found in the full-length mice. However, striatal degeneration 
remains relatively rare in the mouse models (figure 96). Dark profiles are found within 
the striata o f all mice (arrows) at comparable frequency; yet, as with the R6/2 mice, 
the cortex has considerably greater levels o f degeneration.
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Figure 91 Toludine blue-stained 
semi-thin sections of primary motor 
cortices from full-length black 6 
(FLB6), full-length FVB (FLFVB) and 
truncated black 6 (TrB6) Hdh mice; 
and from wild-type black 6 (WTB6) 
and  FVB m ice (W TFV B). 
Degenerating neurons exhibit a 
darkened appearance.
Scale bar applies to  all «  50pm
FLFVB
WTFVB
Figure 92 Toludine blue-stained 
semi-thin sections of somatosensory 
cortices from full-length black 6 
(FLB6), full-length FVB (FLFVB) and 
truncated black 6 (TrB6) Hdh mice; 
and from wild-type black 6 (WTB6) 
and  FVB m ice (W TFV B). 
Degenerating neurons exhibit a 
darkened appearance.
Scale bar applies to  all *  50|jm
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Figure 93 Toludine blue-stained 
semi-thin sections of insular cortices 
from full-length black 6 (FLB6), full- 
length FVB (FLFVB) and truncated 
black 6 (TrB6) Hdh  mice; and from 
wild-type black 6 (WTB6) and FVB 
mice (WTFVB). D egenerating 
neu ro n s  exh ib it a d a rk en e d  
appearance.
Scale bar applies to  all *  50pm
FLB6 FLFVB
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Figure 94 Toludine blue-stained 
semi-thin sections of pyriform 
cortices from full-length black 6 
(FLB6), full-length FVB (FLFVB) and 
truncated black 6 (TrB6) Hdh mice; 
and from wild-type black 6 (WTB6) 
and  FVB m ice (W TFV B). 
Degenerating neurons exhibit a 
darkened appearance.
Scale bar applies to  all »  50pm
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Figure 95 Toludine blue-stained 
semi-thin sections of the preoptic 
areas from full-length black 6 (FLB6), 
full-length FVB (FLFVB) and 
truncated black 6 (TrB6) Hdh mice; 
and from wild-type black 6 (WTB6) 
and  FVB m ice (W TFVB). 
Degenerating neurons exhibit a 
darkened appearance.
Scale bar applies to  all «  50pm
FLFVB
Figure 96 Toludine blue-stained 
semi-thin sections of the striatum 
from full-length black 6 (FLB6), full- 
length FVB (FLFVB) and truncated 
black 6 (TrB6) Hdh mice; and from 
wild-type black 6 (WTB6) and FVB 
mice (WTFVB). D egenerating 
n eu ro n s  exh ib it a d a rk en e d  
appearance (arrows).
Scale bar applies to  all *  50pm
WTB6 WTFVB
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In the R6/2 model, the hippocampus is devoid o f degeneration in spite o f its 
possessing some o f the largest inclusions. In contrast, the hippocampi in the Hdh mice 
show numerous degenerating neurons with a complete lack o f nuclear huntingtin. 
Degeneration is rare in the CA3 region (figure 99), and infrequent among the CAI 
neurons (figure 97), yet the CA2 field (figure 98) exhibits frequent darkened neurons. 
The wild-type mice show similar levels o f degeneration, therefore this degeneration 
cannot be attributed to  the disease process, but it is interesting to  note such focal and 
substantial degeneration.
Also interesting to  note is the degeneration seen within the cerebella o f these 
mice (figure 100). Within each mouse, knock-in or wild-type, nearly every Purkinje 
cell shows signs o f degeneration (arrows). Given that these mice are phenotypically 
normal, and show no impairment on testing of motor function, one must assume that 
the cerebellum is perfectly functional in spite of the clear degeneration seen in the vast 
majority o f Purkinje cells and their processes (arrowheads).
3.2.4 The UltrastructuralAppearance of 'Degeneration
It has been shown at the semi-thin section level that darkened profiles exist in both 
the Hdh knock-in mice and their littenmate controls. The ultastructural study o f these 
mice thus now extends from a comparison o f the knock-ins and the transgene to  
include a comparison o f the degeneration seen in all HD model mice to  that seen in 
the aged wild-type mice.
When ultra-thin sections are viewed under the electron microscope a greater 
degree o f pathologic change is revealed than was apparent at the semi-thin level. In 
the R6/2 m ouse the condensation o f  nucleoplasm and cytoplasm occurs 
concomitantly (see figure 52). In contrast, it appears the darkening o f the Hdh  
neurons occurs first in the cytoplasm, with a delayed onset o f nudeoplasmic 
condensation. Figure 10 1 shows a section through the striatum of a full-length Hdh 
expressing black 6 mouse at 29 months o f age. In the centre o f  the figure are 
condensed neurons, which would be dearly identifiable as degenerating using the
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Figure 97 Toludine blue-stained 
sem i- th in  s e c t io n s  o f  th e  
hippocampal CAI fields from full- 
length black 6 (FLB6), full-length FVB 
(FLFVB) and truncated  black 6 
(TrB6) Hdh  mice; and from wild- 
type black 6 (WTB6) and FVB mice 
(WTFVB). Degenerating neurons 
exhibit a darkened appearance.
Scale bar applies to  all *  50pm
fFLFVB
WTFVB
Figure 98 Toludine blue-stained 
se m i- th in  s e c t io n s  o f  th e  
hippocampal CA2 fields from full- 
length black 6 (FLB6), full-length FVB 
(FLFVB) and trunca ted  black 6 
(TrB6) Hdh  mice; and from wild- 
type black 6 (WTB6) and FVB mice 
(WTFVB). Degenerating neurons 
exhibit a darkened appearance.
Scale bar applies to  all «  50pm
FLB6 FLFVB
WTFVBWTB6
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Figure 99 Toludine blue-stained 
sem i- th in  s e c t io n s  o f  th e  
hippocampal CA3 fields from full- 
length black 6 (FLB6), full-length FVB 
(FLFVB) and trunca ted  black 6 
(TrB6) Hdh  mice; and from wild- 
type black 6 (WTB6) and FVB mice 
(WTFVB). Degenerating neurons 
exhibit a darkened appearance.
Scale bar applies to  all »  50pm
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Figure ICX) Toludine blue-stained 
semi-thin sections of the cerebella 
from full-length black 6 (FLB6), full- 
length FVB (FLFVB) and truncated 
black 6 (TrB6) Hdh  mice; and from 
wild-type black 6 (WTB6) and FVB 
mice (WTFVB). The vast majority of 
Purkinje cells exhibit a darkened 
appearance (arrows).
Scale bar applies to  all «  50pm
toludine blue semi-thin method (arrows). However, the remaining neurons in this 
section all show signs o f  cytoplasmic condensation (arrowheads) whilst maintaining a 
healthy nuclear appearance. They may not be registered as degenerating in the semi- 
thin sections.
Perhaps one o f the most important features to  note, conspicuous in figure 10 1 
by its absence, is the intranuclear inclusion. It has been shown that inclusions, whilst 
relatively rare compared to  the R6/2, are found throughout the full-length Hdh  
striatum when immunostained for N-terminal huntingtin. However, whilst the  
inclusion is clearly identifiable as a structural element in the R6/2, they are rarely 
identifiable in the Hdh mice. In viewing hundreds o f EM sections from Hdh mice, I 
have found fewer than ten obvious structural correlates; and only in those mice 
expressing full-length Hdh. They are more likely to  be identified in cells at the later 
stages o f degeneration as the condensation o f  the nucleoplasm increases contrast 
between itself and the inclusion; as illustrated in figure 102 (arrow).
They can be revealed in neurons at earlier stages o f degeneration by 
immunolabelling. Figure 103 contains a neuron from a full-length black 6 Hdh mouse 
immunolabelled for N-terminal huntingtin and stained with DAB. This reveals a clear 
intranuclear inclusion (arrow) as well as pan-neuronal staining. Such inclusions are 
hard to  identify without staining, as they do not possess the distinct structure o f the 
R6/2 inclusions. There are areas o f nucleoplasm that possess slightly different textures, 
and N-terminal huntingtin immunogold labelling confirms that these are accumulations 
o f huntingtin (figure 104), yet in uncondensed cells these are difficult to  identify.
Figure 102 also illustrates an uftrastructural feature o f degeneration apparently 
limited to  the FVB background: chromatin condensation. Within the condensed 
nucleoplasm o f the FVB Hdh mouse, one can clearly identify areas o f condensed  
chromatin (arrowheads), a certain amount o f which has marginated to  the nuclear 
membrane -  a characteristic o f  apoptosis -  yet in none o f the neurons observed does 
this chromatin coalesce to  form the bodies seen during apoptosis (see figures 4 5 ,4 6  & 
48). Figure 105 contains examples o f striatal neurons in comparable stages o f  
degeneration from each o f the Hdh mice. Both the nucleoplasm and the cytoplasm 
show considerable condensation, and there are dark foci within the nuclei, which may
Figure 101 Electron micrograph of a cortical section from a full-length black 6 Hdh 
mouse at 29 months of age. Note the numerous dark cells (arrows), with cytoplasmic 
condensation occurring more rapidly than nucleoplasmic condensation (arrowheads).
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Figure 102 Electron micrograph of degenerating striatal neurons from a full- 
length FVB Hdh mouse at 27.5 months of age. Note the mild condensation of 
the chromatin (arrowheads) and the nuclear inclusion (arrow).
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Figure 103 Electron micrograph of a striatal neuron from a full-length 
black 6 Hdh mouse; immunolabelled for N-terminal huntingtin. revealed 
using ABC/DAB. An intranuclear inclusion is revealed by staining 
(arrow).
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Figure 104 Neuronal Intranuclear Inclusion from the striatum of a full-length 
htt-expressing black 6 Hdh  mouse, immunogold-labelled for N-terminal 
huntingtin. A structural correlate is visible and labels (gold particles) for N- 
terminal hrtt (arrows). Scale bar » 500nm
225
Figure 105 Electron micrographs of nuclei 
from degenerating striatal neurons in (A) a 
full-length FVB Hdh mouse at 27.5 months 
of age, (B) a full-length black 6 Hdh mouse 
at 29.5 months and (C) a truncated black 6 
Hdh  mouse at 29.5 months. Note that 
chromatin condensation appears to  be 
confined  to  th e  FVB background  
(arrowheads).
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be regions o f chromatin, but only in the FVB background does one find the patchy 
accumulations.
The Hdh mice share many features with the R6/2 degeneration. There is clear 
dilation o f the endoplasmic reticulum and golgi apparatus in all Hdh mice, as illustrated 
in figures 106 and 107: striatal neurons from each mouse type (arrowheads). The 
preservation o f other structures, most notably the myelin, indicates that this dilation is 
not a procedural artefact. There is also dilation o f the mitochondria, concomitant with 
loss o f internal structure. Figure 108, a degenerating neuron in the FVB Hdh mouse, 
illustrates these changes. In the face o f well-preserved myelin and non-native 
mitochondria (solid arrowheads), the golgi apparatus (solid arrows) and mitochondria 
(open arrowheads) within the degenerating neuron are clearly dilated. W hether as a 
consequence o f dilation or an independent event the cristae within the mitochondria 
lose their regular layered arrangement and adopt an erratic appearance.
Figure 108 also illustrates one o f the more obvious features seen in these  
neurons, the accumulation o f lipofuscin (yellow arrowheads), and evidence o f  
autophagic activity (open arrow). Lipofuscin is also seen to  accumulate in the R6/2 
but to  a lesser degree. O f course, one might expect greater deposits o f the ‘aging 
pigment’ in mice tw o years’ older, but these deposits are more common in the Hdh 
degenerating neurons than in otherwise healthy cells. The breakdown product is 
membrane-bound (figure 109) and is seen to  accumulate preferentially in one locus 
(figure 110). This apparent preferential localisation occurs due to  the fact that the 
large deposits (arrows) result from the continuous addition o f smaller lysosomes 
(arrowheads), their products processed to  form the mature material.
Autophagic activity is evident to  varying degrees amongst the degenerating 
neurons in the Hdh mice. Figure 111 contains a section o f degenerating neuron from 
a truncated-Hdh expressing mouse. Similar to  the events seen in the R6/2, autophagic 
activity appears to  be highest in the vicinity o f the expanded golgi, supporting the 
suggestion that autophagic vacuoles are formed from budding o f the endoplasmic 
reticulum and/or golgi (arrow). Autophagic vacuoles (AV) vary greatly in size and 
many o f the smaller double-membrane structures seen may be AVs, certainly the 
larger multilamellar structures are autophagic in nature, as are those which sequester
Figure 106 Electron micrograph of striatal degeneration in a full-length black 6 
Hdh mouse at 29 months of age. N ote the dilation of the endoplasmic 
reticulum / Golgi apparatus (arrowhead).
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Figure 107 Electron micrograph of a degenerating striatal neuron from a 
truncated-expression black 6 Hdh mouse at 24 months of age. Note the dilation 
of organelles (arrowheads) within condensed cytoplasm. Also note that whilst 
the nuclear membrane has adopted a slightly ‘ruffled’ appearance (arrow), the 
nucleus remains relatively unaffected.
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Figure 108 Electron micrograph of a degenerating cortical neuron from a full- 
length FVB Hdh  mouse at 27.5 m onths of age. N ote the  dilation of 
motichondria and loss of internal structure (open arrowheads). Dilation is most 
marked when com pared to  unaffected mitochondria in the  neuropil (solid 
arrowheads). Also note the dilation of the Golgi and ER (solid arrow), together 
with the formation of autophagic vacuoles (open arrow) and accumulation of 
lipofuscin (yellow arrow)
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Figure 109 High-magnification electron micrograph of a striatal neuron from a 
full-length FVB Hdh  mouse at 27.5 months of age. Autophagic activity is 
indicated by the presence o f double m em brane-bound autophagic vacuoles 
(open arrowhead) and accumulation of breakdown products, both membranous 
(arrow) and proteinaceous (solid arrowhead).
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Figure I 10 Electron micrograph of degenerating striatal neurons in a 29 month- 
old full-length black 6 Hdh mouse. Both neurons show a darkened appearance 
and accumulation of lipofuscin (arrow) through the  continual addition of 
lysosomal material (arrowheads)
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Figure I I I Electron micrograph of a process from a degenerating striatal 
neuron in a 29 month-old full-length black 6 Hdh mouse. N ote the presence of 
multivesicular bodies (arrowheads) and autophagic vacuoles (arrow).
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entire organelles (see figure 112) -  indeed, autophagic processing appears to  be the 
only means by which whole organelle turnover can be achieved. It is the processing of 
this cytolsolic material within the multivesicular bodies & autophagic vacuoles, and the 
continual fusion o f  these bodies, that yields the product that accumulates with age 
(figure 113). The level o f autophagic activity appears to  be far greater than that seen 
in the R6/2; so much so that in the Hdh mice, late-stage degenerating cells can appear 
‘foamy’ as they contain so many AVs, MVBs and engorged lysosomes (figure 114). 
This may simply be a result o f the advanced age o f the knock-in mice, however, there 
are differences that appear to  be unique to  the Hdh mice. In particular, the presence 
of ‘fingerprint membrane whorls’ within neuronal cell bodies.
W hen autophagy is occurring rapidly, or the lysosomal processing pathway is 
impaired, such as in neuronal ceroid lipofuscinosis (Batten’s) disease, membrane 
whorls are seen to  accumulate. Membrane, presumably from the autophagic vacuoles 
and ingested organelles, forms electron-dense multilamellar bodies, as illustrated in 
figure 115 (arrow). Within striatal or cortical neurons these are visible more 
frequently in the degenerating cells o f the FVB Hdh mouse. However, the greatest 
amount o f autophagy is found in the Purkinje cells o f the cerebellum.
It was shown in 3.2.3 that in each mouse, the vast majority o f Purkinje cells 
show signs o f degeneration. At the semi-thin level these cells exhibited a similar 
profile to  those seen in other brain areas, but when viewed at the EM level a striking 
difference is noted. Figure 116 shows tw o degenerating Purkinje cells from an FVB 
Hdh mouse. The lower cell shows signs o f  autophagy within the cytoplasm 
(arrowheads), but the upper cell, sectioned off-centre, shows a remarkable amount of 
autophagic breakdown (arrows). Figure 117 is a higher power micrograph o f the cell 
in the previous figure. O ne can see numerous multi-lamellar autophagic vacuoles 
(open arrows), som e o f which contain entire mitochondria (solid arrowhead); and a 
fingerprint whorl in the process o f forming (solid arrow). In spite o f the severity of 
autophagic breakdown, perhaps because o f  it, the cell appears relatively uncondensed; 
and the majority o f  mitochondria appear undilated and structurally sound. It appears 
there is an inverse correlation in the Purkinje cells between degree o f autophagic 
activity and cell density. Figure 118 contains a second example o f a Purkinje cell with
Figure I 12 High-magnification electron micrograph of part of a degenerating 
striatal neuron in a 24 month-old truncated black 6 Hdh  mouse. N ote the 
dilation of the endoplasmic reticulum/Golgi (open arrowhead), from which form 
numerous endosom es (solid arrowheads). N ote also the sequestration of an 
entire mitochondrion within an autophagic vacuole (arrow).
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Figure I 13 Electron micrograph of a degenerating striatal neuron in a 24 
month-old truncated black 6 Hdh mouse. N ote the presence of multivesicular 
bodies (open arrowhead), which may form from the ER shown to  be dilated and 
forming vesicles (open arrow). N ote also the mature lysosome (solid arrow) 
and the accumulation of material by fusing of smaller to  larger lysosomes (solid 
arrowhead).
Figure I 14 Electron micrograph of a degenerating striatal neuron in a 27.5 
month-old full-length FVB Hdh mouse. The dilation of ER (arrow) and degree of 
lysosomal activity (arrowheads) can produce a ‘foamy’ appearance to  some 
degenerating neurons.
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Figure I 15 High magnification o f an electron micrograph of a degenerating 
striatal neuron in a 27.5 m onth-old full-length FVB Hdh  mouse. Dilated, 
vacuolating endoplasm ic reticulum and th e  accumulation o f m em brane, 
producing an autophagic membrane whorl (arrow).
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Figure I 16 Electron micrograph of degenerating Purkinje cells in the cerebellum 
of a 29 month-old full-length black 6 Hdh  mouse. All Purkinje cells show a 
marked accumulation o f lipofuscin (arrowheads), but som e show intense 
autophagic activity with numerous membrane whorls (arrows).
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Figure I 17 Electron micrograph of a degenerating Purkinje cell in the  
cerebellum of a 29 m onth-old full length black 6 Hdh  mouse. N ote the  
remarkable accumulation of membrane creating a ‘fingerprint’ membrane whorl 
(solid arrow); and the  num erous multilamellar autophagic vacuoles (open 
arrows), which often contain entire mitochondria (solid arrowhead). N ote also 
the extreme vacuolation (open arrowhead).
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high levels o f late-stage autophagic activity, further illustrating the lack o f condensation 
in the cytoplasm; but this section also includes part o f the nucleus, which appears 
normal. In contrast, figure 119 contains a Purkinje cell that whilst showing evidence o f  
autophagy -  autophagic vacuole formation (solid arrows), multivesicular bodies (solid 
arrowheads) and engorged lysosomes (open arrows) -  it is to  a lesser degree. The 
cytoplasm and nucleoplasm o f this cell have condensed and darked; likewise, other 
degenerative changes seen in cortical and striatal cells are evident, including dilation 
and loss o f mitochondrial structure (yellow arrowhead) and condensation o f  
chromatin (open arrowheads)*.
In addition to  the Purkinje cells o f  the cerebellum, the presence o f such 
numerous multi-lamellar autophagic vacuoles is also seen in cell processes. As 
observed in the R6/2 mice (see figure 68), within axons, autophagic breakdown 
dominates. Figure 120 contains a myelinated fibre in a full-length Hdh black 6 mouse, 
illustrating the presence o f  condensing autophagic vauoles (arrows), and the  
sequestration o f entire mitochondria (arrowheads). From my work on the R6/2 mice,
I had speculated that autophagic breakdown o f processes may occur when neurite 
aggregates block transport to  and/or from the soma. As I have not observed neurite 
inclusions in these mice, this is therefore unlikely. Rather, it appears that a separate 
programme exists for the degradation o f processes.
Figure 12 1 illustrates an interesting side-point. In the R6/2 mice, the Cajal 
body was seen to  relocate to  the nuclear inclusion. Whilst the inclusions are not easily 
identifiable by structure in the Hdh mice, it is certain that in at least in a percentage o f  
the striatal neurons they are present The neuron in figure 121 is striatal in origin and 
may or may not contain an inclusion. Figure 122 is a high power image o f the same 
cell, showing more clearly the presence o f the nucleolus and its associated Cajal body 
(arrow). It is tempting to  believe that the unidentified body (arrowhead) is part o f an 
inclusion, but this is speculative. However, what can be said is that the Cajal body in 
this neuron remains associated with the nucleolus; if this cell does indeed contain an 
inclusion it would be an interesting difference between transgenic and knock-in models 
if the Cajal body failed to  relocate.
*  Expected in this exam ple as this Purkinje cell is from  and FVB Hdh m ouse.
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Figure 118 Electron micrograph o f a degenerating Purkinje cell in the  
cerebellum of a 29 month-old full length black 6 Hdh mouse. Intense autophagic 
activity is once again present, but the neuronal nucleus (n) retains a healthy 
appearance.
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Figure I 19 Electron micrograph o f  a degenerating Purkinje cell in the  
cerebellum of a 27.5 month-old full length FVB Hdh mouse. Autophagy can be 
seen in the form of multivesicular bodies (solid arrowheads), mature lysosomes 
(open arrow), and the  formation of imultilamellar autophagic vacuoles (solid 
arrows). This Purkinje cell shows nuclear condensation with signs of 
condensation of chromatin (open arrowheads).
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Figure 120 Electron micrograph of a degenerating axon in a 27.5 month-old full 
length FVB Hdh mouse. The axon is filled with autophagic vacuole ‘whorls’ 
(arrows), yet the mitochondria appear healthy (arrowheads).
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Figure 121 Electron micrograph of a degenerating neuron in a 29 month-old 
full length black 6 Hdh mouse. The Cajal body (arrowhead) remains associated 
with the nucleolus (arrow).
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Figure 122 Section from full-length black 6 Hdh striatum showing 
nucleolus and perinucleolar cap (labelled). It is tempting to  assume that 
the unidentified body (arrowhead) is part of an inclusion. However, 
w hatever the nature of this structure, the Cajal bodies of Hdh neurons 
show normal nucleolar association (arrow).
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3.2.5 Degeneration in Aged Wild Type Mice
Perhaps the most interesting result obtained for this thesis stems from work on the 
littermate controls. The nature o f the Hdh mice is such that degeneration is not 
evident until the mice are older than tw o years o f age: the last days o f the mouse 
lifespan. Wild-type littermate mice have, o f course, been used in this study to  control 
for effects outside those o f the Hdh mutation. Two batches o f mice have been used 
to  obtain the data presented here. The first consisted o f mice ranging from 23 to  29 
months o f age. In these mice the Hdh animals showed variable levels o f degeneration, 
predominantly in the cortex, but also in the striatum. The littermate controls (27.6 
months FVB; 29 & 29.2 months black 6) showed heavy accumulations o f lipofuscin 
(expected with age) but no other obvious changes. However, the second set o f mice 
ranged from 28 to  almost 30 months o f age. In these, the Hdh showed far greater 
levels o f degeneration and, interestingly, pathology was also evident in the wild type 
controls. Detailed ultrastructural analyses were therefore carried out on the wild type 
mice to  identify similarities and differences between these mice and their mutant 
siblings.
Initial ultrastructural analysis was carried out on the 29 months and 2 1 day-old 
black 6 wild-type and it was found that the degenerating neurons are strikingly similar 
to  those seen in each o f the Hdh siblings; and to  the degeneration seen in the R6/2. 
Figure 123 is a section through the cortex o f this mouse. A healthy neuron is visible at 
the bottom o f the section (arrow), highlighting the degree o f condensation seen in the 
degenerating neurons (arrowhead). Both the cytoplasm and nucleoplasm have 
condensed in the degenerating cells and as a result they have adopted the ‘scalloped’ 
or ‘ruffled’ appearance seen in the Hdh and R6/2 mice. In contrast to  the  
degeneration o f the Hdh mice, where cytoplasmic condensation generally appears to  
slightly precede nuclear condensation, the condensation o f wild type cytoplasm and 
nucleoplasm occurs concomitantly. Figure 124 contains a higher magnification 
micrograph o f a cortical neuron; whilst the nucleus is still easily discernible (arrow), it is 
of similar electron-density to  the cytoplasm (arrowhead).
Figure 123 Electron micrograph of neurons in the cortex of a 29 month-old 
wild-type black 6 mouse. A neuron in an advanced stage of degeneration 
(arrowhead) can be compared to  an adjacent healthy neuron (arrow)
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Figure 124 Electron micrograph o f a degenerating cortical neuron from a 29 
m onth-old wild-type black 6 mouse. Cytoplasm (solid arrow head) and 
nucleoplasm (arrow) exhibit similar levels of condensation. N ote also the large 
accumulation of lipofuscin (open arrowhead).
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Figure 124 also illustrates the large amounts o f  lipofuscin found within the  
degenerating control neurons (open arrowhead). Whilst lipofuscin is present within 
the vast majority o f neurons of this age, there does appear to  be a greater amount in 
neurons undergoing degeneration. However, this may in fact be a misleading 
observation. Figure 125 contains an otherwise healthy striatal neuron from a wild-type 
mouse. The lipofuscin appears to  be less than that seen in figure 124, but the 
condensation o f this cell, together with the tendency for lipofuscin to  agglomerate, 
would most likely yield a cell with a profile similar to  that o f figure 124.
A further similarity is represented in figure 126: dilation o f the golgi and 
endoplasmic reticulum (arrows). As with the R6/2 and Hdh mice, the dilation is most 
apparent in the later stages o f degeneration, but this may also be a consequence o f 
condensation. Whatever the timing o f the even t the dilation certainly occurs to  
varying degrees in all mice. The dilation appears to  be greater in the Hdh mice when 
compared to  the R6/2, but similar to  the wild-type mice. Therefore, any differences in 
the effect are most likely to  be dependent on the ages o f the animals.
There is also evidence o f loss o f mitochondrial integrity. Figure 126 contains 
degenerating mitochondria (solid arrowheads), which can be compared to  healthy 
mitochondria (open arrowheads) in the neuopil. Mitochondrial dilation is certainly 
apparent but it is hardest to  identify in these mice as it is less severe. There is also a 
loss o f internal structure, though, once again, not as sever as that seen in the knock-ins 
or R6/2s. Given that the endoplasmic reticulum and golgi dilate to  levels comparable 
to  those seen in the Hdh mice and yet the mitochondria in the age-matched black 6 
do not it is reasonable to  assume that mitochondrial dilation, whilst ‘natural’ in mice o f 
this age, is exacerbated by the presence o f mutant huntingtin.
There is evidence o f  autophagic activity within the degenerating cortex and 
striatum, suggested by the presence o f multivesicular bodies and autophagic vacuoles 
(figure 127) however it does not appear to  reach the levels observed in the Hdh mice; 
the exception being the Purkinje cells o f  the cerebellum. As with the knock-ins, the 
Purkinje cells exhibit autophagic activity ranging from large numbers o f multivesicular 
bodies and lysosomes (figure 128) to  the filling o f  a cell with autophagic profiles 
suggesting a complete deconstruction (figure 129). It is therefore probably that the
Figure 125 Electron micrograph of a striatal neuron from a 29 month-old wild- 
type black 6 mouse. This neuron shows a relatively healthy profile with the 
exception of mild invagination of the nuclear m em brane (arrow head) and 
accumulation of lipofuscin (arrows)
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Figure 126 Electron micrograph of a section of degenerating cortical neuron 
from a 29 m onth-old wild-type black 6 mouse. N ote th e  dilation of 
endoplasmic reticulum/Golgi (arrows) and the dilation of mitochondria (solid 
arrowheads), which can be com pared to  healthy mitochindria in the neuropil 
(open arrowhead).
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Figure 127 Electron micrograph of a degenerating cortical neuron from a 29 
month-old wild-type black 6 mouse. In spite of the dilated organelles (solid 
arrowheads) and accumulation of lipofuscin (open arrowheads), the nucleus and 
nucleolus (arrow) remain intact.
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Figure 128 Electron micrograph of a cerebellar Purkinje neuron from a 29 
month-old wild-type black 6 mouse. Autophagic activity is indicated by the 
dilation and vacuolation of the Golgi/ER (open arrowheads), the formation of 
multivesicular bodies (open arrows), autophagic vacuoles (solid arrowheads) and 
accumulation of lipofuscin (solid arrows).
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Figure 129 Electron micrograph of a cerebellar Purkinje cell from a 29 month- 
old wild-type black 6 mouse. The neuron appears to  be undergoing autophagic 
breakdown.
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Purkinje cell degeneration seen within each o f these mice reflects merely a process 
associated with age. Indeed, section 3.2.3 showed comparable levels o f degeneration 
in each mouse. Perhaps the high levels o f autophagy within this cell type reflects the 
amount o f membrane associated with the cell. As discussed in 4.5 neuronal processes 
are seen to  be ‘pruned back’ in HD, if the products o f dendritic breakdown are 
transported to  the soma it may explain the appearances of cells such as that shown in 
figure 129.
Analysis o f the FVB wild-type yielded similar results, which in itself is rather 
surprising as the oldest surviving FVB wild-type mouse was 28 months old, and is being 
compared to  mice o f 29 months and 20 days (± 2  days). The degenerating neurons 
also exhibit condensation o f cytoplasm and nucleoplasm at comparable rates, with 
many cells in a single area undergoing apparently simultaneous degeneration (figure 
130). Furthermore, each wild-type background shows comparable dilation o f the golgi 
and endoplasmic reticulum, the wild-type FVB shows a greater accumulation o f  
lipofuscin. Figure 13 1 contains a degenerating and relatively healthy neuron; dense 
deposits o f lipofuscin are evident in both (arrows). The accumulation is greater than 
that seen in the black 6 in healthy as well as dark cells. Figure 132 is a section o f  
degenerating cortical neuron in which remarkable levels o f all stages o f autophagy are 
evident the fomation o f autophagic vacuoles (open arrows), multivesicular bodies 
(solid arrowheads) and lysosomes filled with product at varying stages o f processing 
(open arrowhead). Furthermore, many o f the mitochindria appear dilated (figure 133, 
solid arrowheads) when compared to  healthy examples (open arrowheads), but the 
internal structure is generally better preserved in the wild-type degenerating neurons 
that in the dark cells o f the Hdh or R6/2 mice.
Comparison o f toludine blue-stained semi-thin sections has revealed similar 
levels o f degeneration in the black 6 and FVB wild-type mice, is spite o f the FVB mice 
being seven weeks younger. Furthermore, EM analysis has revealed that whilst very 
similar overall, the levels o f autophagy and lipofuscin build up are apparently higher in 
the younger FVB background. This may be indicative o f a general state o f health in the 
FVB background. This strain may be more sensitive to  stress, including simply age- 
related stress. The variation in dark cell distribution combined with the small number
Figure 130 Degenerating neurons in the striatum of a 28 month-old wild-type 
FVB mouse.
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Figure 131 Degenerating neurons in the striatum of a 28 month-old wild-type 
FVB mouse. N ote the  degree of condensation in the dark neuron. Also note 
the high levels of lipofuscin (arrows) in both dark and ‘healthy’ neurons.
Figure 132 High-magnification electron micrograph of a degenerating neuron in 
the striatum of a 28 month-old wild-type FVB mouse. W idespread autophagy is 
evidenced by the presence of multivesicular bodies (solid arrowheads), mature 
lysosomes (open arrowheads), dilation and vacuolation of the ER/Golgi (open 
arrow), and accumulation of lipofuscin (solid arrow).
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Figure 133 Electron micrograph of a degenerating neuron in the striatum of a 
28 month-old wild-type FVB mouse. Concomitant with widespread autophagy, 
m itochondria appea r dilated (solid arrow heads) -  m ost noticeable on 
comparison to  mitochondria in the neuropil (open arrowheads).
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of mice that have been made available to  me, make a quantitative analysis on levels of 
degeneration difficult. It appears that there is no difference whether the Hdh mutation 
is expressed on a black 6 or FVB genetic backgound, but this is based on qualitative 
observation alone. Given that the younger wild-type FVB shows comparable 
pathologic change, it may be that the FVB is indeed more susceptible, which could 
have implications for the observations o f other mouse models.
3.2.6 The Biochemical Profile ofDegeneration
Whilst there are no inclusions within the cortices o f any o f these mice, it is the cortex 
that shows the largest degree o f degeneration. It is unlikely that this is due entirely to  
the disease these mice seek to  model, although it does appear to  modify the ‘natural’ 
degeneration seen. Whilst all areas o f the brain have been analysed, the sections 
presented herein are from the mid-cingulate cortices o f each o f the mice. This area 
shows modification by expression o f the expanded mouse huntingtin, in that the Hdh 
mice undergo greater degeneration in the cingulate that littermate controls, particularly 
the anterior cingulate, although this is unlikely to  be a primary event Nevertheless, by 
the mid-cingulate sections all mouse types show cells undergoing degeneration 
morphologically very similar to  those seen in the R6/2 and striata o f the Hdh, thus the 
molecular events underlying one should underlie the other.
Using the same antibodies used for similar studies on the R6/2 mice, the 
involvement o f the apoptotic machinery in neurodegeneration was investigated. 
Positive controls were not sought as these antibodies have been shown to  be 
successful in identifying apoptotic activation.
The results obtained were similar to  those for the R6/2 degeneration. Each 
antibody produced identical staining patterns in each mouse type and in each area, 
whether or not degeneration had been shown to  occur in the semi-thin analyses. 
Figures 134 to  139 illustrate the staining obtained with several antibodies for each 
mouse. I will not labour the observations as descriptions have been given for the R6/2 
staining patterns. In short; once again, distinctive staining patterns are obtained for
Cleaved Caspase 3 CM1
CDGO B6
FVB FVB
WT WT
Figure 134 Sections from the  anterior cingulate cortices o f full-length Hdh black 6
(B6), FVB (FVB) and wild-type black 6 (W T) mice, each 29 months, 2 1 days’ old,
immunolabelled for activated caspase-3. Scale bar (~  I Opm) applies to  all.
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AIF Apaf-1
B6 B6
FVB FVB
WT WT
Figure 135 Sections from the  anterior cingulate cortices o f full-length Hdh black 6
(B6), FVB (FVB) and wild-type black 6 (W T) mice, each 29 months, 2 1 days’ old,
immunolabelled for AIF and Apaf-1. Scale bar (~  I Opm) applies to  all.
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Cleaved C a sp a se  9 (SC) C leaved C asp ase  9 (CST)
B6 B6
FVB FVB
WT WT
Figure 136 Sections from th e  anterior cingulate cortices o f full-length Hdh black 6
(B6), FVB (FVB) and wild-type black 6 (W T) mice, each 29 months, 21 days’ old,
immunolabelled for activated caspase-9. Scale bar (~  I Opm) applies to  all.
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Caspase 2 Cleaved Caspase 6
B6 B6
FVB FVB
WT WT
Figure 137 Sections from the  ant. cingulate cortices of full-length Hdh black 6 (B6),
FVB (FVB) & wild-type black 6 (W T) mice, each 29 months, 21 days’ old, labelled
for caspase-2 and cleaved caspase-6. Scale bar (~  I Opm) applies to  all.
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C leaved PARP (CST) Cleaved PARP (NEB)
B6
FVB FVB
WT WT .
Figure 138 Sections from th e  an terior cingulate cortices o f full-length Hdh black 6
(B6), FVB (FVB) and wild-type black 6 (W T) mice, each 29 months, 21 days’ old,
immunolabelled for cleaved PARP. Scale bar (~  I Opm) applies to  all.
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CAD Cleaved I CAD
COCD B6
FVB FVB
WT WT
Figure 139 Sections from th e  anterior cingulate cortices o f full-length Hdh black 6
(B6), FVB (FVB) and wild-type black 6 (W T) mice, each 29 months, 21 days’ old,
immunolabelled for CAD and cleaved ICAD. Scale bar (~  I Opm) applies to  all.
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som e antibodies, and, interestingly, variation exists when different companies have 
made antibodies to  the same protein. For example, figure 136 highlights the 
differences in staining pattern between the Santa Cruz antibody for activated caspase-9 
and the Cell Signalling Technologies antibody for the same. However, importantly, the 
staining patterns are identical from mouse to  mouse, including those obtained in the 
R6/2 analyses. Thus, as with the R6/2, it appears that the apoptotic machinery is not 
active in those cells undergoing dark cell degeneration.
Discussion
HE field o f Huntington’s disease research is fraught with numerous contradictory
reports. There is also so much w e still do not understand that it is difficult to
draw conclusions about what factors underlie the disease process, and which may be 
therapeutic targets.
In order than I might explain my observations, and defend them in light o f the 
wealth o f evidence which appears to  contradict my findings, I begin this chapter with a 
more detailed discussion on the evidence presented for the involvement o f apoptosis 
and its factors in the pathology o f Huntington’s disease. I then introduce the process 
o f autophagy and discuss the reports o f its involvement in HD.
In light o f these discussions, I evaluate my own results on degeneration in the 
HD models. I then discuss my observations o f  inclusions within the different models, 
and how these observations relate to  the disease process and to  the reports o f  
others.
I am then left to  summarise the hypotheses that may explain some o f the 
questions that remain unanswered; most importantly, ‘how does the accumulation of 
mutant huntingtin cause such a powerful phenotype?’
Finally, I summarise the other major mouse models o f Huntington’s disease 
and the differences between them; and evaluate the relevance o f such models to  the 
human disease they seek to  replicate.
4.1 Apoptosis
4,1.1 From Factor to Fact
A n  introduction to  the basic biology o f apoptosis has been presented in section
1.7, together with a brief summary on why apoptosis is believed to  underlie 
the degeneration in Huntington’s disease in section 1.8. Each paper that claims proof 
for apoptosis underlying the cell death o f Huntington’s disease often reports the 
involvement of one or tw o factors. It is surprising that so many make the leap from 
identifying the possible involvement o f one factor to  stating that apoptosis as a 
complex multifactor process is active and all-central to  the disease process. Apoptosis 
is certainly a hot topic, hence the exponential increase in publications shown in figure 
14, and as a result there seems to  be a need for researchers to  extrapolate beyond 
the bounds o f logic such that they might add weight to  their papers; as well as making 
them fashionable’.
Nevertheless, there is no consensus as to  which molecular events define 
apoptosis. This in itself negates any logical debate on the topic. The original definition 
of apoptosis was based solely on morphological criteria (Kerr et al. 1972). Each 
biochemical action that has subsequently been identified has not been objectively 
weighted as a criterion and as such there can be no objective determination as to  its 
level o f importance when observed in other phenomena. There does appear to  be a 
tacit agreement that those events that occur in the central arms o f apoptosis, as 
opposed to  the peripheral events, are more important As described in 1.7 there are 
numerous inhibitors acting to  suppress spontaneous activation o f apoptotic cell death; 
as a result it is not unreasonable to  ascribe more weight to  those events further along 
the branches given that many ‘checks’ have to  be passed before these stages can be 
reached.
There is one further point that is often missed in weighing up the importance 
of one’s apoptotic observation, which is also at the very heart o f the phenomenon: 
apoptosis is a self-propagating process. Some papers report effects that are, or can
be, merely secondary phenomena produced as a result o f the activation by other 
apoptotic players; both through forward and back-propagation. Furthermore, one 
most also take into account that apoptosis seems to  vary from cell type to  cell type. 
The processes seen in cultured, transformed cells may not apply to  fully differentiated 
adult neurons.
In light o f these caveats the literature needs careful reviewing.
4.1.2 Caspases
The most powerful weapons in the apoptosis arsenal are the caspases and it is 
therefore these that have received the most attention in the studies on cell death.
The involvement o f caspases in the disease process is suggested most directly 
by the observation that huntingtin is itself a substrate for cleavage by caspases 
(Goldberg et al. 1996). The relevance o f this to  the disease is not entirely clear. As 
described in 1.7 inactive caspases show mild activities, but in order for lar^ge-scale 
cleavage to  occur the enzyme has to  be active. For caspase-3 to  be active, apoptosis 
probably has to  be active. Cheryl Wellington has adapted her work into the toxic 
fragment hypothesis (see 1.6.3) based on tw o notions: that accumulation o f the n- 
terminal fragement of mutant htt activates caspase, and that activated caspases cleave 
mutant htt (Wellington et al. 2000). This explains neither what underlies the initial 
cleavage events nor how the accumulation o f mutant n-terminal htt causes caspase 
activation. The initial cleavage even may result from the low level o f tonic activity in 
pro-caspases, but given the amount o f accumulation seen in vivo before pathologic 
changes are evident if, as the hypothesis suggests, accumulation o f mutant htt activates 
caspase, such cells would no doubt have activated caspase contributing to  further 
deposition. Work on mice has found caspase cleavage o f huntingtin long before the 
onset o f any signs o f pathology (Wellington et al. 2002), bearing in mind the self- 
propagating nature o f the caspase cascade, such a cell would not be devoid o f  
pathological change for such an extended period. The same group has subsequently 
found evidence o f caspase cleavage of huntingtin human tissue, o f both expanded and
wild-type protein, but, importantly, in non-HD individuals as well as those with the 
disease (Kim et al. 2 0 0 1). They reconcile this with earlier work by stating that whilst 
caspase cleavage o f huntingtin is a normal event occurring even in non-HD individuals, 
in the case o f disease patients such cleavage would generate the toxic fragment 
inducing further caspase activation. Subsequent work on mice has found caspase 
cleavage o f huntingtin long before the onest o f any disease symptoms (Wellington et 
al. 2002). This still leaves unanswered perhaps the most important factor in a model 
of apoptotic cell death in HD: how does accumulation of mutant htt activate caspases?
Caspase cleavage o f mutant huntingtin may indeed contribute to  accumulation 
of the protein, but only significantly once the cell is in its death throes. At this stage 
the importance o f caspase cleavage o f huntingtin to  the disease process is negligible.
Caspases have been further implicated in the disease process through their 
detection in inclusions. O ne group reported the recruitment and subsequent 
activation o f caspase-8 to  aggregates in cultured neurons expressing GFP-tagged 
mutant ataxin 3 (Sanchez et al. 1999). Inhibition o f caspase-8 with CrmA or the 
prevention o f recruitment via the expression o f a dominant-negative form o f FADD 
(see 1.75) increased cell survival; as did expression o f the construct in caspase-8- 
lacking Jurkat cells. To support a role for caspase-8 in vivo they report the finding of 
activated caspase-8 by western blot in tissue form affected areas in human HD 
patients. Within the report they state ‘...w e  provide preliminary evidence for the 
contribution o f caspase-8 ... in vivo’ (ibid, italics added). Given the importance o f such 
a finding in the human condition, it is probably o f significance that they have not 
published anything further on caspase-8, nor have their results been replicated. 
Furthermore, they suggest activation o f  caspase-8 occurs by induced proximity (see 
1.7.5). It has been demonstrated by a number o f groups that the presence o f  
inclusions rarely correlates with cell death (see 1.6.2), undermining their hypothesis 
that it is the aggregate that recruits and activates the caspase.
The activation o f caspase-8 as a secondary phenomenon has been suggested 
to  occur in the disease through the loss o f binding o f normal huntingtin to  HIP I, as 
described in 1.6.4. This work has been reproduced and seems reliable; free HIP I 
contains a DED and is thus able to  induce apoptosis. However, given the dominant
nature o f the disease and the almost digital threshold for manifestation, I find it unlikely 
that this underlies cell death. The loss o f HIP I-huntingtin association occurs 
proportionally to  polyQ length, there is no sudden loss of binding. Furthermore, it has 
long been established that there is no greater severity o f disease in homozygotes, if 
liberation o f HIP I is the cause o f cell death one would expect homozygotes to  show  
twice as much death. The greater number of free DEDs in the form o f HIP I in HD 
patients may increase susceptibility to  apoptosis contributing in som e form to  the 
death seen in the human disease, but I do not believe it is the underlying cause.
The addition o f caspase inhibitors to  other model systems has also been cited 
in support o f their involvement in the disease process. By overexpressing wild-type or 
mutant huntingtin in clonal striatal cells Kim et al. ( 1999) found cell death induced by 
either, but to  a greater degree in those expressing mutant huntingtin. The addition o f  
the caspase-1 and caspase-3 inhibitor Z-VAD-FMK increased cell survival. The 
addition o f Z-DEVD-FMK, which inhibits only caspase-3, did not affect survival. This 
implies that caspase-1 is involved in the disease process. In support o f this in vivo, the 
crossing o f R6/2 mice with dominant negative caspase-1 mutants delays the onest o f  
motor symptoms and prolongs mouse survival (Ona et al. 1999). It is suggested that 
the presence o f intranuclear huntingtin increases expression o f caspase-1 leading to  its 
activation (Li et al. 2000). The administration o f minocycline, which inhibits both 
caspase-1 and caspase-3, has been found to  prolong the life o f R6/2 mice (Chen et al. 
2000). In contrast, the work o f Ivelisse Sanchez cited previously suggests that caspase- 
I is not involved. CrmA was used to  inhibit caspase-8, but at similar concentration it is 
also an inhibitor o f caspase-1 (Zhou et al. 1997). Thus, to  support her suggestion that 
caspase-8 is the crucial factor she also expressed mutant ataxin-3 in caspase I -negative 
cells. She reports no effect on toxicity o f the Q79 expression (Sanchez et al. 1999), 
contradicting the reports implicating caspase-1 as a crucial player. Interestingly, she 
also found no effect in MCF7 cells, which do not possess the caspase-3 (Janicke et al.
1998), thereby casting doubt on the second target o f minocycline.
4.1.3 Life in the Balance
The Wellington study mentioned in the previous section documented reduced 
toxicity in cells transfected with the caspase-resistant huntingtin, implying that caspase 
cleavage o f huntingtin generates fragments which accumulate and induce apoptotic cell 
death (Wellington et ol. 2000). However, the expression of mutant huntingtin alone 
was not sufficient to  induce measurable levels o f cell death; rather, all cultures were 
exposed to  tamoxifen, a known inducer o f apoptosis, and cells containing caspase- 
deaved huntingtin were more affected. This is an important feature in many o f the 
studies on the toxicity o f huntingtin. Often studies that show increased apoptosis in a 
system actually show increased sensitivity to  external induction o f apoptosis.
As should be evident from section 1.7 there are a plethora o f interacting 
proteins regulating apoptosis. In other words, there are continual pressures in each 
direction; a delicate balance between pro-life and pro-death drives. In each cell type, 
in each stage o f its life, these drives may be differently weighted. For example, to  
demonstrate the efficacy o f the antibodies used in the work for this thesis, x-irradiation 
was used to  induce apoptosis in recently divided cells; utilising the fact that cells still in 
the cell cycle are more likely to  initiate apoptosis in response to  damaging stimuli. If 
proximity to  the cell cycle directly affects the weighting of a cell’s life and death drives, 
then one is also forced to  question the validity o f work comparing adult neurons to  
cultured cells, many o f which are used precisely because they are permanently in the 
cell cycle. Mutant huntingtin may indeed act as a mild pro-apoptotic stimulus, but this 
appears to  be countered by the cells many anti-apoptotic factors. Tipping the balance 
in favour o f death, physically, chemically or even as a course o f aging, will have varying 
results depending on the affected cell and the strength o f its anti-apoptotic drives.
The concept I describe as a balance o f drives, tipped towards death by mutant 
huntingtin, led some groups to  examine the incidence o f cancers among HD patients. 
If huntingtin predisposes cells to  apoptosis, there should be fewer cases than among 
otherwise healthy individuals. The results have confused the issue further. O ne group 
reported a lower incidence o f cancers o f  most major tissues in Danish HD patients
(Sorensen and Fenger 1992; Sorensen et al. 1999) whilst others have suggested 
increased cases o f  cancers (Ferluga 1989). Further support for increased pro- 
apoptotic weighting comes from another study that showed increased susceptibility in 
HD patient-derived lymphocytes to  apoptosis induced by UVB-irradiation flakab et al. 
2001).
The HD mutation may increase susceptibility to  the induction o f apoptosis by 
other harmful stimuli, but in such cases cell death is largely dependent on the nature of  
the toxic stimulus, not its accomplice.
4.1.4 Studying Cell Death
The brief review presented here shows how the field o f  cell death in the  
polyglutamine diseases is full o f contradictory evidence. Some studies report one  
factor active in the death process, others will report that the same factor has no effect 
at all; as illustrated by the work on caspase-1. The majority o f these conflicting studies 
use a variety o f models and constructs, and it is my belief that this is the source o f the 
confusion.
Further confusion has arisen due the ever-present desire to  ascribe a name to  
an event As mentioned, w e have no biochemical definition o f what apoptosis is, and 
yet many will apply the term to  events which posses an active element o f the process. 
Caspases are the central executioners o f the apoptotic death programme, and the 
presence o f any activated caspase seem s sufficient for som e to  apply the term  
apoptosis; yet caspases have also been shown to  be involved in ‘house-keeping’ 
activities such as altering synaptic plasticity (Chan and Mattson 1999).
Increasingly, it is becoming clear that there are many variations on the theme 
of cell death. Abortosis, aposklesis, paraptosis and dark cell degeneration all stem from 
different reports o f non-apoptotic, non-necrotic cell death (see Graeber and Moran 
(2002) for review). W hilst these neologisms have yet to  becom e defined 
commonplace terms, they are indicative o f a field that is not ‘black and white’. In spite
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of this, Robert M. Friedlander, head o f the Neuroapoptosis Laboratory, Harvard 
Medical School, opens his 2003 review o f apoptosis in neurodegenerative disease with 
‘Cell death occurs by necrosis or apoptosis’.
As mentioned previously, the nature o f some cells may negate som e o f the 
conclusions drawn; cells closer to  the cell cycle are more sensitive to  harmful stimuli. 
Furthermore, the m ode o f cell death may depend on cell type. As an extreme 
example, human erythrocytes, which do not contain a nucleus, do not undergo 
apoptosis when stimulated to  do so (Weil et al. 1996). Mouse sperm and chicken 
erythrocytes do contain a nucleus, but it is transcriptionally inactive. In these cells -  
the former o f which dies spontaneously in culture, the latter induced -  the death 
process does not appear to  involve caspases (Weil et al. 1998). Whilst this may be 
due to  a protein synthesis requirement for apoptosis to  occur, it also suggests discrete 
cell death can occur in the complete absence o f caspase activation. It also highlights 
the importance o f cell type in studying cell death. Furthermore, whilst the study found 
no caspase activation in mature erythrocytes, activated caspases were occasionally 
detectable in immature erythrocytes; highlighting also the importance o f  the  
developmental maturity o f the cell.
There is also the need for careful control when conducting cell culture 
experiments. The degree o f interventional control over the experimental process, the 
main advantage o f such work, permits the careful adjusting o f conditions, but may lead 
to  misleading results and conclusions. For example, Hackam et al. ( 1998) found that 
expression o f wild-type huntingtin N-terminus also reduces cell viability. Likewise, Kim 
et al. ( 1999) report clonal striatal cells with apoptotic morphology even in control cells 
expressing only wild-type huntingtin. Experimental conditions may thus end up 
showing a stark contrast between mutant and wild-type huntingtin purely due to  the 
nature o f the experimental set up. Cell culture experiments must therefore be 
conducted carefully, and the relevance to  the clinical situation closely monitored. A 
situation also true o f other in vitro work. The work of Bucciantini et al. (2002) suggests 
that ‘any’ protein can form amyloid-like fibres, however, the conditions required to  
induce such fibrilisation are often markedly unphysiological. Rather than proving 
proteins readily forms such fibres in vivo, I rather believe it proves this unlikely.
4.2 Autophagy
4.2.1 Degradation o f CeU Contents
W ITHIN a cell the balance between formation and degradation of proteins and organelles has to  be tightly maintained. This balance must also be alterable, to  respond to  demands o f growth and development There exist two broad 
categories o f process by which this occurs, lysosomal and non-lysosomal.
The non-lysosomal process has been described in section 1.5.2: the ubiquitin- 
proteasome system (UPS). To reiterate: this involves the highly selective tagging o f  
target proteins with ubiquitin, followed by controlled hydrolysis via the proteasome. 
The UPS has long been implicated in the Huntington’s disease process; its components 
co-localising with the Nil, suggesting an attempt by the cell to  specifically degrade the 
abnormal huntingtin. Indeed, given the accumulations seen in HD are o f the N- 
terminal region alone, one may assume that the UPS successfully degrades the C- 
terminal portion. However, there is increasing evidence for involvement o f the 
second process: lysosomal degradation or autophagy.
The lysosomal processes are most noted for their degradation o f extracellular 
proteins via endocytosis or pinocytosis. Extracellular contents are taken-up into 
isolated endosomes, which are then targeted by lysosomes, which in turn release an 
array o f hydrolases into the endosome. Likewise, as mentioned in 1.7.8, phagocytes 
degrade ingested apoptotic bodies by fusing lysosomes with phagosomes, resulting in 
degradation o f the entire phagosome content In this way, the lysosomal processes 
act on a wide range o f targets, degrading them in a bulk fashion. However, the action 
of the lysosome is not limited to  the contents o f the endosome. Rather, the lysosome 
acts also to  degrade ‘self components. Indeed, lysosomal degradation is the sole 
means o f turnover o f whole organelles such as the mitochondria. This degradation of 
the cell’s own contents is known as autophagy.
4 2 2  Autophagy
Autophagy is further divided into three processes: macroautophagy, microautophagy 
and chaperone-mediated autophagy.
Macroautophagy is the major inducible form o f autophagy. It is a highly 
conserved mechanism involved in the bulk turnover o f cell components. It was first 
described as a response to  starvation, as one o f the primary functions o f autophagy is 
to  produce free amino acids from the breakdown o f non-essential proteins when 
amino acid levels fall (Mortimore and Poso 1986). It is also regulated by a large 
number o f factors linked to  nutrition and growth, including glucagon (Hopgood et al.
1980), insulin (Blommaart et al. 1997) and growth factors (Ballard et al. 1980) via a 
number o f  second m essengers (C odogno et al. 1997). Further to  this, 
macroautophagy also plays a role in the turnover o f cell constituents under normal 
conditions. Generally, the tw o processes -  starvation induced and normal turnover -  
are distinguished according to  their associated vesicular bodies. Under starvation 
conditions, autophagosomes or autophagic vacuoles (AVs) are seen, which are between 
8 and 200 times greater in volume than the CVT (cytosol to  vacuole targeting) vesicles 
seen under conditions o f  normal turnover (Baba et al. 1997).
The first ultrastructural signs o f macroautophagy appear as the sequestration of 
portions o f the cytoplasm within double membrane-bound structures termed 
endosomes, autophagosomes or autophagic vacuoles. The nature o f the autophagic 
vacuole varies greatly from species to  species and from cell to  cell. The majority of 
the work on autophagy has been conducted using yeast, and so the traditional’ picture 
may, more or less, be limited to  yeast cells. In mammals, whilst the traditional double 
membrane-bound autophagic vacuoles are seen, some cells also form multilamellar 
bodies. The source o f the sequestering membrane remains under debate, but in 
mammalian cells it is believed to  be the endoplasmic reticulum. Certainly, in this study 
autophagic activity is seen most frequently in areas o f high ER/golgi density. Once the 
AV is fully formed, and its contents isolated from the cytosol, it docks and fuses with a 
lysosome -  a process dependent on microtubule function. After fusion, the outer 
membrane o f the AV is incorporated into the lysosomal membrane thereby releasing
a now single membrane-bound autophagic body into the lumen o f the lysosome, 
which is readily broken down by the lysosomal hydrolases.
Microautophagy, active under basal conditions, involves the internalisation o f  
cytosol directly into the lysosome. The situation is akin to  that o f endocytosis, in that 
invaginations form in the lysosomal membrane, which bud off into the lumen forming 
muhjvesicular bodies (Ahlberg et al. 1982; Dice et al. 1987). The process was initially 
thought to  be non-selective, however there is now evidence to  suggest that there is a 
preferential degradation o f  specific substrates (Luiken et al. 1992; Yokota et al. 1993; 
Yuan et al. 1997).
Substrate specificity is even more restricted in the third class: chaperone- 
mediated autophagy. This also occurs during periods o f starvation, as a secondary 
response to  macroautophagy, and involves the elimination o f proteins possessing a 
particular amino acid sequence (KFERQ-related) (Dice et al. 1990). This sequence is 
recognised by the cytosolic form o f the chaperone (see 1.5.1) hsc73 (Teriecky and 
Dice 1993), which, on binding to  the target sequence, is recognised by the lysosomal 
membrane receptor lpg -96 llam p-2a  and the chaperone/protein com plex is 
internalised (Cuervo and Dice 1996). Estimates suggest almost 30% o f cytosolic 
proteins contain this sequence (or related); therefore a restricted but varied set o f 
target proteins is degraded during starvation by chaperone-mediated autophagy (Dice 
1992).
For detailed reviews o f the molecular mechanisms underlying autophagy see  
Stromhaug & Klionsky (2001) and Reggiori & Klionsky (2002).
4.2.3 Autophagy and Cell Death
Lysosomal involvement was described in the seminal apoptosis paper, but the role 
was limited to  the breakdown o f phagocytosed apoptotic bodies (Kerr et al 1972). It 
was long believed that autophagic cell death constituted a class o f death programme 
distinct from that o f apoptosis. There were many cases o f cells being removed by
autophagy, most dramatically during insect metamorphosis, but also in vertebrates the 
process was shown to  be a prominent feature o f organ morphogenesis, the shaping of 
extremities and cavity formation (Beaulaton and Lockshin 1982; Schweichel and 
Merker 1973). As cells can be completely degraded by autophagy alone: autophagic 
cell death is a complete process that can act independently o f apoptosis.
The features o f autophagic cell death first appear in the cytoplasm with a 
degradation o f its components resulting in a loss o f electrondensity. The number of 
mitochondria declines, but those that remain appear to  be structurally (and 
functionally) intact The bulk o f the cytoplasm is removed before the nucleus begins 
to  collapse (Beaulaton and Lockshin 1982; Clarke 1990; Schweichel and Merker 1973). 
All steps o f macroautophagy are ATP-dependent and require an intact cytoskeleton 
(and proper acidification) for vesicle transport (Blommaart et al. 1997; Klionsky and 
Emr 2000).
In terms on the machinery involved, a number o f studies suggest that the 
death process can pass to  completion independently o f caspases (Bomer and Monney 
1999; Quignon et al. 1998). Given that most features one would define as ‘classically 
apoptotic’ are believed to  be dependent on the action o f caspases (Hengartner 2000), 
it is feasible that the molecular machinery o f autophagic cell death remains completely 
distinct from that of apoptotic cell death.
However, several studies have reported considerable overlap between these 
two processes and it seems both can occur simultaneously, sharing much o f the same 
molecular machinery and with interplay between these tw o different paths o f cell 
death (Bursch 2001; Bursch et al. 2000a; Bursch et al. 2000b; Terwel and van de Berg 
2000; Uchiyama 2 0 0 1).
Opinion now is o f a continuous spectrum between purely apoptotic cell death 
and purely autophagic cell death. Xue, Fletcher and Tolkovsky (Xue et al. 1999) 
studied the effects o f apoptotic stimuli on cultured sympathetic neurons; they found 
that withdrawal o f NGF from the growth medium, traditionally used to  induce 
apoptosis, produced autophagic morphology (autophagic vacuoles, organelle 
engulfment and membrane whorls), initially in the absence o f any observable nuclear 
changes. As the cells persist in NGF-negative growth media (> l6hr), nuclear
morphology begins to  alter and apoptotic changes, including caspase-3 activation, 
begin to  appear. This situation is also seen using apoptotic inducers, such as araC; 
also, the presence o f autophagic profiles correlates with increased sensitivity to  araC- 
induces apoptosis. Application o f the caspase-inhibitor BAF does not eliminate the 
autophagic death pathway but does reduce autophagic activity slightly, suggesting that 
whilst autophagy can proceed in the absence o f apoptotic activation, it is enhanced by 
it. Furthermore, both apoptotic and autophagic death can be blocked using the 
compound 3-MA; which is not a caspase inhibitor, rather it appears to  act upstream of 
both caspase activation and autophagosome formation, suggesting a common  
activation mechanism for both pathways.
It appears, therefore, that autophagic activity can be triggered by apoptotic 
signals (probably due to  a common signalling factor) and that autophagy directly affects 
the execution o f  apoptosis. W hen the tw o processes co-activate, the onset o f  
autophagy appears to  occur prior to  the initiation o f apoptosis. Whilst (Xue et al.
1999) suggest that autophagic activity promotes apoptosis, another study on HT-29 
cells found increased sensitivity to  apoptosis following 3-MA treatment which would 
suggest that autophagy delays the onset o f  apoptosis, perhaps by isolating 
mitochondria which would otherwise release cytochrome c into the cytosol (Bauvy et 
al. 2001).
The current view o f the relationship between autophagy and apoptosis is 
illustrated in figure 140. In summary, autophagy appears before apoptosis; whether 
autophagy feeds forward into apoptosis or whether it is an attempt by the cell to  
prevent premature committal to  death remains under debate. The amount o f 
autophagic activity I have documented in this thesis, combined with an apparent lack 
of apoptotic activity, seems to  suggest that autophagy does not feed forward into 
apoptosis. It is more likely that it delays (perhaps indefinitely) activation o f apoptosis. 
Certainly, apoptosis appears to  enhance autophagy in those cells in which it is seen. 
Given that that purpose o f apoptosis is a "tidy deconstructin’ of the cell ready for 
phagocytosis, the advantages o f an autophagic component to  apoptotic cell death are 
obvious. One conclusion is becoming increasing dean in contrast to  earlier views, the 
tw o traditional processes o f  apoptotic and autophagic cell death are not distinct;
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Figure 140 The relationship between autophagy and apoptosis. Each is stimulated in 
the face of sufficient insult, probably through the action of a common signalling factor. 
The activation of autophagy normally precedes the activation of apoptosis, and, 
depending on the  strength of the insult, can prevent the activation of apoptosis. 
However, once apoptosis is active, it enhances autophagic activity.
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though neither absolutely requires the other, they often occur in the same dying cell 
and appear to  share some component o f upstream signalling.
4.2.4 Autophagy and Huntingtin
Autophagy has been implicated in Huntington’s disease as mutant huntingtin is seen to  
accumulate in lysosomal structures. (Sapp et al 1997), documented a granular 
appearance of mutant huntingtin within the cytoplasm of HD neurons. When viewed 
at the electron microscope level these structures corresponded to  multivesicular 
bodies. Subsequent work on cultured striatal cells has shown that mutant huntingtin 
accumulates in autophagosomes which internalise the lysosomal proteinase, cathepsin 
D in proportion to  polyglutamine length, suggesting an active response by the cell, 
proportional to  the size o f the insult to  degrade the accumulating huntingtin (Kegel et 
al. 2000). Furthermore, this work has also shown that activation o f the endosome- 
lysosome system affects the structure o f the golgi, endoplasmic reticulum and 
mitochondria; a situation mirrored in this work in the Hdh and, to  a lesser extent, the 
R6/2 mice.
It has since been demonstrated that lysosomal processing is able to  successfully 
degrade mutant huntingtin. Following transfection o f COS-7 cells with EGFP-tagged 
huntingtin exon I, Ravikumar et al. (2002) monitored aggregate formation. In the 
presence o f  the autophagic inhibitors 3-MA (inhibiting sequestration) or BafAl 
(preventing autophagosome-lysosome fusion) aggregates were more frequent and 
larger. Conversely, addition o f the autophagy-inducer Rapamycin increased clearance 
of expanded huntingtin, resulting in fewer, smaller aggregates.
Interestingly, it has been suggested that the autophagic response o f striatal 
neurons underlies the specificity in HD. Petersen et al. (2001) found no difference 
between survival rates o f dissociated striatal neurons from wild-type and R6/2 mice. 
However, a single exposure to  high concentrations o f dopamine had a greater effect
on neurons form the transgenic animals*; namely the formation o f structures 
associated with autophagy. Hence, they suggest that the presence o f mutant 
huntingtin, together with high levels o f dopamine in the striatum underlies HD regional 
specificity.
Superficial evidence for autophagy in the human condition has been provided 
by Mantle et al. ( 1995) who demonstrate an increase in the activity o f the lysosomal 
proteinases dipeptidyl aminopeptidase II, cathepsin H and cathepsin D in sample from 
HD postmortem tissue.
*  A  further exam ple o f  increased sensitivity t o  to x ic  stimuli, rather than an inherent to x ic  
effec t as discussed in 4 . 1
4.3 Dark Cell Degeneration
4.3.1 Apoptosis in the R6/2
IN light of these reports, the observations o f this thesis must now be evaluated. I have confirmed the presence o f neurons undergoing dark cell degeneration in 
the R6/2 mouse model. As discussed previously, there are many reports of the 
activation o f apoptotic components in model systems, particular attention being placed 
on the activation o f caspases. In spite o f  this wealth o f data, I have found no evidence 
of activation o f caspases in the R6/2. In areas known to  contain dark degenerating 
neurons, immunohistochemistry labels cells no differently to  healthy littermate control 
tissue. I have sought labelling for a variety o f  caspases, however for some, antibodies 
that exclusively label the activated form o f the protein are not available. Given the 
apparent evidence for the involvement o f caspase-1 in huntingtin-mediated cell death, 
this forced me to  analyse its involvement via western blotting. However the self- 
propagating nature o f the apogtosis machinery should mean that one should not have 
to  study each and every caspase in order to  establish an apoptotic mode o f cell death. 
My work on the x-irradiated animals clearly shows that when apoptosis is active, not 
only can my methods detect it but also that more than one marker labels the process. 
If I have been unable to  detect caspase-3 activation, with more than one antibody, in 
the degenerating neurons o f the R6/2 mouse, then one would not expect to  see  
PARP cleavage and TUN EL, as is indeed the case. Thus, from my extensive, though 
not complete, study o f the components o f apoptosis in areas o f known dark cell 
degeneration, I can reasonably conclude than that the molecular machinery o f  
apoptosis is not active in dark neurons.
Furthermore, my thorough analyses at the level o f the electron microscope 
reveal that dark degenerating neurons possess a unique, and consistent ultrastructural 
morphology that does not resemble that o f reported apoptosis. I have also used
electron microscopy to  study early postnatal mouse brain and have successfully 
located dying cells, which do resemble the ‘classical picture’ o f apoptosis. Thus, my 
ultrastructural methods are also capable o f preserving the appearance o f apoptotic 
cells; and I can easily recognise them as such.
This yields further consistency to  my results. Within the same areas, o f the 
same mouse model, I have shown the clear presence o f dark degenerating cells, which 
do not possess an apoptotic ultrastructural morphology, and do not contain active 
elements o f the apoptotic machinery.
Further support for a lack o f apoptosis is provided by a lack o f astrocytic 
response. Immunolabelling glia can produce highly variable, and thus unreliable, results 
when viewed using light microscopy. Therefore, I did not attempt to  quantify 
astrocytes. However, as electron microscopy work has revealed glial cells often in 
contact with degenerating neurons I attempted to  identify these cells using 
immunofluorescence and confocal microscopy. Whilst degenerating cells are 
detectable from their pyknotic appearance when stained with the nucleic acid dye 
DAPI, the GFAP-positive glia do not associate with such cells. There does appear to  
be an increased density o f glia with oligodendrocyte morphology, but the significance 
of this is unclear. Certainly, the glial response seen during apoptosis within a neuronal 
cell population is not replicated in the R6/2 mice, in spite o f the significant levels o f  
degeneration.
How then to  reconcile this with the observations o f others? I have already 
questioned the transferring o f observations from cultured cells onto adult neurons. 
My EM analysis o f neonatal mice, and immunocytochemical analyses o f x-irradiated 
pups, supports this criticism. The affected cells in each case are in close proximity to  
the cell cycle and show apoptosis as means o f cell death. Just as x-irradiation o f adult 
neurons proves to  be a weak apoptotic stimulus, so too, huntingtin may be more likely 
to  induce cell death in a recently divided cell in culture. Whilst these studies provide 
important insights into the disease, I do not believe the conclusions drawn about 
toxicity and cell death can be accurately projected onto the situation in vivo.
If one limits one’s criteria for evidence to  the R6/2 mouse model, the only 
consistently implicated factor is caspase-1. Y et when analysed more carefully, even
this evidence proves to  be flawed. In their original description o f the involvement of 
caspase-1 in Huntington’s disease, Ona et al. ( 1999) show dear improvements o f  
phenotype when crossing the R6/2 with a caspase-1 dominant negative mouse (as 
described in 4.1). Y et crossing the R6/2 onto another background may be sufficient 
to  reduce phenotype severity. However, the involvement o f caspase-1 is further 
supported by the use o f caspase-1 inhibitors, including minocycline. This suggests that 
caspase-1 inhibition does indeed improve overt phenotype, but does not prove 
caspase-1 activation in vivo, and proves the existence o f apoptotic cell death even less 
so.
Caspase-1 activation is not shown directly in the original paper (O na et al.
1999); rather, levels o f converted interleukin-13 (IL-13) are measured. Increases in 
mature IL-IG do indeed seem to  correlate with phenotype, and caspase-1 inhibition 
does lessen this increase, but this still fails to  show direct evidence for caspase-1 
activation. In subsequent work, evaluating minocycline, IL-1B conversion is once again 
used a measure, but mRNA levels are also measured, and western blots performed. 
The results show an increase in expression o f both caspase-1 and caspase-3 in the 
R6/2 (negated by the action o f minocycline); and the generation o f caspase-1 and -3 
fragments o f the correct molecular weight for the cleaved enzymes (Chen et al.,
2000). As this is the strongest evidence I sought to  repeat it
Having used antibodies to  cleaved caspase-3 in my extensive  
immunohistochemica! studies, I attempted to  replicate the caspase-1 western blots. A 
sample blot is presented in figure 78. I consistently found the presence o f the 
zymogen and, in the cortex, other precursor forms, but failed to  find a band 
corresponding to  the active caspase (~20kDa). This is at odds with the results o f the 
Friedlander group. As the protein is not confined to  a single, comparable band, it is 
not possible to  accurately quantify the levels of protein; but there may be an indication 
o f increased levels o f caspase-1 in the cortex o f the R6/2 mouse. If so, weight is 
added to  the evidence of increased caspase-1 expression, but this appears to  remain 
in the form o f the inactive precursor. Whilst the area between 15 and 30 kDa 
appears to  be clear o f protein in my caspase-1 western blots, I cannot ignore the 
possibility that the levels o f the active protein from degenerating neurons are so
dramatically lower than those of the precursors from surrounding healthy cells -  which 
are the vast majority -  that the technique would not detect them. This is why 
immunohistochemistry has been my weapon o f choice. I have shown in my toludine 
blue-stained semi-thin sections that degenerating neurons in the R6/2 are relatively 
few and rather isolated. Using immunohistochemistry I am able to  detect apoptotic 
activation within a single cell o f a population; should It be present Therefore, given 
these limitations in using western blots, I am forced to  doubt the Chen et al. (2000) 
results further. The published western blot proving caspase-1 activation shows not 
single bands as my results do, but a ‘smear’ o f labelled protein between the 50 and 
20kDa marks. There is a break somewhere around 30kDa, but are w e to  assume that 
everything above this is the inactive form and everything below cleaved caspase-1 ? I 
have shown that the different forms o f caspase-1 are easily resolvable using this 
technique. Further, the antibodies used by Chen et al. are identical to  those I have 
used to  produce clean bands from R6/2 lysates. Also, the published blot seems to  
indicate comparable levels o f precursor and active protein (though quantification is 
even more difficult here as a result o f the lar^ ge spread o f protein). Given the 
frequency o f degenerating neurons in the R6/2 I have shown in 3 .1.3 ,1 find it unlikely 
that the levels o f activated caspase-1 in those cells equal levels o f precursor caspase-1 
in all healthy neurons and glia.
I believe the evidence for apoptotic cell death in the R6/2 model is 
inconclusive. The techniques I have used here allow the direct comparison o f cell 
morphology to  immunohistochemical data. Within a defined area I can easily locate 
degenerating neurons. I have also shown that my techniques are capable o f detecting 
the cleavage o f apoptotic proteins when it occurs; even in single cells, and yet I can 
find no evidence for such activation in cells known to  be degenerating. Logically, it is 
infinitely more difficult to  prove that something does not occur than to  prove it does. 
But I believe the evidence I have presented here strongly suggests that dark cell 
degeneration does not involved the activation o f the apoptotic machinery
4 3 2  The Nature o f the Dark Neuron
One is therefore left to  question the nature o f the degeneration. It appears that even 
those cells in the most advanced stage o f degeneration in the R6/2 have not initiated 
apoptosis. Yet something must be causing the phenotype. Is it, therefore, the dark 
neuron? If so, what property causes the dysfunction. An insight into this is provided 
by my comparisons o f the R6/2 model to  the Hdh model.
The R6/2 mouse, most probably due to  the repeat size, shows a more rapid 
progression and more severe disease. The severity o f the neuronal dysfunction is such 
that it kills the mouse before the large-scale cell death seen in the human condition 
can occur. Conversely, the progression in Hdh mice is so slow that the mice die 
naturally before onset o f large-scale neuronal dysfunction. However, the insult -  
expanded polyglutamine within huntingtin protein -  is the same for each model; thus, 
they most likely undergo the same pathogenic changes, albeit at differing rates. 
Indeed, I have shown that the appearances o f the dark cells in the R6/2s and Hdh mice 
are strikingly similar.
The greatest similarity between the ultrastructural changes seen in each o f the 
mouse type is the evidence o f  autophagic activity. The formation o f autophagic 
vacuoles, multivesicular bodies and accumulation o f lysosomes are observed early 
among the ultrastructural changes. As discussed in 4.2, such activity has long been 
implicated as a response to  mutant huntingtin. There is work to  suggest that 
autophagy is successfully able to  remove mutant huntingtin, and thus the observed 
activity may indicate an attempt by the cell to  remove accumulated huntingtin that 
cannot be degraded via the ubiquitin proteasome system. Such a response would 
explain why I have observed the activity before any other consistent ultrastructural 
changes. Autophagy may also bring about the alterations to  Golgi bodies, 
endoplasmic reticulum and mitochondria also seen in both mouse models. Mutant 
huntingtin has been shown to  induce such autophagic changes in vitro, and the R6/2 
results presented here certainly suggest the same applies in vivo.
The most notable feature in each model is the condensation, which gives the dark 
neuron its eponymous feature. Such condensation must be an active process, and 
must becom e increasingly energy consuming. As the cell condenses, the osmotic 
potential difference between cell and neuropil increases. The condensation differs 
slightly between the tw o types of HD mice. In the R6/2 condensation o f cytoplasm 
and nucleoplasm occur, as far as I can detect, simultaneously. Whereas the Hdh mice 
tend to  show cytoplasmic condensation before nuclear changes are evident This may 
be o f significance to  the disease process. I have shown that the Hdh possess relatively 
few inclusions, and even those cells that possess some form of structural inclusion at 
EM show that these inclusions are not as mature as those seen in the R6/2 mice. 
Furthermore, figure 122 suggests that the Cajal body does not relocate to  the nuclear 
inclusion. In the R6/2 mice, such relocation is evident before marked condensation. 
The nucleoli o f R6/2 neurons also tend to  show greater variation from the normal 
appearance. Thus, there is an earlier involvement o f the nucleus in the R6/2 model. 
The degenerative process as a whole may be led by the nucleus in the R6/2. It is 
feasible that these changes are indicative o f  what may be the most important 
difference between the tw o models.
As discussed in 4.5, the behavioural phenotype o f HD and the R6/2 model is 
likely to  arise not from neuronal degeneration per se, but from the interaction 
between accumulated mutant huntingtin and cellular components, most notably, 
nuclear components. I have demonstrated that the nuclear accumulation o f huntingtin 
in the Hdh model is confined to  far fewer cells than seen in the R6/2; the formation of 
inclusions even fewer. Thus, it may be that the accumulation in the Hdh has not 
reached the levels required to  cause significant impairment, hence the lack o f  
significant phenotype. This might underlie the differences between the ultrastructural 
morphologies o f the tw o models. As discussed in the following section, the 
cytoplasmic changes, and simple nuclear condensation, can be accounted for by the 
stimulation o f autophagy. However, autophagic activity is largely confined to  the 
cytoplasm, its effects spreading to  the nucleoplasm in autophagic cell death only after 
the vast majority o f cytoplasm has been degraded. The nuclear condensation seen in 
the Hdh model may, in some cases, bear relation to  nuclear huntingtin, but as they are
seen after cytoplasmic condensation, they are more likely to  occur as secondary 
phenomena. The active process o f cytoplasmic condensation would set up an 
osmotic gradient which would draw water from an otherwise healthy nucleus.
The reported effects o f mutant huntingtin are described in section 4.4. The 
details o f the molecular events are beyond the scope o f my own experimental work, 
but as part o f my ultrastructural analyses I have reported the relocation o f the Cajal 
body (which remains intact) to  the nuclear inclusion. This is clearly a sign o f the major 
effects mutant huntingtin has in the nucleus; effects that do not appear to  be as great, 
or even present in the Hdh mice.
Therefore, whilst the cytoplasmic changes observed may be a consequence of 
secondary autophagic activity (see 4.3.3), the nuclear changes may be the most 
important in understanding Huntington’s disease.
4 3 3  Degeneration in Aged Mice
The observations of the aged wild-type mice are perhaps the most startling findings of 
this work. Prior to  this study it has been claimed that dark cell degeneration is a novel 
form o f cell death occurring in a variety o f neurodegenerative diseases. However, 
section 3.2 clearly documents an extremely similar process occurring in wild-type 
mice. This must surely alter our perception o f the degeneration seen to  occur in the 
mouse models. I have demonstrated that the same process can occur throughout the 
brain as a consequence o f aging alone.
The Hdh mice show widespread dark neurons from 26 months o f age. The 
wild-type littermates show such cells from around 28 months o f age. Therefore, rt 
may be that mutant huntingtin accelerates the ‘natural’ decay o f a neuron. Aging mice 
show accumulation o f dark cell profiles in much the same way their cells show  
accumulation o f lipofuscin. Likewise, just as the accumulation o f mutant huntingtin has 
been shown to  increase levels o f lipofuscin, so too  it increases the appearance of 
darkened profiles.
I have argued that individual dark cells must be metabolically functional in order to  
maintain structure, especially against an increased osmotic gradient If dark cells 
possessed significantly impaired energy metabolism they would swell and lose 
structural integrity, I have clearly shown they do not I believe the dark neurons of the 
wild-type aged mice, at least, must also be behaviourally functional. Using an easily 
identifiable cell type as an example: if almost all the Purkinje cells of a mouse are dark, 
as is the case in all the Shelboume mice presented, then they cannot be significantly 
impaired. The loss o f function of the vast majority o f any animal’s Purkinje cells would 
not render it asymptomatic. In spite o f this, the Shelboume mice have been subjected 
to  motor testing, and there is no sign o f ataxia.
How then to  reconcile the ultrastructural changes seen in dark cells with the 
picture o f an active, functional cell? Many o f  the ultrastructural changes I have 
described here are reported to  occur as a consequence o f an increase in autophagic 
activity. As mentioned in the previous section, at least the cytoplasmic changes seen 
to  occur in the R6/2 are reconcilable with autophagy; and these changes are similar to  
those seen in the aged mice. The one exception appears to  be the timing o f the 
condensation events. The R6/2 neurons show apparently concomitant cytoplasmic 
and nudeoplasmic condensation, whereas the Hdh mice show cytoplasmic events 
preceding nuclear events. This second is, in fact more in line with autophagy. The 
descriptions o f autophagic cell death consistently report the degradation o f  
cytoplasmic components before nuclear involvement (see 4.2). Macroautophagy is 
active under basal conditions producing small CVT vesicles, but the larger autophagic 
vacuoles (and multilamellar bodies) are also present in wild-type cells during starvation 
conditions. Furthermore, the observation that autophagy can delay or even suppress 
apoptosis has led to the suggestion that it functions as an attempt by the cell to  save 
itself. In light o f this, it is reasonable to  suggest that autophagic activity is part o f a 
cellular stress response designed to  prolong the life o f a cell for as long as possible. If 
the stimulus is strong enough, or the insult protracted enough, autophagy may not be 
able to  protect the cell. Certainly, the inhibition o f autophagy can enhance cell death.
The insults o f mutant huntingtin accumulation, or the stresses o f  old age 
produce a similar neuronal appearance. I have argued that the consequences o f
neuronal loss are so  great that mechanisms to  protect the cell from summary 
apoptosis must have evolved. The levels o f autophagy seen in dark cell degeneration 
may be such a response. As discussed in 4.2, autophagy has also been implicated in 
the human disease. The important difference between the mouse models I have 
studied and the human condition may be that the disease is so protracted in the 
human that a point is reached where autophagy can delay cell deletion no longer. In 
the mouse models I have studied, before such events occur to  any significant degree, 
the mouse is either overpowered by its phenotype or has com e to  the end o f its 
natural lifespan.
The important difference I have noted between the degenerative profiles of  
the Hdh & wild-type mice and those o f the R6/2 is the advanced nuclear condensation 
in the R6/2. This, I believe, it where the most important elements lie. I have observed 
the relocation o f the Cajal body, but this is merely a gross indicator o f the numerous 
nudear-led changes occurring as part of the disease.
4.3.4 Death
If the lifespan o f the Hdh mice could be extended, or the phenotype o f the R6/2 
ameliorated, I believe the dark neurons would eventually die, by which I mean cell 
deletion. This is speculation, but I believe such a neuron cannot survive in its 
dysfunctional state indefinitely. I have demonstrated that autophagy has been 
stimulated in the mouse models. The ‘common signalling factor’ in figure 140 is active, 
therefore degeneration is underway. I have also demonstrated that those cells 
undergoing dark cell degeneration do not show apoptotic morphology and there is no 
sign o f activation o f the molecular machinery o f apoptosis. Thus, autophagy is able to  
delay cell deletion; but I do not believe this could be maintained indefinitely.
4.4 Inclusions
4.4.1 Inclusions & Phenotype
THE R6/2 mice show the most severe phenotype. They also show the greatest inclusion formation, in terms o f number, size and distribution. Conversely, the 
Hdh mice show limited inclusion formation and possess a relatively mild phenotype. 
Thus, the original postulation, based on the R6/2 mouse model, that ‘formation of 
neuronal intranuclear inclusions underlies the neurological dysfunction’ is not 
unreasonable (Davies et al. 1997).
However, the Hdh mice do show inclusions throughout the striatum; which 
are comparable to  inclusions seen in the early stages o f observable behavioural 
phenotype onset in the R6/2 mice. Is it therefore, that inclusion formation within the 
striatum alone is insufficient to  cause a phenotype? Human patients also exhibit 
cortical inclusion formation, a similarity with the R6/2 and not the Hdh knock-ins; 
therefore it may be that nuclear inclusion formation within cortical neurons underlies 
the behavioural phenotype. This is supported by analysis o f cortico-striatal 
electrophysiological dysfunction (see 4.5).
It must be the case that the mutant protein causes the phenotypic change: 
such is the nature o f genetic disorder. But whilst inclusion formation in a cell may 
correlate with dysfunction, it may not be the underlying cause. Whilst many o f the 
proteins known to  interact with huntingtin may be recruited to  the inclusion, others 
also interact with soluble huntingtin. I believe there is an important distinction to  be 
made between the inclusion being seen as the cause o f neuronal dysfunction and 
being viewed as an indicator o f mutant huntingtin load within a particular cell.
4.4.2 Inclusions & Degeneration
The R6/2 mice show the greatest number o f inclusions and size thereof, with the most 
widespread distribution. They also show the fewest dark cell profiles. Conversely, the 
Hdh mice show the greatest number o f darkened profiles, in the face o f the fewest 
inclusions. However, whether the degeneration seen in the Hdh mice is due to  the 
effects o f huntingtin remains under question. As described in 4.3, whilst all mice, 
control and knock-in, display comparable amounts o f degeneration beyond 29 
months, at 26 months o f age the knock-in black 6 mouse shows moderate amounts o f 
degeneration whilst the wild-type appears healthy. It may be that as a secondary 
consequence of the mutation, some cells exhibit an accelerated aging; and thus much 
o f the degeneration seen in the knock-ins is not a direct consequence o f  the 
huntingtin mutation within those cells.
Nevertheless, even if one ignores the Hdh data, the degree o f degeneration 
seen in the R6/2 mouse cannot be said to  be proportional to  the degree o f inclusion 
formation. There are areas that show frequent inclusions, both nuclear and neurite, 
and yet have never been seen to  contain degenerating cells. For example, the 
hippocampal CAI neurons are seen to  be among the first to  develop inclusions, and 
go on to  contain the largest o f all inclusions, and yet I have failed to  find a single 
degenerating neuron within the R6/2 hippocampus.
As described in 1.6, there is still debate on whether the formation o f the 
inclusion is toxic to  the cell or beneficial. Certainly any inhibition o f the ubiquitin- 
proteasome system results in increased inclusion formation, suggesting a response by 
the cell to  degrade mutant huntingtin. Many have taken this to  mean that the 
formation o f the inclusion is an active response to  deal with the mutant protein, 
sequestering it away. Others believe the formation o f the aggregate is toxic; indeed, 
the Bucciantini study implies that any aggregate is toxic (Bucciantini et al. 2002). 
However, there is the possibility that inclusion formation is neither beneficial nor toxic; 
rather it occurs as a consequence o f accumulation o f protein that cannot be degraded. 
From my work on the Hdh mice it has become apparent that even in healthy cells o f 
healthy animals, there is considerable accumulation o f lipofuscin with age. I have come
to  view the accumulation o f huntingtin as a similar phenomenon. There is some other 
factor, or factors, which underlie the degeneration of neurons in response to  mutant 
huntingtin. If one could identify the relevant difference between a neuron in the 
hippocampal CAI field and one from the anterior cingulate cortex, one might find a 
therapeutic target for preventing the degeneration o f the latter. O f course, whether 
this would save the phenotype is another matter.
4.4.3 The Formation o f the Inclusion
The tw o leading theories for the formation o f aggregates -  polar zippers and tissue 
transglutaminase -  are summarised in 1.5.5. Recent evidence has suggested that tissue 
transglutaminase has no role in in vivo in polyglutamine aggregation, as the enzyme 
does not associate with aggregates nor does altering the level o f the protein affect 
aggregation (Chun et al. 2 0 0 1). However, the polar-zipper model has remained a 
favoured hypothesis. To reiterate: expanded polyglutamine repeats form stable, 
hydrogen bonded, paired antiparallel 13-strands. Such aggregates then precipitate out 
further soluble polyglutamine-containing protein, and inclusions form.
If such a mechanism o f aggregation does indeed occur then one would expect 
the formation o f regular structures. This has been demonstrated in vitro using a variety 
of huntingtin exon I -gluthathione S-transferase fusion proteins expressed in £  coli. 
Expanded glutamine repeats cause the formation o f aggregates with fibrillar 
morphology (Huang et al. 1998) reminiscent o f scrapie prion rods (Prusiner 1998), (3- 
amyloid fibrils in Alzheimer’s disease (Caputo et al. 1992) and a-synuclein fibres in 
Parkinson’s disease (Conway et al. 1998). When viewed with electron microscopy 
these fibres form digested exon I constructs, which are 10 -12nm in diameter and vary 
in length from lOOnm to  several micrometers. They also stain with Congo red 
showing green birefringence, indicative o f  the presence o f (3-pleated sheets; which 
supports the polar-zipper model. Likewise, huntingtin aggregates prepared from
human tissue exhibit similar staining properties suggesting similar aggregation 
mechanisms in vivo (Huang et al. 1998).
However, such structures, like the Lewy bodies formed from a-synudein 
fibres, have a readily identifiable structure when viewed at EM (figure 141). As should 
be apparent from the numerous examples o f huntingtin inclusions presented herein, 
there is very little structure to  the inclusions o f either the R6/2 or (where visible at 
EM) the Hdh mice.
Inclusions normally present as a granular structure with a defined texture, but 
lacking any fibrous assembly. Fibrous elements are occasionally visible, but are rarely 
10 -12nm in diameter and certainly n o t ' I OOnm to  several micrometers’ in length. As 
described in 3.1.7, these elements are considerably more frequent in the neurite 
aggregates o f the R6/2 mouse, being rarely visible in the nuclear inclusion. The 
situation is similar in human tissue examined. Figure 142, represents a nuclear 
inclusion from a human patient with approximately 100 CAG repeats. The 
appearance is similar to  those inclusions seen in the R6/2 neuronal nuclei: a 
predominantly granular structure. There are som e elements that may be fibrous in 
nature (arrowheads), but these are small and, importantly, located toward the 
periphery. The fibrous elements o f the R6/2 neurite inclusions are also located 
towards the periphery. The polar-zipper model o f aggregation relies upon a 
nucleation-dependent event the seed for aggregation is formed by fibrilisation and 
further fibres are added onto this seed (Scherzinger et al. 1997). Thus, fibres are 
literally the central element to  inclusion formation. If this were true, one would 
expect any fibrous elements to  be located at the centre o f inclusion and not towards 
the periphery.
There is clearly a vast difference between the aggregation seen in vitro and the 
inclusions seen in vivo. W hat underlies this difference? Any answer is currently 
speculative, but it is my opinion that this difference is the result o f complexity. The 
inclusions formed in vivo are in a simple system. As mentioned previously, proteins 
not previously associated with aggregation can be induced to  form aggregates in vitro. 
The experiments described above on huntingtin exon I -GST fusion proteins were 
conducted by purifying the expressed protein from E. coli lysate by affinity
Figure 141 High-magnification electron micrograph of a Lewy Body from a 
patient with Parkinson’s disease. The Lewy body is form ed through 
sequential addition of fibres and as a consequence has a defined structure.
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Figure 142 High-magification electron micrograph of a neuronal intranuclear 
inclusion from a Huntington’s disease patient with approximately 100 CAG 
repeats (expanded allele). The structure is akin to  that seen in the R6/2 mice: a 
granular appearance with possible fibrous elements tow ards the periphery 
(arrows).
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chromatography, then digesting away the GST with trypsin. Aggregation is therefore 
taking place in a solution dominated by the protein in question. It is not unreasonable 
to  assume that aggregates o f Protein X  are more likely to  form in a concentrated 
solution o f entirely Protein X
Similar reasoning may explain why fibres occasionally form in neurite 
aggregates and very rarely in nuclear inclusions, as neurite aggregates contain fewer 
proteins than those of the nucleus. Colloquially, there isn’t  as much to  get in the way 
of any fibrillisation that may occur. Conversely, within the nuclear inclusions there are 
numerous large proteins such as molecular chaperones, com ponents o f the  
proteasome and molecules such as the 265kDa CRER-binding protein. The situation 
in vivo is certainly not akin to  that in vitro.
Nevertheless, inclusions do contain some fibrous elements. Notably, these are 
more frequent in the more mature aggregates. This further argues against a fibrillar 
nudeation event It is my belief that these elements are indeed the 13-stands o f the 
polar zipper models, which, as the in vitro work has shown, will form spontaneously 
when expanded polyglutamine-containing proteins are in sufficient concentration. 
However, I believe this is a secondary event to  inclusion formation, occurring as a 
result o f proximity induced by another mechanism.
4.5 Neuropathology
4.5.1 Dark Cells and Phenotype
HE R6/2 mice possess an aggressive phenotype in the face o f no apparent cell
death and relatively few dark cells. In contrast, the Hdh mice show an extremely
mild phenotype and whilst there is little or no cell death, there are a considerable 
number o f dark cells. It has also become apparent through this study that aged mice 
possess numerous dark neurons, and show no observable phenotype. It seems clear 
that in these mice, the presence o f dark cells does not correlate with disease 
phenotype, and thus is unlikely to  be the cause.
The human condition is dominated by cell loss, occurring over a protracted 
period, thus one cannot easily claim any correlation. Certainly, by the time the 
patients reach Grade 4 pathology, with up to  95% cell loss from the striatum, the 
patients are in the rigid akinetic stage o f symptoms. Furthermore, there is a recent 
report o f a patient with confirmed Huntington’s disease (CAG 42/23) exhibiting all the 
choreaform symptoms, but with no observable cell loss at post-mortem (Caramins et 
al. 2003). It is likely that the initial symptoms o f HD, and those one traditionally 
associates with the disorder, stem not from cell loss but from cell dysfunction.
In seeking a treatment for the human condition, prevention o f cell loss may 
therefore do very little to  reduce the symptoms and suffering o f patients. For 
example, as described in 4.1, minocycline inhibits caspase-1, and has been shown to  
protect against polyglutamine-induced cell death in vitro and prolong the life o f  R6/2 
mice. However, subsequent analyses have revealed neither behavioural benefits nor 
any affect on inclusions detectable at post-mortem (Smith et al. 2003). Likewise, the 
glutamate antagonist Riluzole has been suggested as a therapeutic agent. Whilst this 
also increases the survival time o f R6/2 mice, it has no effect on motor performance 
(Schiefer et al. 2002). Cell death is no doubt responsible for the latter, ‘negative’
symptoms o f HD, but the personality changes and hyperkinetic ‘positive’ symptoms of 
early HD bear no relation to  neuronal loss. Thus, quests for therapies should centre 
on ameliorating cell dysfunction.
4.5.2 Interactions
Cell dysfunction in Huntington’s disease must be a result of the mutation, most likely 
through perturbed or abnormal interactions with other cell components. The number 
of proteins with which huntingtin and/or mutant huntingtin are reported to  interact is 
ever increasing. Furthermore, as huntingtin is found to  interact with one protein, so 
that protein is reported to  interact with numerous others. It is therefore unlikely that 
dysfunction arises from a simple altered interaction, rather that many interacting 
elements contribute to  upsetting neuronal function.
The suggestion that huntingtin may be involved directly in gene transcription 
came soon after the cloning o f the gene, as proteins with long polyglutamine or 
polyproline stretches often serve such roles (Gerber et al. 1994), such as the androgen 
receptor and TATA-binding protein, which themselves cause SBMA and SCA-17 
when their polyQ sequences are expanded. However, wild-type huntingtin appears 
to  be predominantly cytoplasmic and so its function is unlikely to  be gene 
transcription.
Nevertheless, numerous alterations in gene expression have been detected in 
HD. Using microarray technology, Luthi-Carter et al. (2000) analysed the expression 
of over 6000 genes in the R6/2 striatum and found that between 1.2 and 1.7% 
percent o f those genes showed altered expression in the R6/2; the majority o f  which 
were down-regulations (at a ratio o f 3:1). O f particular interest to  cell dysfunction and 
death, they report decreased expression o f neural signalling molecules but no change 
in molecules associated with degeneration, such as glial markers. This supports the 
notion that cell dysfunction, in particular signalling pathways, are impaired before 
degeneration is evident
Current thinking now tends towards perturbations in gene transcription occurring as a 
result o f mutant huntingtin abnormally binding or sequestering away factors directly 
involved in transcription. A number o f factors have been identified in nuclear 
inclusions, including TBP, CBP, TFIID and mSin3, each of which has a central role in 
transcription. mSin stabilises p53 and thus sequestration o f mSin in the inclusion may 
result in p53 degradation and a loss o f p53-dependent transcription (Boutell et al.
1999). Further inhibition o f transcription is believed to  occur through huntingtin’s 
interaction with CBP, a crucial factor in CRE-mediated transcription. Several polyQ- 
containing proteins have been shown to  bind CBP (McCampbell et al. 2000), and early 
down-regulation o f CRE-regulated genes has been reported in both cell models of 
HD and the human condition (Wyttenbach et al. 2001). Interestingly, mutation in 
CBP causes Rubinstein-Taybi syndrome, a rare condition which involves severe mental 
retardation; supporting a causative relationship between CBP dysregulation and a 
neurological phenotype. Conversely, overexpression o f CBP reduces mutant 
huntingtin toxicity in cell culture models, as does preventing CBP-huntingtin interaction 
(Nucifora et al. 2 0 0 1). Another factor in CRE-mediated transcription has also been 
implicated in HD: TAF„I30. This cofactor in has also been located in huntingtin 
aggregates, and, as with CBP, overexpression restores CRE-dependent transcription 
(Shimohata et al. 2000).
Recently, it has been shown that another transcription factor, NeuroD, which 
is neuronal specific, interacts with HAP I, via which it may interact with huntingtin 
(Marcora et al. 2003). This is an interesting finding in that it may help to  explain why 
mutant huntingtin predominantly affects neurons. It also serves to  illustrate how the 
effects o f mutant huntingtin may reach beyond direct interactions and recruitment, 
affecting transcription via numerous intermediate factors.
On a more general level, there appears to  be a downregulation o f  
transcription in various HD models due to  histone deacetylation. The availability o f  
DNA to  the transcription complexed is tightly regulated by the action o f histone 
acetyl transferases (HATs), which open up chromatin, and histone deacetylases 
(HDACs), which cause the tight binding o f DNA to  the histones. Mutant huntingtin 
has been reported to  interact with a number o f HATs (including CBP, p300 and
P/CAF), inhibiting their action and causing general transcriptional inhibition (Steffan et 
al. 2001). Such a widespread action may explain why the majority o f transcription 
changes document by Luthi-Carter et al. (2000) were down-regulations. Therapeutic 
intervention to  address the imbalance, the administration o f HDAC inhibitors has 
shown promising preliminary results. Hockly et al. (2003) administered the HDAC 
inhibitor SAHA (suberoylanilide hydroxamic acid) to  R6/2 mice and found a significant 
improvement in motor performance. It should be noted, however, that approximately 
2mg o f SAHA was administered daily via drinking water; doses greater than this 
proved to o  toxic. In their preliminary studies, Hockly et al. had found that doses less 
than 200mg injected s.c. produced no effect on histone acetylation. Therefore, it is 
uncertain as to  whether tolerable doses o f SAHA can significantly inhibit HDACs. 
Nevertheless, a tolerable HDAC inhibitor may one day prove to  be o f great 
therapeutic value.
4.5.3 Pathophysiology
Huntingtin has also been shown to  interact with numerous proteins involved in vesicle 
trafficking. Indeed, the eponymous protein itself has been implicated in the role (see 
1.3.2). Huntingtin-associated protein I (HAP I) binds the p 150 subunit o f dynactin 
(Engelender et al. 1997), an activator protein required for the retrograde vesicle 
transport along microtubules. It has been implicated in dathrin-mediated endocytosis, 
along with huntingtin (Velier et al. 1998), and huntingtin-interacting protein I (HIPI) 
(Metzler et al. 2001). In support o f a role for HIP I in endocytosis, the rat homologue 
has been shown to  localise to  postsynaptic spines in small vesicular structures (Okano 
et al. 2003), and it is over-expressed in certain human endothelial cell cancers, which, 
when replicated in vitro, results in altered receptor trafficking (Rao et al. 2003). HIP I 
knock-out mice show  impaired endocytosis, but, importantly, also exhibit a 
neurological phenotype reminiscent o f some o f the features o f HD: tremor and ataxia
(Metzler et al. 2003). Given these observations, one would expect mutant huntingtin 
to  interfere with synaptic function, and this appears to  be the case.
Perturbations in electrophysiology have been reported in many o f the mouse 
models o f HD, most o f the original work was conducted on hippocampal neurons. In 
the R6/2 mouse, basal neurotransmission across CAI synapses in unaffected, however 
during intense activity a deficit becom es apparent (Murphy et al. 2000). 
Measurements o f  presynaptic function indicate that neurotransmitter release is 
impaired, but said impairment does not affect function at basal levels. This may be 
due to  a deficit o f complexin II, part o f the SNARE-complex, which has been shown 
to  be progressively lost in R6/2 mice (Morton et al. 2 0 0 1) and PC 12 cells expressing 
expanded huntingtin, where this loss results in decreased calcium ion-triggered 
exocytosis (Edwardson et al. 2003). In support o f this loss causing the dysfunction 
seen, complexin II knockout mice exhibit aberrant hippocampal electrophysiology 
similar to  that seen in the R6/2 (Takahashi et al. 1999).
More recent work has investigated the electrophysiology o f the medium spiny 
striatal neurons: those directly affected in human HD. In the transgenic model o f  
Marian DiFiglia (see 4.6), expressing a longer huntingtin N-terminal fragment with 
either 46 or 100 glutamine repeats, striatal neurons showed decreased responsiveness 
to  induced cortical stimulation and to  NMDA exposure. They also report the onset 
of behavioural phenotype occurring after striatal inclusion formation, but concomitant 
with nuclear accumulation o f  huntingtin within cortical neurons, suggesting that 
phenotype onset is caused either by cortical dysfunction, or by the potentiating effect 
of striatal and cortical dysfunction (Kegel et al. 2000).
In the R6/2 mice, this functional deficit has been investigated more thoroughly 
and more objectively. Cepeda et al. (2003) monitored the spontaneous excitatory 
post-synaptic currents (EPSCs) in striatal medium spiny neurons at three time points: 
presymptomatic (3-4 weeks), at onset o f symptoms (5-7 weeks) and severely 
impaired (11-15 weeks). They report a decrease in EPSCs at 5-7 weeks, becoming 
more pronounced at 11 - 15 weeks. This supports previous data reporting that greater 
electrical stimulation is required to  induce inward current in R6/2 striatal neurons 
(Klapstein et al. 2001). As these activities are not blocked by bicuclline or
tetrodotoxin, one can infer they are generated as a result o f glutamatergic input and 
therefore likely to  be o f cortical origin. In addition to  a reduction o f basal activity, they 
also report the appearance o f isolated large synaptic inward currents in the R6/2, most 
pronounced in the 5-7 w eek  animals. Interestingly, Riluzole, which decreases 
glutamate release (Cheramy et al. 1992) and has been reported to  prolong the life of  
R6/2 mice (Schiefer et al. 2002), reduces the number o f these large-current events. In 
an attempt to  identify the causes o f this dysfunction, Capeda et al. (2003) examined 
the distribution o f synaptophysin and PSD95, key pre- and post-synaptic proteins 
respectively, and found significant reductions in both markers in the 11-15 week mice.
This work may indicate that complicated cortico-striatal dysfunction, with 
transient as well as progressive changes, may underlie the phenotype o f the R6/2 and 
the symptoms of human HD. It may also help to  explain why the Shelboume Hdh 
mice show so little phenotypically in the face o f evident pathological changes, as these 
mice show no nuclear huntingtin in cortical neurons.
Filling neurons with biocytin, or Golgi impregnation, allows for isolated cell 
morphology to  be examined. Such work on the R6/2 mouse has revealed a reduction 
of dendritic spine density, a decreased dendritic field diameter, and a decrease in the 
diameter o f dendritic shafts o f medium spiny neurons (Klapstein et al. 2 0 0 1). Such 
neurons also show numerous varicositites along the dendritic shafts, possible as the 
result o f a ‘pruning’ process. In support o f this, the reduction in dendritic spines is 
greatest the further from the cell soma. The reduction in dendritic spine density, and 
a decreased arborisation is likely to  underlie the decreased activity seen in these  
neurons; and explains the loss o f synaptophysin and PSD95 staining. Furthermore, this 
is likely to  underlie the reports that R6/2 striatal neurons are more resistant to  
excitotoxicity (Hansson et al. 1999; Morton and Leavens 2000).
Such changes are not confined to  the striatal medium spiny neurons, but are 
also found in cortical and hippocampal pyramidal neurons (Klapstein et al. 2001). As I 
have found that the cell bodies o f hippocampal neurons do not show signs o f dark cell 
degeneration in the R6/2 (see 3 .1.3), the Klapstein et al. report serves to  further 
highlight the lack o f a causative relationship between degeneration and dysfunction.
4.6 Mouse Models and Huntington s Disease
4.6.1 Mouse Models
HERE are a growing number o f models o f Huntington’s disease, including C
zlegans, Drosophila and yeast models. However, the most evolutionary
‘advanced’ models, and therefore those one assumes to  have the greatest relevance to  
the human disorder, are the mouse models*. For this reason they have been the 
most extensively studied. Tables o f those mouse models which have been most 
extensively studied are found in figures 143 to 145.
Three broad strategies have been used to  generate these mice. First, the 
insertion o f a fragment o f the human gene, containing the region associated with the 
disease, the polyglutamine tract, randomly into the mouse genome: truncated 
transgenics, such as the R6 mice. Secondly, the insertion o f the full-length human gene 
into the mouse genom e (the mouse model o f Michael Hayden’s research group 
involved the insertion o f the full-length gene into a Yeast Artificial Chromosome 
(YAC), which is replicated in the mouse along with endogenous genetic material): full 
length transgenics. The final method, as used by Peggy Shelboume, involves the 
elongation of the CAG repeat sequence within the mouse homologue of IT 15: knock-
This thesis has examined the differences between the R6/2 and Shelboume 
Hdh mice, but further differences are brought to  light when examining the full range of  
mice. As described in 1.5, the cleavage o f mutant huntingtin is believed to  be an 
important event in the pathogenesis o f HD, as a result one would expect those mice 
expressing a truncated mutant huntingtin construct to  show a more rapid pathology.
*  A  rat genetic m odel o f  H D  has recently b een  generated by von  H orsten e t  al. (2003). The  
m odel w as gen erated  using truncated  H D  cD N A , containing 51 CAG  repeats, exp ressed  
using th e  rat huntingtin p rom oter. T he animals produced exhibit an adult-onset phenotype  
with m otor & cognitive com p on en ts and p ossess Nils.
ins.
R 6/2
(Bates)
IT 15 exon 
1 and 1 kb 
upstream 
elements
I50Q
(now 
expanded 
to approx. 
200)
Human
huntingtin
prom oter
C57B6/CBA Frequent large, 
widespread 
inclusions 
throughout brain -  
Nils and neurite 
inclusions -  
appearing first at 
approx. 4 weeks
Motor deficits 
detectable at 5-6 
weeks; overt at 8 
weeks, progressing to 
severely impaired 
behavioural deficits.
Death at 13-15 
weeks
Dark neurons found 
predominantly in cortex 
(cingulate, and motor) 
and in the striatum; 
apparent at 12 weeks. 
Overall brain atrophy.
N I 7 I
(Borchelt)
First 171 
amino 
acids of 
IT 15
82Q
(also 
unaffected 
44Q  & 
I8Q)
Prion
prom oter
C3H/C57B6 Incusions found in 
striatum, cortex, 
hippocampus, 
amygdala & 
cerebellum; 
appearing at 6-8 
months
Motor deficits 
detectable at 3 
months; progressing 
to overt phenotype 
of tremors & 
abnormal gait. 
Death at 24-30 
weeks.
Degenerating neurons 
reported within the 
striatum. Overall mild 
brain atrophy.
H D 9 4
(Y am am oto)
Adapted 
exon 1
94Q’
interrupted
sequence
BiTetO-CMV
prom oter
Controllable
expression
CBA/C57B6 Inclusions in 
striatum, septum, 
cortex and 
hippocampus; first 
at 8 weeks; 
reversed by turning 
off transgene.
Motor deficits 
detectable at 2.5 
months; tremor and 
abnormal gait at 4.5 
months. Normal 
lifespan.
Astrocytic response but 
no neuronal 
degeneration reported. 
Overall brain atrophy.
Figure 143 Transgenic mouse models of Huntington’s disease expressing a fragment of the huntingtin gene.
Model PolyQ Prom oter Background Inclusions Phenotype Degeneration
3kb N- 
terminal 
fragment
(DiFiglia)
I00Q Rat neuron 
specific 
enoclase
SJL/C57B6 Inclusions 
reported, both 
Nil and neurite
Onset of symptoms (clasping 
phenotype) at 3-4 months; 
hyperactivity to end-stage 
hypoactivity.
Cell loss (20%) reported in 
some animals. Overall brain 
atrophy also only in certain 
animals.
HD89
(Tagle)
89Q CMV FVB/N Very few 
inclusions
Onset of symptoms (clasping 
phenotype) at 4 months; 
hyperactivity followed by end- 
stage hypoactivity. Death at 
18-20 months for 
heterozygotes (homozygotes 
12-15 months)
Neuronal loss reported in the 
striatum, cortex, hippocampus 
and thalamus. Gliosis also 
reported.
YAC72
(H ayden)
72Q HD gene, 
including 
promoter, 
inserted into 
yeast artificial 
chromosome
FVB/N Inclusions only in 
striatum
Onset of symptoms (clasping 
phenotype) at 3 months; 
hyperactivity and circling 
behaviour. Age at death not 
reported (greater than 12 
months)
Dark neurons in the striatum. 
No evidence of cell loss.
Figure 144 Transgenic mouse models of Huntington’s disease expressing truncated huntingtin (continued) or full-length human huntingtin.
Shelboume 72Q
80Q
FVB
C57B6
Late inclusions (>18 
months), predominantly in 
striatum, nucleus 
accumbens and olfactory 
tubercle.
No motor deficits, but behavioural 
phenotype (aggressiveness) 
reported.
Age-related degeneration in 
oldest mice. No cell loss.
Zeitlin 7IQ
94Q
C57B6 Inclusions only found in 
94Q mice at late stage 
(> 18 months); nuclear 
microaggregates found 
earlier (6 months)
Behavioural phenotype 
(aggressiveness) reported. Mild 
hyperkinesias also reported in 94Q.
No cell loss or degeneration, 
but dysfunction (swelling in 
response to NMDA) 
reported. Striatal cell 
shrinkage.
MacDonald 11 IQ
92Q
129/CD 1 Striatal nuclear inclusions 
at 10 months in 1 1 1Q and 
12 months in 92Q
Phenotype apparently unaffected; 
normal lifespan
No cell loss
DetlofF I50Q 129/Ola x 
C57B6/6J
Striatal nuclear inclusions 
evident at 10 months
Motor deficits detectable at 15-40 
weeks
No cell loss
Figure 145 Knock-in mouse models of Huntington’s disease.
This is certainly true when comparing the truncated transgenics to  the knock-ins, 
which show few, late-stage inclusions and no neuronal degeneration until the last days 
o f the mouse lifespan. However, the comparison o f transgenic mice expressing just 
exon I (or the first 17 1 amino acids) o f  huntingtin to  those expressing the full-length 
protein yields interesting results. All truncated-expression mice show similar 
phenotypes to  the R6/2, occurring at different rates presumably due to  differences in 
polyQ length, and frequent inclusions but show no cell loss. Conversely, transgenic 
mice expressing the full-length mutant protein (reportedly) show cell loss in the 
striatum, extending to  (in the case o f the Tagle mice, with the greater polyQ length) 
cortex, hippocampus and thalamus. Whilst showing similar initial phenotypes to  the 
truncated transgenics, they show very few inclusions, limited to  the striatum. This 
further undermines the notion that the formation o f  inclusions induces, or even 
correlates with, cell death. The mice o f Marian DiFiglia provide an interesting ‘halfway’ 
between the tw o extremes o f transgenic modelling, for her group have generated 
transgenic mice expressing mutant huntingtin that whilst truncated, is considerably 
longer than the proteins o f  the other truncated transgenics: one third of the complete 
sequence as opposed to  one sixty-seventh (Laforet et al. 2 0 0 1). This mouse shows 
features of the other truncated transgenic mice -  frequent inclusions, both nuclear and 
neuritic, and a progressive motor phenotype -  but also the cell loss (in some animals) 
associated with the full-length protein models.
These observations suggest that whilst truncation o f the mutant protein 
accelerates inclusion formation, it prevents against cell loss. These may be inextricably 
linked, supporting the notion that the formation o f the inclusion reduces toxicity.
There is an important factor that cannot easily be controlled for expression 
level. The promoters used to  express the construct in each o f the transgenic mice are 
included in the figures. Each differs in some way. Whilst the R6/2 and the YAC72 
models each make use o f the human IT 15 promoter, one cannot be certain that the 
nature o f the YAC does not interfere with expression. Furthermore, the HD94 and 
HD89 models each make use o f  the cytomegalovirus promoter, but this has been 
adapted in the HD94 for the very purpose o f altering its native properties. The 
methods used to  attempt to  quantify levels o f expression in each of the models vary,
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even down to  the question o f whether to  quantify protein o f RNA. As stability of 
mRNA and translation rates may vary within each mouse, and the important molecule 
is the protein, it would seem wisest to  quantify levels o f mature huntingtin. However, 
the very nature o f the mutant protein makes this a difficult task the longer the 
polyglutamine length, the greater the tendency for aggregation. As huntingtin 
aggregates are resistant to  being broken apart they are unlikely to  travel well through 
electrophoretic gels, thus western blot-based quantifications may yield only 
information on soluble or oligomeric huntingtin. As an aside, this may bear some 
relevance to  work reporting that increasing polyglutamine length causes decreasing 
expression levels (Persichetti et al. 1995; Trottier et al. 1995).
As a result, any comparison o f expression levels based on the available data 
would be tenuous, particularly as the degree o f aggregation and inclusion formation 
varies among mice. However, there are some points that need mentioning. The mice 
o f Danio Tagle were generated using full-length HD cDNA inserted not into a YAC 
but directly into the mouse genome. They may thus be considered the most faithful 
transgenic model. Indeed, they develop a complex motor and cognitive phenotype 
akin to  many o f the other mice, but, importantly, they also progress to  a hypokinetic 
stage before death, thereby mimicking the complete range o f symptoms seen in the 
human condition. These mice also substantial neuronal loss, particularly in those mice 
sacrificed after entering the hypokinetic stage (Reddy et al. 1998). This model 
therefore seems to  replicate the human condition in all aspects. The levels o f mutant 
huntingtin protein in these mice, examined by western blotting and therefore prone to  
underestimation depending on aggregation, has been estimated at up to  5 times the 
levels o f endogenous wild-type huntingtin. Is it, therefore, protein load that kills the 
neurons o f these mice?
This makes the DiFiglia 3kb fragment mice even more interesting. As 
described previously, these mice show frequent inclusions; exhibit a progressive 
phenotype, from hyperactivity through to  hypoactivity; and lose neurons. Yet, whilst 
the results are variable, the mutant protein appears to  be expressed at levels below  
that o f endogenous protein (Laforet et al. 2 0 0 1).
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The knock-in mice are all under as equivalent promoter the Hdh promoter. Each 
model has been reported to  have protein expression levels close to  endogenous. At 
this level o f expression, even with the 111 repeats in the Marcy MacDonald mouse, 
there is very little effect Inclusions are evident only in animals well into adult-hood. 
The fact that there is little in the way o f detectable phenotype suggests that cells have 
yet to  enter the period o f dysfunction that precedes detectable cell degeneration. 
The degeneration in the Hdh mice presented herein appears to  occur primarily as a 
result o f senescence modified by the disease process. Thus, expression o f even 
greatly expanded huntingtin driven by the endogenous mouse promoter is not 
sufficient to propel the mouse through the full range o f the human condition.
The remaining question here concerns the truncated transgenic mice. Why do 
the R6/2 and N17 1 mice show degenerating neurons when levels o f mutant protein 
are reported to  be below those o f wild-type? Yu et al. (2003) compared the 
degeneration o f these mice and also o f the Detloff Hdh 150 knock-in mouse and 
reported activated caspase-3 only in the N17 1 mouse. To investigate this further they 
transfected human embryonic kidney (HEX) cells with a variety o f constructs, varying 
the length o f  either polyQ or non-polyQ regions. As expected, they find increasing 
the polyQ length results in greater caspase activation. However, they also find that 
increasing the length o f protein beyond the exon I boundary increased toxicity, peaking 
at around 208 amino acids at which point further expansion towards the C-terminus 
decreases toxicity (the constructs used o f lesser and greater size than the 208 
construct involved the first 63 [exon I] and 508 amino acids o f huntingtin; therefore 
the peak lies anywhere between these tw o points). Whilst the relevance o f caspase-3 
activation in a HEK model is questionable, the fact remains that in a single model 
system there appears to  be a context-dependent toxicity. This translates well onto 
the mouse models as it could explain the peculiarity o f the DiFiglia 3kb fragment mice, 
and also why the N17 1 mice show severe phenotype and darkened striatal neurons 
whilst having only 82 repeats in a protein estimated to  be expressed at 10-20% that of 
endogenous (the lowest expressing model o f all).
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W e can therefore derive the three most important factors required to  cause maximal 
neuronal dysfunction and death, which, w e have established, is unrelated to  inclusion 
formation.
1) Polyglutamine length
2) Non-polyQ protein length
3) Promoter Expression Level
The transgenic mouse exhibiting the greatest neuronal toxicity would thus use the 
CMV promoter to  express the first 200 amino acids o f huntingtin, which would 
contain 9 0 -150 glutamines. O f course, neuronal toxicity and the ‘positive’ symptoms 
of HD are not causatively linked, therefore such a mouse might possess a phenotype 
more severe than the R6/2 mouse and, likewise, die prematurely before neurons are 
lost Thus, such a mouse may not be the ‘best’ mouse.
4.6.2 Mouse Models and the Human Disease
The ‘gold standard’ against which all o f these models must be judged is, o f course, the 
human condition. Human HD shows slow accumulation o f huntingtin and late onset 
of disease symptoms. It is also shows substantial cell death. The tw o combine to  
produce a behavioural phenotype progressing from personality changes and cognitive 
impairment through hyperkinesia and chorea, to  hypokinesia and akinesia. The latter, 
‘negative’ symptoms corresponding to  cell loss. In these respects none o f the mice 
accurately reproduce the human condition.
The Hdh knock-in mice fail to  significantly reproduce the disease  
characteristics. The Shelboume model shows minor behavioural abnormalities -  
increased aggressive behaviour -  a phenomenon shared with the Zertlin mice, of 
which the 94Q  model also exhibits mild hyperkinesia. Interestingly, the MacDonald 
and Detloff mice are o f  similar nature, yet whilst the MacDonald mice are
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phenotypically unaffected, there are reports o f motor deficits in the Detloff mice. In 
none of these models is cell loss reported, and dark neurons are infrequent
The transgenic mice expressing the smaller N-terminal fragments exhibit the 
majority o f the symptomatic behavioural alterations seen in the human, including 
motor deficits, hyperkinesia, tremors and abnormal gait. However, in spite o f the early 
onset o f symptoms and rapid disease progression, these mice show no cell loss. 
Hence, they do not progress to  the hypokinetic stage of the phenotype.
The mice that appear to  replicate the human disease most fully are those 
presented in figure 144. These mice express either full-length huntingtin or a large N- 
terminal fragment Y et as mentioned previously, it is not simply a matter o f fragment 
length. The knock-in mice studied as part o f this thesis demonstrate that neither full- 
length nor truncated mutant huntingtin expressed under the endogenous promoter is 
sufficient to  carry the disease phenotype beyond the initial stages. The DiFiglia mice 
remain an interesting mystery. The expression levels o f huntingtin, or rather the first 
one thousand amino acids o f huntingtin, are believed to  be lower than endogenous 
and yet the disease process passes through all stages. The neuropathological 
investigations have yielded inconsistent results, with cell loss reported for only some of  
the mice. However, if there is an extra property inherent to  longer N-terminal 
fragments, as suggested previously, then this model may lead the way to  others which 
replicate fully the behavioural spectrum, show widespread inclusions and exhibit cell 
loss.
Ignoring the nature o f the transgenics, the Hayden YAC mouse and the Tagle 
mouse are rather similar; yet whilst the Tagle mice exhibit widespread neuronal loss 
and a full progression o f symptoms including hypoactivity, the Hayden mice progress 
only to  the hyperactivity/dark neuron stage. Thus, it may be said that the Tagle mice 
are the closest to  the human condition. However, in order to  achieve this replication 
of HD, the expression level o f the protein is up to  five times that o f the endogenous 
huntingtin. Is such a model an accurate recreation o f the human disease?
The knock-in models show that inserting CAG repeats to  extend the Hdh 
gene into the range known to  pathogenic in the human condition does not necessary 
produce a disease phenotype in the mouse. The Detloff mouse has 150 CAG repeats
and yet whilst showing inclusion formation a third o f the way through its lifespan there 
is only a minor detectable phenotype. Such an expansion in the human would kill the 
individual before adulthood. Therefore, in order to  replicate human HD within the 
lifespan o f the mouse the disease process has to  be accelerated. Truncation of the 
mutant protein combined with repeat lengths known to  cause juvenile HD accelerates 
the onset of symptoms, but in the case o f the R6/2 and N17 1 mice it may be that the 
phenotype is accelerated to  such a level that the complications arising from 
dysfunction kill the mice before cell death can occur. In the case o f the DiFiglia mice, 
the juvenile HD-causing repeat length is contained within one third o f the huntingtin 
protein. This appears to  accelerate the disease process such that phenotypes are 
observable within the lifespan o f the mouse, yet allows it to  progress to  completion in 
some animals. The Tagle mice bring about acceleration by increasing the amount of 
mutant protein produced. This appears to  produce the most faithful replication o f the 
human disease.
However, the human condition also shows numerous inclusions. The Tagle 
mice show very few. As the relevance o f each o f the components -  huntingtin 
accumulation, inclusion formation, neuronal darkening, and cell death -  to  human HD 
has yet to  be conclusively weighted, the true value o f the Tagle model, and the values 
o f the others are open to  debate. What this does serve to  illustrate, is that even the 
most faithful model cannot replicate all of the human condition.
Conclusion
5.1 Dysfunction, Degeneration and Death
onset o f this project, the thesis title was An Ultrastructural Analysis o f Cell 
Death in Huntington's Disease. However, it soon became clear that there 
is little to  no cell deletion in the R6/2 mouse models. Thus, the title was altered to  
reflect the fact that this work is a study of the degenerative changes seen in those cells, 
which, potentially, may be deleted if the process were to  continue to  completion.
As the R6/2 exhibits such a powerful phenotype in the face o f no apparent cell 
loss, one can conclude that cell death does not underlie the symptoms o f the R6/2. 
The human condition, and some o f the other mouse models, progresses to  an akinetic 
stage, which is likely to  be the result of the cell loss, but the initial ‘positive’ symptoms 
o f HD and its models do not stem from cell deletion.
The ‘positive’ symptoms o f HD must therefore result from cell dysfunction 
brought about by the expression o f the mutant protein. The Hdh and aged wild-type 
mice show lar^ ge numbers o f dark degenerating neurons and yet show an extremely 
mild phenotype. Thus, one can conclude that cell dysfunction does not correlate with 
dark cell degeneration. The nature of such dysfunction is beyond the confines o f this 
thesis, but I have speculated that, independently from dark cell degeneration, the  
interaction o f mutant huntingtin with cell components underlies this dysfunction.
One is therefore left with the question o f the nature o f the dark neuron. In 
the mouse models I have studied, including the aged wild-type controls, neurons 
persist in a darkened, degenerative state; and, given the lack o f a severe phenotype, 
must be (largely, at least) functionally intact I have also provided evidence for a lack 
of activation o f the machinery o f apoptosis during dark cell degeneration, which may 
explain how such persistence can occur. The dark neuron may therefore be 
degeneration, but not dying.
Such persistent ‘dark degeneration’ may be unique to  neurons. It seems clear 
that there is a vast difference between dividing cells in culture and post-mitotic 
neurons, particularly in susceptibility to  apoptotic stimuli. This appears to  be a logical
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state o f affairs. A cycling cell has not terminally differentiated and, therefore, is unlikely 
to  have taken on its functional role. An adult CNS neuron has developed countless 
synaptic connections via intensely reticulated dendritic arbours, and grown axons many 
times the length o f its own cell body. The consequences of losing the former cell are 
far outweighed by the consequences o f losing the latter. Applying evolutionary 
principles, it is likely that a mechanism has evolved to  protect neurons from summary 
apoptosis. Such a system will be negated in a neuron that is severely compromised 
(ischaemic or overpowered by calcium ion influx, for examples) but in the case of 
Huntington’s disease, the insult is slow and protracted. So much so, that a cell can 
apparently survive for decades in the face o f the accumulating insult
The upregulation o f autophagy has been shown in response to  various stressful 
stimuli, including transfection with huntingtin. It has been demonstrated that 
autophagy can delay or even suppress the activation o f apoptosis. Given the large- 
scale activation o f autophagy seen in the mice I have studied, this may help to  explain 
how dark neurons can persist for so long without undergoing apoptosis.
Autophagy has also been shown to  successfully degrade mutant huntingtin. It 
is unlikely that this is a directed response, rather, in times o f stress, autophagy is 
induced to  non-specifically degrade cellular constituents, liberating raw materials for 
the construction o f more essential components. This may also be true for the 
dendritic remodelling shown to  occur. As part o f a stress response, dendritic arbours 
may be retracted, though this does seem  contrary to  the hypothesis that such 
mechanisms would act to  protect a neuron precisely because it is so highly 
differentiated.
However, such protective mechanisms may produce a ‘double-edged’ result in 
the human condition. I have argued that the ‘positive’ symptoms o f Huntington’s 
disease are produced by cell dysfunction and that cell loss yields the ‘negative’ 
symptoms. The persistence o f  the dark dysfunction neuron prolongs the ‘positive’ 
phase. O f course, whether a dead neuron is better than a dysfunctional neuron is a 
m oot point. Certainly for the relatives o f HD patients, the positive symptoms are 
more disturbing; but once a neuron is dead there is no return.
5.2 The Relevance o f Models
ONE must not lose sight o f the reason for generating each mouse model: to  understand the human condition such that effective therapies might be 
developed. Mouse models have already provided great insights into the mechanisms 
behind Huntington’s disease. Furthermore, insights into HD often apply to  the other 
polyglutamine disorders, and vice versa,
Huntington’s disease is a multifaceted, prolonged disorder with changes ranging 
from genetic alterations through to  dendritic pruning and cell loss. In evaluating the 
mouse models I sought the ‘best’ model using complete replication o f the human 
disease as my criterion. But is it necessary to  replicate the full progress o f the human 
disease in order to  understand one element? Is it even wise?
I have, reluctantly, been forced to  conclude that neither the R6/2 not the 
Shelboume knock-in mice are wise choices for studying cell death. The Tagle or 
DiFiglia mice seem more suited to  such studies as they (reportedly) show the greatest 
cell loss. But that does not mean that these are the best models for studying every 
element o f HD. The work o f Peggy Shelboume is centred on the somatic instability of 
the HD mutation (see 1.3.4). The expansion o f genomic CAG repeat sequences 
within somatic cells is perhaps the first step in the disease process. It may also 
underlie the cell selectivity seen HD. It is likely that such processes depend on genetic 
context, thus such investigation in the Hayden YAC mouse would probably be 
meaningless. Likewise, the Tagle mice express mutant huntingtin from the CMV 
promoter at up to  500% that o f normal huntingtin. This level o f expression may affect 
the somatic expansion events. Thus, whilst they show only the first stages o f the 
disease before the effects o f old age take over, the Shelboume mice are perfect for 
the work of Dr Shelboume.
Likewise, I have criticised the R6/2 model for showing no detectable cell loss. 
But the very fact that so many neurons are ‘stuck’ in the dysfunctional phase, yielding 
the severe phenotype, means this model is perfect for one studying dysfunction. 
Furthermore, the R6/2 is an excellent candidate for the testing o f therapeutic
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compounds that are hoped to  restore function in human patients, and is indeed widely 
used for such purposes (though this is primarily due to  the low cost o f housing a 
mouse that will develop a phenotype within weeks rather than months).
However, the R6/2 also provides an insight that cannot be ignored when 
developing therapeutics. In the previous section I questioned the benefits o f  
prolonging the life o f a dysfunctional neuron. The R6/2 shows more widespread 
nuclear accumulation o f mutant huntingtin than that seen in the human condition, but 
that aside, the model has confirmed that the greater the number o f dysfunctional 
neurons in the brain at any one time, the greater the overall phenotype. Preventing 
the death o f dysfunctional neurons in the human condition would lead to  an 
accumulation o f such cells. This may well exacerbate the phenotype.
In spite o f this, work continues on various model systems to  find compounds 
that prevent cell death. Inhibitors o f almost all caspases have been used on model 
systems. This work provides important insights into the mechanisms o f cell death, but 
one is forced to  question the authors of such papers ending with a sentence along the 
lines of: This may provide a basis for therapy in Huntington’s disease’. Human therapy 
should indeed always be the goal in working on mouse models o f disease, but the 
prevention of cell death is far beyond the therapeutic window in HD. Y et clinical 
trials are underway on such compounds. Prevention o f cell death may be beneficial if 
the elements underlying dysfunction can also be inhibited. Perhaps the eventual 
treatment for HD will be a cocktail o f drugs designed to  prevent cell death, increase 
histone acetylation & restore inhibited transcriptional pathways, and sustain dendritic 
morphology. The question then is ‘how would such interference in fundamental 
biological processes affect the rest of the body’?
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5.3 Future Directions
W HILST this thesis has provided insights into the nature o f the dark cells seen to  accumulate in Huntington’s disease and its mouse models, it has left unanswered som e o f the questions it sought to  address. The process by 
which cells are deleted in human HD may indeed be apoptotic. I have argued that the 
autophagy seen in all mouse models I have studied may allow the cell to  persist in 
spite o f the insult o f nuclear, mutant huntingtin. However, dark neurons may 
eventually become overwhelmed and autophagy can no longer delay the initiation of 
apoptosis. It seem s clear from the human condition, that a point is reached 
whereupon the dark cell, which has struggled to  survive in the face o f mutant 
huntingtin accumulation, commits to  death. The nature o f  that point, and the 
processes leading to  deletion o f the cell remain to  be confirmed. Studies such as 
those presented here should be carried out on mice were there is clear cell death, 
such as the Tagle mice.
I suggested in 5 .1 that the dendritic remodelling seen in the transgenic mice 
may also be part o f the general ‘insult’ response in neurons. This would be relatively 
simple to  investigate. Golgi impregnations o f neurons in aged wild-type would reveal 
such changes; however, by definition, age-matched controls would not be available. 
Nevertheless, there may be a correlation between loss o f dendritic arborisation, cell 
somal condensation and autophagy. If so this would suggest that the changes seen in 
the HD mice are a result o f a general response to  insult throwing up more questions 
concerning the specificity o f HD pathology. However, if cells showing age-induced 
dark cell degeneration possess healthy processes, one can be certain that the dendritic 
changes in the HD mice occur as a direct result o f the huntingtin mutation, and are 
therefore certainly behind much o f  the dysfunction, and thus phenotype o f  
Huntington’s disease.
I have also suggested that the only real distinguishing element between the 
ultrastructural changes o f the R6/2 and those o f the Hdh or aged mice is the 
involvement of the nucleus. Whilst the R6/2s show similar cytoplasmic events to  the
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Hdh and aged wild-type mice, they also exhibit a nuclear-based pathology, which, I 
believe, is central to  the neuropathology o f HD. My investigations o f nuclear changes 
have been limited to  those visible with osmium-uranyl-lead staining at EM, which, 
fortunately, includes the position o f  the Cajal body. However, there is an ever­
growing number o f other ‘bodies’ within the nucleus, it is certainly not the 
homogenous structure it was once believed to  be (see Spector, 2 0 0 1 for review). Each 
of these bodies, as well as each o f the countless free proteins within the nucleus may 
be affected in Huntington’s disease. Such interactions have already been shown to  
dramatically affect models o f HD, and, I believe, it is in the nucleus that the most 
important elements are to  be found. To that end, investigations are already underway 
and should provide interesting results.
Appendices
6.1 Transcript o f ‘On Chorea ’ by George Huntington
CHOREA is essentially a disease o f the nervous system. The name “chorea” is given to  the disease on account o f the dancing propensities o f those who are affected by it, and it is a very appropriate designation. The disease, as it is 
commonly seen, is by no means a dangerous or serious affection, however distressing 
it may be to  the one suffering from it, or to  his friends. Its most marked and 
characteristic feature is a clonic spasm affecting the voluntary muscles. There is no loss 
of sense or o f volition attending these contractions, as there is in epilepsy, the will is 
there, but its power to  perform is deficient, the desired movements are after a 
manner performed, but there seems to  exist some hidden power, something that is 
playing tricks, as it were, upon the will, and in a measure thwarting and perverting its 
designs; and after the will has ceased to  exert its power in any given direction, taking 
things into its own hands, and keeping the poor victim in a continual jigger as long as 
he remains awake, generally, though not always, granting a respite during sleep. The 
disease commonly begins by slight twitchings in the muscles o f the face, which 
gradually increase in violence and variety. The eyelids are kept winking, the brows are 
corrugated, and then elevated, the nose is screwed first to  the one side and then to  
the other, and the mouth is drawn in various directions, giving the patient the most 
ludicrous appearance imaginable. The upper extremities may be the first affected, or 
both simultaneously. All the voluntary muscles are liable to  be affected, those o f the 
face rarely being exempted.
If the patient attempts to  protrude the tongue it is accomplished with a great 
deal o f diffcutty and uncertainty. The hands are kept rolling— first the palms upward, 
and then the backs. The shoulders are shrugged, and the feet and legs kept in 
perpetual motion; the toes are turned in, and then everted; one foot is thrown across 
the other, and then suddenly withdrawn, and, in short, every conceivable attitude and 
expression is assumed, and so varied and irregular are the motions gone through with, 
that a complete description o f them would be impossible. Sometimes the muscles of 
the lower extremities are not affected, and I believe they never are alone involved. In 
cases o f death from chorea, all the muscles of the body seem to  have been affected, 
and the time required for recovery and degree o f success in treatment seem to  
depend greatly upon the amount o f muscular involvement Romberg refers to  tw o  
cases in which the muscles o f respiration were affected.
The disease is generally confined to  childhood, being most frequent between 
the ages o f eight and fourteen years, and occurring oftener in girls than in boys. 
Dufosse and Rufe refer to  429 cases; 130 occurring in boys and 299 in girls. Watson 
mentions a collection o f 1,029 cases, o f whom 733 were females, giving a proportion 
of nearly 5 to  2. Dr. Watson also remarks upon the disease being most frequent 
among children o f dark complexion, while the tw o authorities just alluded to, Dufosse 
and Rufe, give as their opinion that it is most frequent in children of light hair. In every 
case visiting the clinics at the College o f Physicians and Surgeons o f N ew  York, and of 
which I have the notes, the subjects were o f dark complexion. Temperature is said to  
exert an influence over the disease, it being according to  some authors, most frequent
during the winter months, and scarcely known in the tropics. Its mean duration is from 
thirty to  sixty days, and although it is chiefly confined to  children is not entirely so. 
Spontaneous terminations frequently occur upon the establishment o f the menses in 
girls and o f puberty in boys. There appears to  be in certain cases o f unusual severity or 
long continuance a degree of fatuity established, but it is usually recovered from upon 
the subsidence of the disease.
According to  Rilliet and Barthez, as quoted by Dr. Condie in his work on 
diseases o f children: “Patients laboring under chorea, being attacked by measles, 
scarlatina, variola, or other acute febrile disease o f childhood, the chorea will generally 
be diminished in intensity or entirely removed.”
They state that “out o f nineteen cases nine were attacked with other diseases, 
and eight were evidently influenced by them." M. Rufe, denies that concurrent diseases 
exert any influence upon the severity or duration o f chorea. There is generally 
constipation with disordered stomach and appetite, it sometimes being defective and 
at others ravenous. Pain is not a common attendant upon the disease, although 
headache may frequently be present and sometimes tenderness along the course o f  
the spinal cord, which is increased by pressure. “Epilepsy and hemiplegia,” remarks Dr. 
Condie, “are not uncommon results o f chorea,” and in many cases falling under his 
notice the patients had died of tubercular meningitis. Dr. Todd states that “paralysis of 
a limb which has been affected by chorea is not uncommon.” He also states that the 
sounds o f the heart are often changed in chorea; a bellows sound is frequently 
observed, and is either aortic, systolic, dependent upon anemia, or much more 
frequently mitral, systolic or regurgitant
Rheumatism and rheumatic pericarditis, have been shown by Dr. Copland to  
be frequent accompaniments to  chorea. M. Lee, Begbei, Naim, Kirkes, Trousseau, and 
others point out its frequent occurrence in connection with pericardial inflammation, 
and internal and external rheumatism. Trousseau says that examinations into the  
condition o f the heart and inquiry as regards rheumatism, should always be instituted.
As regards the pathology o f chorea, very little satisfactory information has been 
gained, and indeed in a large number o f persons who have died of chorea, and upon 
whom autopsies have been performed, in the hope o f illuminating this dark subject no 
morbid changes have been found o f a nature to  lead to  the supposition that they 
were in any way connected with the disease, while lesions discovered in others, such 
as inflammation o f portions o f the brain, turgescence o f its vessels, with effusion of 
serum; hypertrophy and injection o f the brain and spinal cord; turgescence o f the 
vessels o f the brain and spinal cord, with several bony plates half way up the spine 
upon the piamater; a concretion in the left hemisphere o f the brain; a tumor pressing 
upon the tubercular quadrigemina, with inflammation and sanguineous effusion; 
ecchymosis o f the membranes, and a pulpy condition o f the spinal cord, and an 
abscess within the cerebellum, as reported by Clutterbuck, Serrs, Cox, Patterson, 
Roser, Willan, Copland, Monad, Hutten, Beight, Brown, Keir and Schrode, these might,
I say, have exerted and doubtless did exert powerful influences over the cases in 
which they occurred.
The most probable theory, and one which I believe is most generally accepted 
at the present day is, that the disease depends upon some functional derangement in 
the cerebellum. Modem physiologists pretty generally agree upon the opinion first
advanced by Flourens, that the function o f  the cerebellum is to  direct, govern and 
coordinate the movements o f the muscular system. This being the case, then, the 
irregular ungovemed movements o f the muscles in chorea would most decidedly and 
emphatically point to  the cerebellum as the seat o f the difficulty. Undoubtedly, the 
abscess o f the cerebellum discovered by Schrode was the exciting cause in that 
instance. But even if w e take it for granted that w e have discovered the sedes morbi 
w e are still left in ignorance in regard to  the nature o f the derangement And there w e  
must leave the interesting subject o f the pathology o f this disease, and trust that the 
science, which has accomplished such wonders, through the never-tiring devotion of 
its votaries, may yet “overturn and overturn, and overturn it,” until it is laid open to  
the light of day.
The causes predisposing to  chorea are various: Improper and indigestible 
articles of diet confinement in illy ventilated apartments, with want o f proper exercise; 
disordered digestion, etc. While the exciting causes are irritation from dentition, 
irritation in the stomach and alimentary canal; by worms, retained faeces, etc., anger, 
fright rheumatism and injuries to  the head. It is, also, singular as it appears, sometimes 
the result o f imitation.
Some authors mention the disease as occurring epidemically in schools, and in 
one instance among a religious sect in Kentucky and Tennessee. The disease 
sometimes assumes a character different from ordinary chorea, and a number of cases 
of this kind are alluded to  by Watson. Some keep beating measured time as if they 
were marching to  music, others are seized with an irresistible propensity to  roll over 
and over, others to  stand on their heads, others to  walk forward or backward, 
sometimes rapidly and in one direction, until exhausted or checked by some obstacle.
The treatment o f chorea now most generally adopted is by purgatives, tonics, 
counter-irritants, and anti-spasmodics. The first indication is, if possible, to  remove the 
exciting cause and it will probably be different in each individual case. Bleeding used to  
be employed, and it is said with good results, but it is rarely used at present except in 
cases when there is much pain in the head, or along the spine, when rt may be taken 
moderately by cups or leeches.
Purgatives should be used to  unload the intestines, and the bowels should be 
kept open, and in a condition as near normal as possible, not allowing a day to  pass 
without a full and free evacuation. In the early stages the mild cathartics may be 
employed, as the fluid extract taraxacum and senna, calomel combined with rhubarb 
or jalap, and followed by castor oil.
The pit. comp, cath., or ol. ric., may be required when constipation is resisting, 
and the bowels are in a torpid state. Spts. turpentine is highly recommended by some, 
either by itself, or in combination with castor oil, tr. senna, etc
Tartarized antimony has been recommended by some in as large doses as can 
be bom e by the stomach. In the British and Foreign Medical and Surgical Review for 
January, 1858, tw o cases are reported as being successfully treated by it In the first 
case the chorea had lasted a month and was increasing in intensity. Large doses of tart 
emetic w ere given on tw o  successive days, and thirty hours after its first 
administration, all choreic movements had ceased. The chorea reappeared under a 
severe fit o f passion, but again yielded to  tartar emetic. In the second case the chorea 
was at first general, but immediately became partial. It resisted tonic and other
treatment for six months, but yielded to  tartar emetic in twenty-eight hours. Counter­
irritation is often employed, either by blisters along the spine, pustulation by croton oil, 
or by friction with tartar emetic ointment this last method being considered by some 
good authorities as preferable. The most essential part o f the treatment consists in the 
administration o f tonics, nearly all o f which, both vegetable and mineral are found 
serviceable. O f the vegetable tonics, the best are the different preparations o f bark, 
and the salts o f quinia. O f the minerals, the chalybeates, arsenic and zinc, are 
undoubtedly the most valuable. Iron may be given in form o f sesquioxide, proto 
carbonate or sulphate, and, indeed, will be found useful in any o f its forms.
The proto-carbonate o f iron, gr. v.-vii., given in syrup, will often be found very 
useful. The zinci sulph. has a great deal of testimony in its favor; the disease yielding to  
it when many other medicaments have failed. Its use is generally begun in small doses, 
say one grain, and gradually increasing a grain at a time until the stomach will bear 
twelve or fifteen grains. The effects produced in individual cases must guide the 
practitioner, and if one tonic fails, another must be substituted and persevered in as 
long as any benefit accrues from its use, and so on throughout the whole catalogue, if 
necessary. Cimicifuga, nux vomica and iodine have been used with marked su[c]cess 
by some, and are highly recommended by them. Opium, belladonna, hyoscyamus, 
stramonium, etc., are often serviceable in quieting muscular action and producing 
sleep, and the same may be said in favor o f chloral hydrate and chloroform, the latter 
being used in event o f failure o f the other remedies. These drugs can be considered, 
however, only as adjuvants to  the tonics. In conjunction with these means the cold 
bath or sea-bathing, plenty o f exercise in the open air, and a strict attention to  diet will 
in most cases prove successful.
Electricity applied along the spine has proven in the hands o f some a powerful 
curative agent in chorea. It should never be applied directly to  affected parts, as the 
disease is thereby aggravated, rather than relieved, and it should not be continued 
after the patient is convalescent The diet should be nourishing and easy o f digestion, 
the food to  consist o f such articles as beef extract milk, eggs, etc., the condition of 
each patient indicating the kind and quantity o f food to  be given. Gymnastic exercise is 
often o f much good and is employed by som e as the sole means o f cure. After 
recovery care should be taken to  remove all exciting causes; the bowels are to  be 
kept free and in a soluble condition, and in short all irritation to  both mind and body 
are to  be removed as far as it is possible to  do so.
And now I wish to  draw your attention more particularly to  a form of the 
disease which exists, so far as 1 know, almost exclusively on the east end o f Long 
Island. It is peculiar in itself and seems to  obey certain fixed laws. In the first place, let 
me remark that chorea, as it is commonly known to  the profession, and a description 
of which I have already given, is o f exceedingly rare occurrence there. I do not 
remember a single instance occurring in my father’s practice, and I have often heard 
him say that it was a rare disease and seldom met with by him.
The hereditary chorea, as 1 shall call it, is confined to  certain and fortunately a 
few families, and has been transmitted to  them, an heirloom from generations away 
back in the dim past. It is spoken o f by those in whose veins the seeds o f the disease 
are known to  exist, with a kind o f horror, and not at all alluded to  except through dire 
necessity, when it is mentioned as ‘'that disorder.” It is attended generally by all the
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symptoms o f common chorea, only in an aggravated degree, hardly ever manifesting 
itself until adult or middle life, and then coming on gradually but surely, increasing by 
degrees, and often occupying years in its development until the hapless sufferer is but 
a quivering wreck  o f his former self.
It is as common and is indeed, I believe, more common among men than women, 
while I am not aware that season or complexion has any influence in the matter. 
There are three marked peculiarities in this disease: I. Its hereditary nature. 2. A 
tendency to  insanity and suicide. 3. Its manifesting itself as a grave disease only in adult 
life.
1. O f its hereditary nature. W hen either or both the parents have shown 
manifestations o f the disease, and more especially when these manifestations have 
been o f a serious nature, one or more o f the offspring almost invariably suffer from 
the disease, if they live to  adult age. But if by any chance these children go through life 
without it, the thread is broken and the grandchildren and great-grandchildren o f the 
original shakers may rest assured that they are free from the disease. This you will 
perceive differs from the general laws of so-called hereditary diseases, as for instance 
in phthisis, or syphilis, when one generation may enjoy entire immunity from their 
dread ravages, and yet in another you find them cropping out in all their hideousness. 
Unstable and whimsical as the disease may be in other respects, in this it is firm, it 
never skips a generation to  again manifest itself in another; once having yielded its 
claims, it never regains them. In all the families, or nearly all in which the choreic taint 
exists, the nervous temperament greatly preponderates, and in my grandfather’s and 
father’s experience, which conjointly cover a period o f 78 years, nervous excitement in 
a marked degree almost invariably attends upon every disease these people may suffer 
from, although they may not when in health be over nervous.
2. The tendency to  insanity, and sometimes that form of insanity which leads 
to  suicide, is marked. I know o f several instances o f suicide o f people suffering from 
this form o f chorea, or who belonged to  families in which the disease existed. As the 
disease progresses the mind becomes more or less impaired, in many amounting to  
insanity, while in others mind and body both gradually fail until death relieves them of 
their sufferings. At present I know o f tw o married men, whose wives are living, and 
who are constantly making love to  some young lady, not seeming to  be aware that 
there is any impropriety in it. They are suffering from chorea to  such an extent that 
they can hardly walk, and would be thought by a stranger, to  be intoxicated. They are 
men of about 50 years o f age, but never let an opportunity to  flirt with a girl go past 
unimproved. The effect is ridiculous in the extreme.
3. Its third peculiarity is its coming on, at least as a grave disease, only in adult 
life. I do not know of a single case that has shown any marked signs o f chorea before 
the age o f  thirty or forty years, while those who pass the fortieth year without 
symptoms o f the disease, are seldom attacked. It begins as an ordinary chorea might 
begin, by the irregular and spasmodic action o f certain muscles, as o f the face, arms, 
etc. These movements gradually increase, when muscles hitherto unaffected take on 
the spasmodic action, until every muscle in the body becomes affected (excepting the 
involuntary ones), and the poor patient presents a spectacle which is anything but 
pleasing to  witness. I have never known a recovery or even an amelioration o f 
symptoms in this form o f chorea; when once it begins it clings to  the bitter end. N o
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treatm ent seems to  be of any avail, and indeed nowadays its end is so well-known to  
the sufferer and his friends, tha t medical advice is seldom sought. It seems at least to  
be one o f the incurables.
Dr. W ood, in his w ork on the  practice of medicine, mentions the  case of a 
man, in the  Pennsylvania Hospital, suffering from aggravated chorea, which resisted all 
treatm ent. He finally left th e  hospital uncured. I strongly suspect tha t this man 
belonged to  one of the families in which hereditary chorea existed. I know nothing of 
its pathology. I have drawn your attention to  this form of chorea gentlemen, not tha t I 
considered it o f any great practical im portance to  you, but merely as a medical 
curiosity, and as such it may have some interest.
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6 .2  C o m p a r iso n  o f  H u m a n  a n d  M o u se  H u n tin g tin
Human MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQPPPPPPPPPPPQLPQPPPQA 60 
Mouse MATLEKLMKAFESLKSFQQQQQQQPPPQ-------------- APPPPPPPPPQPPQPPPQG 47
Human QPLLPQPQPPPPPPPPPPGPAVAEEPLHRPKKELSATKKDRVNHCLTICENIVAQSVRNS 120 
Mouse Q PPPPPPPLPGPAEEPLHRPKKELSATKKDRVNHCLTICENIVAQSLRNS 97
Human PEFQKLLGIAMELFLLCSDDAESDVRMVADECLNKVIKALMDSNLPRLQLELYKEIKKNG 180 
Mouse PEFQKLLGIAMELFLLCSNDAESDVRMVADECLNKVIKALMDSNLPRLQLELYKEIKKNG 157
★  * 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k -k -k 'k 'k
Human APRSLRAALWRFAELAHLVRPQKCRPYLVNLLPCLTRTSKRPEESVQETLAAAVPKIMAS 240 
Mouse APRSLRAALWRFAELAHLVRPQKCRPYLVNLLPCLTRTSKRPEESVQETLAAAVPKIMAS 217
'k 'k -k 'k 'ic 'k 'k 'k 'k 'k -k 'k 'k 'k 'k 'k -k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k 'k -it-k -k -it 'k -k 'k 'k 'ic 'k 'k 'k 'k -k 'k 'k 'k 'k 'k 'k 'k 'k -k ific ic 'k 'k 'k 'k ic
Human FGNFANDNEIKVLLKAFIANLKSSSPTIRRTAAGSAVSICQHSRRTQYFYSWLLNVLLGL 300 
Mouse FGNFANDNEIKVLLKAFIANLKSSSPTVRRTAAGSAVSICQHSRRTQYFYNWLLNVLLGL 277
***★*★★*★★★★★*****★★★****** •  ^* ********
Human LVPVEDEHSTLLILGVLLTLRYLVPLLQQQVKDTSLKGSFGVTRKEMEVSPSAEQLVQVY 360 
Mouse LVPMEEEHSTLLILGVLLTLRCLVPLLQQQVKDTSLKGSFGVTRKEMEVSPSTEQLVQVY 337
* * * . * . * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . * * * * * * *
Human ELTLHHTQHQDHNWTGALELLQQLFRTPPPELLQTLTAVGGIGQLTAAKEESGGRSRSG 420 
Mouse ELTLHHTQHQDHNWTGALELLQQLFRTPPPELLQALTTPGGLGQLTLVQEEARGRGRSG 397
•k 'k ie 'k 'k 'k 'k 'k -k 'k 'it- it 'k 'ic 'k 'k -k 'k -k 'k 'k 'it'k 'k -k 'k 'k ifie 'k ic 'k 'k 'k -k^ -k -ic*  ★ ★  ★ ★ ★
Human SIVELIAGGGSSCSPVLSRKQKGKVLLGEEEALEDDSESRSDVSSSALTASVKDEISGEL 480 
Mouse SIVELLAGGGSSCSPVLSRKQKGKVLLGEEEALEDDSESRSDVSSSAFAASVKSEIGGEL 457
Human AASSGVSTPGSAGHDIITEQPRSQHTLQADSVDLASCDLTSSATDGDEEDILSHSSSQVS 540 
Mouse AASSGVSTPGSVGHDIITEQPRSQHTLQADSVDLSGCDLTSAATDGDEEDILSHSSSQFS 517
•k 'k -k 'k 'k 'k -k 'k ’k-k 'k   ^ ^ ★
Human AVPSDPAMDLNDGTQASSPISDSSQTTTEGPDSAVTPSDSSEIVLDGTDNQYLGLQIGQP 600 
Mouse AVPSDPAMDLNDGTQASSPISDSSQTTTEGPDSAVTPSDSSEIVLDGADSQYLGMQIGQP 577
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . *  * * * * . * * * * *
Human QDEDEE-ATGILPDEASEAFRNSSMALQQAHLLKNMSHCRQPSDSSVDKFVLRDEATEPG 659 
Mouse QEDDEEGAAGVLSGEVSDVFRNSSLALQQAHLLERMGHSRQPSDSSIDKYVTRDEVAEAS 637
* • • ** * * . * . * > . * * * * * ; * * * * * * * * ;  _ * _ * _ * * * * * ★ * • * * • *  *** ^
Human DQENKPCRIKGDIGQSTDDDSAPLVHCVRLLSASFLLTGGKNVLVPDRDVRVSVKALALS 719 
Mouse DPESKPCRIKGDIGQPNDDDSAPLVHCVRLLSASFLLTGEKKALVPDRDVRVSVKALALS 697
*  * _ * * * * * * * * * * * ^ ^ * * * * * * * * * * * * * * * * * * * * * *  * . _ * * * * * * * * * * * * * * * * *
Human CVGAAVALHPESFFSKLYKVPLDTTEYPEEQYVSDILNYIDHGDPQVRGATAILCGTLIC 779 
Mouse CIGAAVALHPESFFSRLYKVPLNTTESTEEQYVSDILNYIDHGDPQVRGATAILCGTLVY 757
* .* * * * * * * * * * * * * .* * * * * * .* * *  _******************************.
Human SILSRSRFHVGDWMGTIRTLTGNTFSLADCIPLLRKTLKDESSVTCKLACTAVRNCVMSL 839 
MOUSe SILSRSRLRVGDWLGNIRTLTGNTFSLVDCIPLLQKTLKDESSVTCKLACTAVRHCVLSL 817
* * * * * * * .  • *  *  *  * • *  ^ * * * * * * * * * * *  ^ * * * * * * • * * * * * * * * * * * * * * * * * * * ■ * * • * *
Human CSSSYSELGLQLIIDVLTLRNSSYWLVRTELLETLAEIDFRLVSFLEAKAENLHRGAHHY 899 
Mouse CSSSYSDLGLQLLIDMLPLKNSSYWLVRTELLDTLAEIDFRLVSFLEAKAESLHRGAHHY 877
* * * * * * . * * * * * . * * . *  _ * . * * * * * * * * * * * * . * * * * * * * * * * * * * * * * * * ( * * * * * * * *
Human TGLLKLQERVLNNWIHLLGDEDPRVRHVAAASLIRLVPKLFYKCDQGQADPWAVARDQ 959 
Mouse TGFLKLQERVLNNWIYLLGDEDPRVRHVAATSLTRLVPKLFYKCDQGQADPWAVARDQ 937
Human s s v y l k l l m h e t q p p s h f s v s t i t r i y r g y n l l p s i t d v t m e n n l s r v i a a v s h e l i t s t  1019 
Mouse SSVYLKLLMHETQPPSHFSVSTITRIYRGYSLLPSITDVTMENNLSRWAAVSHELITST 997
★   ^ •  'k 'k ’k 'k 'k 'k 'k 'k -k ir -k
Human TRALTFGCCEALCLLSTAFPVCIWSLGWHCGVPPLSASDESRKSCTVGMATMILTLLSSA 1079 
Mouse TRALTFGCCEALCLLSAAFPVCTWSLGWHCGVPPLSASDESRKSCTVGMASMILTLLSSA 1057
* * * * * * * * * * * * * * * * . * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * . * * * * * * * * *
Human WFPLDLSAHQDALILAGNLLAASAPKSLRSSWASEEEANPAATKQEEVWPALGDRALVPM 1139 
Mouse WFPLDLSAHQDALILAGNLLAASAPKSLRSSWTSEEEANSAATRQEEIWPALGDRTLVPL 1117
'k 'k 'k -k 'k 'k 'k 'k -k ic -k 'k 'k 'k 'k -k 'k 'k 'k -k 'k 'k 'k 'k lt 'k -k 'k 'k -k -k 'k  •  * *   ^ ie ★  ic • is ir *  •  it ie ie is ie ie ie • ie ★  it  •
Human VEQLFSHLLKVINICAHVLDDVAPGPAIKAALPSLTNPPSLSPIRRKGKEKEPGEQASVP 1199 
Mouse VEQLFSHLLKVINICAHVLDDVTPGPAIKAALPSLTNPPSLSPIRRKGKEKEPGEQASTP 1177
•k 'k 'k 'k ic 'k ic 'k ic it 'k ic ic ic 'k ic 'k ic 'k 'k ic 'k  •  ie ieieieieie ieieieieie ieieieieie ieieieieie ieieieieie ieieieieie ieieieie   ^ ie
Human l s p k k g s e a s a a s r q s d t s g p v t t s k s s s l g s f y h l p s y l k l h d v l k a t h a n y k v t l d l q  1259
Mouse MSPKKVGEASAASRQSDTSGPVTASKSSSLGSFYHLPSYLKLHDVLKATHANYKVTLDLQ 1237
★ ★ ★ ★ ★  # •  'k ie 'k itie ic 'k ie 'k ir ie ie ie ic ie ie ir 'k ic ie 'k ir ir ic ie ic ie ie ic ie ie 'k ie ie ic ie
Human NSTEKFGGFLRSALDVLSQILELATLQDIGKCVEEILGYLKSCFSREPMMATVCVQQLLK 1319 
Mouse NSTEKFGGFLRSALDVLSQILELATLQDIGKCVEEVLGYLKSCFSREPMMATVCVQQLLK 1297
★  • ic ie ie ic 'k 'k ic 'k 'k ic ie 'k ir ie ic ie ic ic ie-k 'k ie ie ie
Human TLFGTNLASQFDGLSSNPSKSQGRAQRLGSSSVRPGLYHYCFMAPYTHFTQALADASLRN 1379 
Mouse TLFGTNLASQFDGLSSNPSKSQCRAQRLGSSSVRPGLYHYCFMAPYTHFTQALADASLRN 1357
Human MVQAEQENDTSGWFDVLQKVSTQLKTNLTSVTKNRADKNAIHNHIRLFEPLVIKALKQYT 1439 
Mouse MVQAEQERDASGWFDVLQKVSAQLKTNLTSVTKNRADKNAIHNHIRLFEPLVIKALKQYT 1417
★  ^ *  •  * * * * * * * * * * *  « ■ k ic ic ir ie 'k itie ie ie ie ie 'k ie ie it'k ie itie ic ie ir ir ie 'k 'k ic ie itie ie ie ie ie ie ie 'k
Human TTTCVQLQKQVLDLLAQLVQLRVNYCLLDSDQVFIGFVLKQFEYIEVGQFRESEAIIPNI 1499 
Mouse TTTSVQLQKQVLDLLAQLVQLRVNYCLLDSDQVFIGFVLKQFEYIEVGQFRESEAIIPNI 1477
Human FFFLVLLSYERYHSKQIIGIPKIIQLCDGIMASGRKAVTHAIPALQPIVHDLFVLRGTNK 1559 
Mouse FFFLVLLSYERYHSKQIIGIPKIIQLCDGIMASGRKAVTHAIPALQPIVHDLFVLRGTNK 1537
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Human ADAGKELETQKEVWSMLLRLIQYHQVLEMFILVLQQCHKENEDKWKRLSRQIADIILPM 1619 
Mouse ADAGKELETQKEVWSMLLRLIQYHQVLEMFILVLQQCHKENEDKWKRLSRQVADIILPM 1597
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . * * * * * * *
Human LAKQQMHIDSHEALGVLNTLFEILAPSSLRPVDMLLRSMFVTPNTMASVSTVQLWISGIL 1679 
Mouse LAKQQMHIDSHEALGVLNTLFEILAPSSLRPVDMLLRSMFITPSTMASVSTVQLWISGIL 1657
★  •  ★ ★  ic ie ie ic itie ie ie ic ie itic iriric ie
Human AILRVLISQSTEDIVLSRIQELSFSPYLISCTVINRLRDGDSTSTLEEHSEGKQIKNLPE 1739 
Mouse AILRVLISQSTEDIVLCRIQELSFSPHLLSCPVINRLRGGGGNVTLGECSEGKQ-KSLPE 1716
* * * * * * * * * * * * * * * * ' * * * * * * * * * . * . * * ' * * * * * * ' * '  * *  *  * * * * *  * ' * * *
Human ETFSRFLLQLVGILLEDIVTKQLKVEMSEQQHTFYCQELGTLLMCLIHIFKSGMFRRITA 1799 
Mouse DTFSRFLLQLVGILLEDIVTKQLKVDMSEQQHTFYCQELGTLLMCLIHIFKSGMFRRITA 1776
★ ************************. **********************************
Human AATRLFRSDGCGGSFYTLDSLNLRARSMITTHPALVLLWCQILLLVNHTDYRWWAEVQQT 1859 
Mouse AATRLFTSDGCEGSFYTLESLNARVRSMVPTHPALVLLWCQILLLINHTDHRWWAEVQQT 1836
* * * * * *  * * * *  * * * * * * * * * *  * ^ * * * . a * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Human PKRHSLSSTKLLSPQMSGEEEDSDLAAKLGMCNREIVRRGALILFCDYVCQNLHDSEHLT 1919 
Mouse PKRHSLSCTKSLNPQKSGEEEDSGSAAQLGMCNREIVRRGALILFCDYVCQNLHDSEHLT 1896
* * * * * * * . * *  * # * *  * * * * * * * # * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Human WLIVNHIQDLISLSHEPPVQDFISAVHRNSAASGLFIQAIQSRCENLSTPTMLKKTLQCL 1979 
Mouse WLIVNHIQDLISLSHEPPVQDFISAIHRNSAASGLFIQAIQSRCENLSTPTTLKKTLQCL 1956
Appendices
Human EGIHLSQSGAVLTLYVDRLLCTPFRVLARMVDILACRRVEMLLAANLQSSMAQLPMEELN 2039 
Mouse EGIHLSQSGAVLTLYVDRLLGTPFRALARMVDTLACRRVEMLLAANLQSSMAQLPEEELN 2016
★  k k k k ^ k k k k k k
Human RIQEYLQSSGLAQRHQRLYSLLDRFRLSTMQDSLSPSPPVSSHPLDGDGHVSLETVSPDK 2099 
Mouse RIQEHLQNSGLAQRHQRLYSLLDRFRLSTVQDSLSPLPPVTSHPLDGDGHTSLETVSPDK 2076
•  ★ ★   ^ k k k k k k k k k k k k k k k k k k k k k  •  k  k  k  •  ★ ★ ★ ★ ★ ★ ★ ★ ★  # ★ ★ ★ ★ ★ ★ ★ ★ ★
Human DWYVHLVKSQCWTRSDSALLEGAELVNRIPAEDMNAFMMNSEFNLSLLAPCLSLGMSEIS 2159 
Mouse DWYLQLVRSQCWTRSDSALLEGAELVNRIPAEDMNDFMMSSEFNLSLLAPCLSLGMSEIA 2136
★ k  k  •  •  ★ ★  •  k k k k k k k k k k k k k k k k k k k k k k k k k k k  k  k  k  k k k k k k k k k k k k k k k k k k k  •
Human GGQKSALFEAAREVTLARVSGTVQQLPAVHHVFQPELPAEPAAYWSKLNDLFGDAALYQS 2219 
Mouse NGQKSPLFEAARGVILNRVTSWQQLPAVHQVFQPFLPIEPTAYWNKLNDLLGDTTSYQS 2196
^ k k k k ^ k k k k k k  ★  ★  k k * ^ ' k k k k k k k k  • k  k  k  k  ★ ★  ★ ★ ★
Human LPTLARALAQYLVWSKLPSHLHLPPEKEKDIVKFWATLEALSWHLIHEQIPLSLDLQA 2279 
Mouse LTILARALAQYLWLSKVPAHLHLPPEKEGDTVKFWMTVEALSWHLIHEQIPLSLDLQA 2256
* _  * * * * * * * * * * * . * * . * . * * * * * * * * *  *  * * * * *  * . * * * * * * * * * * * * * * * * * * * *
Human GLDCCCLALQLPGLWSWSSTEFVTHACSLIYCVHFILEAVAVQPGEQLLSPERRTNTPK 2339 
Mouse GLDCCCLALQVPGLWGVLSSPEYVTHACSLIHCVRFILEAIAVQPGDQLLGPESRSHTPR 2316
Human AISEEEEEVDPNTQNPKYITAACEMVAEMVESLQSVLALGHKRNSGVPAFLTPLLRNIII 2399 
Mouse AVRKEE— VDSDIQNLSHVTSACEMVADMVESLQSVLALGHKRNSTLPSFLTAVLKNIVI 2374
★  •  • * *  k  k  m • k  k  ^ » » k m k k k k k k * k k k k k k k k k k k k k k k k k  • k • k k k ^ • k • k k • k
Human SLARLPLVNSYTRVPPLVWKLGWSPKPGGDFGTAFPEIPVEFLQEKEVFKEFIYRINTLG 2459 
Mouse SLARLPLVNSYTRVPPLVWKLGWSPKPGGDFGTVFPEIPVEFLQEKEILKEFIYRINTLG 2434
k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k   ^ k k k k k k k k k k k k k  •  • ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
Human WTSRTQFEETWATLLGVLVTQPLVMEQEESPPEEDTERTQINVLAVQAITSLVLSAMTVP 2519 
Mouse WTNRTQFEETWATLLGVLVTQPLVMEQEESPPEEDTERTQIHVLAVQAITSLVLSAMTVP 2494
* * m * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . * * * * * * * * * * * * * * * * * *
Human VAGNPAVSCLEQQPRNKPLKALDTRFGRKLSIIRGIVEQEIQAMVSKRENIATHHLYQAW 2579 
Mouse VAGNPAVSCLEQQPRNKPLKALDTRFGRKLSMIRGIVEQEIQEMVSQRENTATHHSHQAW 2554
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * . * * * * * * * * * * * * * . * * *  * * * *  . * * *
Human DPVPSLSPATTGALISHEKLLLQINPERELGSMSYKLGQVSIHSVWLGNSITPLREEEWD 2639 
Mouse DPVPSLLPATTGALISHDKLLLQINPEREPGNMSYKLGQVSIHSVWLGNNITPLREEEWD 2614
* ★ ★ ★ ★ ★  ★ ★ * ★ ★ * * ★ ★ * • ★ * * * * * * * * * ★  k  m k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k   ^ k  k  k  k  k  k  k  k  k  k
Human EEEEEEADAPAPSSPPTSPVNSRKHRAGVDIHSCSQFLLELYSRWILPSSSARRTPAILI 2699 
Mouse EEEEEESDVPAPTSPPVSPVNSRKHRAGVDIHSCSQFLLELYSRWILPSSAARRTPVILI 2674
★  ★ ★ ★ ★ ★  •  ★  9 k  k  k  •  k  k  k  # k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k  •  ^
Human SEWRSLLWSDLFTERNQFELMYVTLTELRRVHPSEDEILAQYLVPATCKAAAVLGMDK 2759 
Mouse SEWRSLLWSDLFTERTQFEMMYLTLTELRRVHPSEDEILIQYLVPATCKAAAVLGMDK 2734
* * * * * * * * * * * * * * * * * ^ * * * • ★ * . * * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * *
Human AVAEPVSRLLESTLRSSHLPSRVGALHGVLYVLECDLLDDTAKQLIPVISDYLLSNLKGI 2819 
Mouse TVAEPVSRLLESTLRSSHLPSQIGALHGILYVLECDLLDDTAKQLIPWSDYLLSNLKGI 2794
★ * * * * * * * * * * * * * * * * * * * * . . * * * * * . * * * * * * * * * * * * * * * * * * * . * * * * * * * * * * *
Human AHCVNIHSQQHVLVMCATAFYLIENYPLDVGPEFSASIIQMCGVMLSGSEESTPSIIYHC 2879 
Mouse AHCVNIHSQQHVLVMCATAFYLMENYPLDVGPEFSASVIQMCGVMLSGSEESTPSIIYHC 2854
* * * * * * * * * * * * * * * * * * * * * * . * * * * * * * * * * * * * * . * * * * * * * * * * * * * * * * * * * * * *
Human ALRGLERLLLSEQLSRLDAESLVKLSVDRVNVHSPHRAMAALGLMLTCMYTGKEKVSPGR 2939 
Mouse ALRGLERLLLSEQLSRLDTESLVKLSVDRVNVQSPHRAMAALGLMLTCMYTGKEKASPGR 2914
******************.*************.********************** ****
Human TSDPNPAAPDSESVIVAMERVSVLFDRIRKGFPCEARWARILPQFLDDFFPPQDIMNKV 2999 
Mouse ASDPSPATPDSESVIVAMERVSVLFDRIRKGFPCEARWARILPQFLDDFFPPQDVMNKV 2974
.  * * *  < * *  .  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  .  * * * *  -5-5 t
Appendices
Human IGEFLSNQQPYPQFMATWYKVFQTLHSTGQSSMVRDWVMLSLSNFTQRAPVAMATWSLS 3059 
Mouse IGEFLSNQQPYPQFMATWYKVFQTLHSAGQSSMVRDWVMLSLSNFTQRTPVAMAMWSLS 3034
* * * * * * * * * * * * * * * * * * * * * * * * * * * *  . ********************  ; ***** ****
Human CFFVSASTSPWVAAILPHVISRMGKLEQVDVNLFCLVATDFYRHQIEEELDRRAFQSVLE 3119 
Mouse CFLVSASTSPWVSAILPHVISRMGKLEQVDVNLFCLVATDFYRHQIEEEFDRRAFQSVFE 3094
**.*********.************************************.********.*
Human WAAPGSPYHRLLTCLRNVHKVTTC 3144 
Mouse WAAPGSPYHRLLACLQNVHKVTTC 3119
k k k k k k k k k k k k k  •  k  k  •  k  k  k  k  "k k  k  ’k
9 1 % h o m o lo g y
Amino Acid Code
G Glycine (Gly) W Tryptophan (Trp)
P Proline (Pro) H Histidine (His)
A Alanine (Ala) K Lysine (Lys)
V Valine (Val) R Arginine (Arg)
L Leucine (Leu) Q Glutamine (Gin)
I Isoleucine (lie) N Asparagine (Asn)
M Methionine (Met) E Glutamic Acid (Glu)
C Cysteine (Cys) D Aspartic Acid (Asp)
F Phenylalanine (Phe) S Serine (Ser)
Y Tyrosine (Tyr) T Threonine (Thr)
Amino Acid Property Code
r e d  Sm all, hydrophobic s id e -ch a in s
g r e e n  Polar, hydrophilic s id e -ch a in s
b l u e  A cidic s id e -ch a in s
m a g e n t a  B a sic  s id e -ch a in s
Homology Analysis Code
k  exact match
• high similarity
• low similarity
Produced using PubMed protein database sequences and Gusto! W  (European 
Bioinfonmatics Institute).
335
A ppendices
6.3 Primary Antibo
AIF Goat Human, m ouse, rat Santa Cruz
Apaf-I (N-19) G oat Human, mouse, rat Santa Cruz
Apaf-1 Rabbit Human, mouse, rat Santa Cruz
Bcl-2 (C-21) Rabbit Human, mouse, rat Santa Cruz
Bcl-2 (N-19) Rabbit Human, m ouse, rat Santa Cruz
Caspase-I plO Rabbit Human, m ouse, rat Santa Cruz
Caspase-I p20 Rabbit M ouse, rat Santa Cruz
Caspase-2 G oat M ouse Santa Cruz
Caspase-3 (cleaved) Rabbit Human, m ouse, rat N ew  England Biolabs
Caspase-3 (cleaved)(CM I) Rabbit Human, m ouse Idun Pharmaceuticals
Caspase-6 (cleaved) Rabbit Human, mouse, rat Cell Signalling Technology
Caspase-7 (cleaved) Rabbit Human, mouse, rat Cell Signalling Technology
Caspase-7 (cleaved) Rabbit Human, rat N ew  England Biolabs
Caspase-8 Rabbit Human, mouse, rat Santa Cruz
Caspase-9 (cleaved) Rabbit Human, rat N ew  England Biolabs
Caspase-9 (cleaved) Rabbit Human Cell Signalling Technology
Caspase-9 p 10 Rabbit Human, m ouse, rat Santa Cruz
Cytochrome c ( H - 104) Rabbit Human, m ouse, rat Santa Cruz
Cytochrome c (Ab-5) Mouse Human, m ouse, rat NeoM arkers
DFF40 / CAD Rabbit Human, m ouse, rat Bioquote
D FF45 /  IC A D  (cleaved) Rabbit Human, m ouse, rat Cell Signalling Technology
PARP (cleaved) Rabbit M ouse Cell Signalling Technology
PARP (cleaved) Rabbit Human N ew  England Biolabs
F-luntingtin N-terminus G oat Human, m ouse Santz Cruz
Huntingtin C-terminus Goat Human, m ouse Santa Cruz
Ubiquitin Rabbit Human, m ouse DAKO
G FA P Rabbrt C ow , m ouse DAKO
F4/80 Rat M ouse Serotec
NG2 Rabbit Mouse Gift
Species specificity bold tex t indicates the species o f protein against which the antibody 
was raised.
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